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INTRODUCTION 
 
 
             The word “siddha” comes from the word „siddhi‟ which means „An object to 
be attained‟ or „perfection‟ or „Heavenly Bliss‟.    
  
            The siddha system of medicine, which is one among the oldest and foremost 
indigenous medical system. Siddha is a significant part of Tamil‟s culture and 
tradition due to its deep roots of Dravidian origin. More than just a medical system, 
siddha is a system dealing with intense spirituality and immense possibilities for the 
betterment of human being. Unlike other systems, siddha system aims in both the 
treatment and prevention of the disease. 
 
“«ñ¼ò¾¢ ÖûÇ§¾ À¢ñ¼õ 
À¢ñ¼ò¾¢ÖûÇ§¾ «ñ¼õ 
«ñ¼Óõ À¢ñ¼Ó ¦Á¡ý§È 
«È¢óÐ ¾¡ý À¡÷ìÌõ§À¡Ð” 
                                               -ºð¼ÓÉ¢ »¡Éõ 
           Man is said to be the Microcosm, and the world the Macrocosm, because what 
exists in the world exists in man. So, man must be looked upon as an integral part of 
universal nature.  Further, corresponding forces acting in and through the organisms 
of the world. This closely related to the 96 constituent principles.  
 
            Nature is the material cause not merely of the outer Universe but also of our 
body with all its grosser and subtler divisions and components. The human body is 
composed of ninety-six principles in nature including elements, bodily and mental 
organs, faculties, matter etc,   
            The world in which the above three processes take place is made up of five 
basic elements viz., Earth, Water, Heat, Air and Ether. And the man is capable of 
identifying all the objects of this world only through his five sense organs involving 
five basic elements.  
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           According to the Siddha system, various psychological and physiological 
functions of the body are attributed to the three humours viz., Vatham, Pitham and 
Kabam represent respectively the air, the fire and the water and seven thathus, first is 
Saram responsible for growth, development and nourishment, second is Cheneer 
responsible for nourishing muscles, imparting colour and improving intellect, the third 
is Oon responsible for shape of the body, fourth is Kollzuppu responsible for 
lubrications, fifth is Elumbu responsible for body structure and posture and 
movement, sixth is Moolai (Brain) responsible for strength, and the last is Sukilam 
responsible for reproduction, which form the connection link between Microcosm and 
Macrocosm.The three humours  when deranged, they bring about diseases peculiar to 
their influence.  
        Siddhar classified diseases occurred to human beings into 4,448, they 
also had many interventions for each disease due to the derangement of three vital 
humours.  
                   According to Tamil vaithyasathagam, the pingalai, urinary bladder, 
stomach, umbilical, epigastric region, sweat, saliva, essence of food, eyes and skin are 
the places where pitham sustains. 
 
¾¡É¡É À¢ò¾õ À¢ý¸¨Ä¨ÂôÀüÈ¢î 
º¡öÅ¡É À¢Ã¡½Å¡Ô Å¾¨Éî §º÷óÐ 
°É¡É ¿£÷ô¨ÀÂ¢ ÄÏ¸¢ ãÄò 
Ð¾¢ò¦¾Øó¾ Åì¸¢É¢¨Â ÔÈ× ¦ºöÐ 
Á¡§É§¸ Ç¢Õ¾Âò¾¢ Ä¢ÕôÒ Á¡¸¢ 
§¸¡É¡É º¢Ãó¾É¢§Ä Â¢Èì¸ Á¡¸¢ì 
¦¸¡ñÎ ¿¢ýÈ À¢ò¾¿¢¨Ä ÜÈ¢§É¡§Á. 
                          - ¾Á¢ú ¨Åò¾¢Â º¾¸õ 
        
  The disease called kalladaippu is caused due to derangement of pitha humour.  
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        In siddha text, Siruneer noi or Moothira noi, this is classified into, 
1. Neerinai arukkal noi  
2. Neerinai perukkal noi 
 
       This has been mentioned by Therayar in his „Therankarisal‟ as follows, 
 
 "¿£Ã¢Õ Å¢¨Éì Ì½ò¨¾ ¿£ÂÈ¢Å¢òÐî ¦º¡øÅ¡õ 
  ¿£Ã¢¨Éô ¦ÀÕì¸¦Ä¡ýÚ ¿£Ã¢¨É ÂÕì¸¦Ä¡ýÚ 
       ¿£Ã¢Æ¢×¼§É ¦¸¡øÖõ ¿£÷¸ðÎ Å¢¨É¸¦Ç¡ýÚ" 
                            -§¾Ãý ¸Ã¢ºø 
 
     The disease kalladaippu is placed under the Neerinai arukkal noi. 
  
     As per Agathiyar Rathina Churukka naadi kalladaippu is classified into 80. 
"«ïº¡Ìí ¸øÄ¨¼ôÒ ±ñÀ ¾¡Ìõ" 
                  -«¸ò¾¢Â÷ þÃò¾¢Éî ÍÕì¸ ¿¡Ê 
 
      Kalladaippu is described well in the classical siddha text Yougi vaithiya 
chinthamani. It is classified into four types and azhalkalladaippu is one among 
them, which is described by Yougi muni.  
 
“§¾¡ýÈ¢É§¾¡÷ ¿¡Ä¢É¢¼ ¿¡Áí §¸Ç¡ö 
âýÈ¢Â§¾¡÷ À¢ò¾ò¾¢ý ¸øÄ ¨¼ôÒ 
-ä¸¢ ¨Åò¾¢Â º¢ó¾¡Á½¢. 
 
 
                   The clinical features of Azhal kalladaippu may be correlated with that of 
Renal Calculi in modern science. It includes  the symptoms like  oliguria, urethral 
pain mimics a  pain caused by an insertion of  hot iron in the urethra,  sweating all 
over body, anuria, agonizing pain, blood stained calculus stagnated in urethra.
 
           
                  Kidney Stone disorders are common in men than in women. Majority of 
the patients are between the 20-55 years of age. The highest incidence of kidney stone 
is in 30-45 years of age group and the incidence declines after the age of 50 years of 
age. It affects 10-12% of the population in industrialized countries.  
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               Epidemiology of Renal calculi varies according to the geographical areas 
and socioeconomic conditions. Renal calculi occurs in all parts of the world, with a 
lower life time risk of 25 percentages in Asia 3-15 percentages in the west 20 
percentage in India.   
 
                Global climate change is the environmental factor that affects stone 
disease rates according to research presented at the 103rdAnnual Scientific Meeting 
of the American Urological Association (AUA) and based on the effects of global 
warming, the percentage of people living in areas designated as high risk for 
kidney stone formation would increase from 40% in 2000 to 56% by 2050, and 
up to 70% by 2095. This would result in a significant “climate-related” increase in 
kidney stone events. 
      Renal calculi can be prevented by the most important thing into drink 
plenty of water daily the goal should be to urinate from two to four liters per day 
make sure you avoided getting dehydrated, there are no specific dietary  
recommendation until a stone from your system has been analysed. After analysis diet 
can be evaluated and changes recommended.
 
Although the surgical techniques have taken greater strides, yet the common 
man in developing country like India may not find it affordable. Hence the 
formulation of KARPOORA SILASATHU PARPAM described in siddha text, 
Agathiyar chendhooram 300, as that of siddha medicine for the management of 
kalladaippu. The mode of preparation seems to be simple. The main Ingredients 
formulation is found to possess Lithotriptic and Diuretic effects. The above said drug 
formulation has not undergone any clinical trial so far. Hence I have selected the 
siddha formulation “KARPOORA SILASATHU PARPAM” for further clinical 
evaluation in AZHAL KALLADAIPPU noi. 
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AIM AND OBJECTIVES 
AIM: 
     To document the siddha drug  Karpoora Silasathu Parpam in the treatment of  
Azhal Kalladaippu (Renal Calculi) by the standard process of evaluation of safety 
and efficacy of the drug. 
OBJECTIVES 
PRIMARY OBJECTIVE:    
       To evaluate the therapeutic efficacy of siddha drug Karpoora Silasathu parpam 
(Internal) in the treatment of  Azhal Kalladaippu (Renal Calculi). 
 
SECONDARY OBJECTIVE: 
 
1. To evaluate the safety profile (acute, long term toxicity studies) of this drug. 
2. To study the effect of other co-factors such as age, sex and siddha 
parameters. 
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«Æø ¸øÄ¨¼ôÒ 
                         Kalladaippu is described well in the classical siddha text Yougi 
vaithiya chinthamani. It is classified into four types and azhal kalladaippu is one 
among them, which is described by Yougi muni based on three vital humours in our 
body. 
“§¾¡ýÈ¢É§¾¡÷ ¿¡Ä¢É¢¼ ¿¡Áí §¸Ç¡ö 
 âýÈ¢Â§¾¡÷ À¢ò¾ò¾¢ý ¸øÄ ¨¼ôÒ 
   -ä¸¢ ¨Åò¾¢Â º¢ó¾¡Á½¢. 
 
¸øÄ¨¼ôÒ - þÂø (DEFINITION)  
According to the text of Siddha maruthuvam (pothu) by Dr. Kuppusamy,  
There is gradual or suddenly obstruction to the flow of urine, pain with 
burning sensation in the urethral tract, Low back pain, renal angle pain and sand like 
crystal deposit in urine. These are characteristic features of Kalladaippu.  
 
According to the text of Jeevarachamirtham, 
Kalladaippu is defined as pain in and around the umbilicus, fever, dysuria 
and urine smelling like that of goat‟s urine. 
 
According to the T. V. Sambasivam pillai, 
 
 Large concretions of minerals in the bladder or kidney produce calculus or 
gravel. It is attended with difficulty in passing urine. 
 
According to the text of Agathiyar gunavagadam, 
 
"¾¡¦ÉýÈ ãò¾¢Ãò¾¡ø ¿È¿È¦ÅýÚ 
 ¾í¸¢Â§¾¡÷ ¦À¡Ê¦ÂÛõ Á½ø¾¡ÉôÀ¡ 
Å¡¦ÉýÈ º¢È¢Â¦¾¡Õ ¸øÄ¡ Å¾ôÀ¡ 
 ÅÇÁ¡¸ ÅóÐÅ¢Øõ §¿¡öìÌò ¾¡§É 
²¦ÉýÈ «îÁÃ¢§Ã¡¸ ¦ÁýÈ §ÀÃ¡õ 
 ±Ç¢¾¡¸ ¸øÖìÌû¾¡ý Å¢ØÌõ §À¡Ð 
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§¸¡¦ÉýÈ ÌñÊì¸¡ö ãò¾¢ÃìÌÆÄôÀ¡ 
 Ì½Á¡É ãò¾¢Ãô¨À ¿£÷¾¡¨Ã §¸§Ç 
§¸Ç¼¡ ÓýÌÈ¢Â¢ø ±Ã¢îºø ¸ñÎ 
 ¦¸ÊÂ¡¸ §Å¾¨É¸û ¸¡ðÎÁôÀ¡ 
Å¡Ç¼¡ º¢È¢Â¦¾¡Õ ¸ü¸û ¾¡§É 
 ÅÇÁ¡É ãò¾¢Ãô¨À ÌÆøÅÆ¢ô ÀÊÂ¡öò 
§¾Ç¼¡ ÅÕõ§À¡Ð ¾¢§Ã ¸ó¾ýÉ¢ø 
 ¦¾Ã¢ôÀÐ §À¡ø Â¢Õ§Å¾¨É ¦ºöäõÀ¡Õ 
¿¡Ç¼¡ ¸ü¸û ¾¡É¢Èí¸¢ Å¢ð¼¡ø 
 ¿ÄÁ¡É §Å¾¨É¸û ¾¡ý ¾£ÕõÀ¡§Ã" 
     -«¸ò¾¢Â÷ Ì½Å¡¸¼õ 
Agathiyar says the definitions of Kalladaippu as sand like crystal deposited in 
urine, followed by small size of stones are excreted in urine. Stones are stagnated in 
kidney, ureter, urinary bladder and urethra. Pain with burning sensation start in 
urethral orifice followed to agonizing pain occurs during the stone moving in urethral 
tract from the bladder, when the stone removed pain also relieved. 
 
§¿¡ö ÅÕõ ÅÆ¢ (ETIOLOGY) 
“¦¾Ç¢ó¾§¾¡÷ ¸øÄ¨¼ôÒ ¯üÀò¾¢ §¸Ç¡ö 
   º¢È¢Ð¿¡ð ¦¼¡¼í¸¢§Â ã¸ó ¾ýÉ¡ø 
¾Ç¢ó¾§¾¡÷ ºÄô¨ÀÂ¢ Ö¾¢Ãó §¾¡öóÐ 
   ºó¾ºò ¾¡¸§Å ÀÕòÐì ¦¸¡ûÙõ 
ÅÇ¢ó¾§¾¡÷ Å¡¾À¢ò¾í §¸¡À¢ò ¾ì¸¡ø 
   ÅóÐ¦ÀÕí ¸øÄ¡ö¿£÷ ÅÆ¢Â ¨¼òÐ 
¿Ç¢ó¾§¾¡÷ ¿¡ÖÅ¢¾ì ¸øÄ ¨¼ôÒ 
   ¿ñÀ¡É ÅÃÄ¡Ú ¿¡ð¼ì §¸§Ç” 
   
                - ä¸¢ ¨Åò¾¢Âº¢ó¾¡Á½¢ 
It is worthwhile to mention the poem of Yougi mamunivar who is authority of 
Siddhars regional and humoral pathology. He has revealed about this disease since 
14
th
 century. 
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Yougi mamunivar says that as blood clotted in urinary bladder due to urinary 
tract diseases followed by swelling of urinary bladder, urinary stones are formed in 
urinary tract induced by humour of vatham and Pitham. 
"¿¡ð¼Á¡öì ¸üÀÆ¢òÐì ¸¼¨Á Å¡í¸¢ 
 ¿Ä¢Àñ½¢ì Ü¼¡Áø ÅÆìÌô §Àº¢ 
Üð¼Á¡öì ÌÕ×¨¼Â ¯¼¨Á ¾ý¨Éì 
 ¦¸¡¼¡Á§Ä ¨¸ì¦¸¡ñ¼ ¦¸¡Î¨Á §Â¡÷ìÌõ 
Å¡ð¼Á¡ö ÅõÒ¾õÒò ¾¢Ã¢ó¾ §À÷ìÌõ 
 Á¡ÚÀ¡¼¡ ¦ÂÎòÐô ¦À¡Õû¸ ¼¨Éì 
¸¡ðÊ§Â ¨¸ì¦¸¡ñÎ ¸ÀÎ ÀñÏõ 
 ¸¡Ä¡ó¾÷ ¸øÄ¨¼ôÀ¢ü ¸¡Ç¡Å¡§Ã" 
     -ä¸¢ ¨Åò¾¢Â º¢ó¾¡Á½¢ 
 
In this explains that mind plays a major role in causing many diseases and 
connection between body and mind and soul is established i.e., the mukkutram 
deranged by internal factors such as sexual perversion, anger and robbery. 
 
¸Äí¸¢É§¾¡÷ ¾ñ½£÷¾¡ý ÌÊò¾ §À÷ìÌí  
 ¸ø¦ÄÖõÒ ÁÂ¢÷Áñ¾¡ý ¸Äó¾ý Éò¾¢ø 
«Äí¸¢É§¾¡ ÃýÉí¸ ÇÕó¾ Ä¡Öõ 
 «Ø¸§Ä¡Î ãò¾Àñ¼ ÁÕó¾ Ä¡Öõ 
ÁÄí¸¢É§¾¡÷ Á¡ôÀñ¼ ÁÕó¾ Ä¡Öõ 
 Áó¾ò¾¢ø Å¡öÅ¡É À¾¡÷ò¾ó ¾ý¨É 
ÐÄí¸¢É§¾¡÷ Õº¢¾ýÉ¢ü Í¨Åò¾ Ä¡Öõ 
 ÍÕì¸¡öì¸ø Ä¨¼ôÒÅóÐ §¾¡ýÚó ¾¡§É 
- ä¸¢ ¨Åò¾¢Âº¢ó¾¡Á½¢. 
 
The causes mentioned here,  
 Intake of turbid water 
 Food contaminated with stones, bones, hair and sand 
 Intake of deteriorated food stuff and starch substances 
 Eating flatulence producing food while indigestion. 
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¿£Ã¢¨Éò ¾Îò¾ø ¦ºöÂ¢ý 
 ¿£÷¸ðÎò ÐÅ¡Ãõ Òñ½¡õ 
À¡È¢Îï ºóÐ ºó¾¢ø 
 ÀñÒÚ §¿¡Å ¾¡Ìõ 
§¿Ã¢Äí ¸ÂÕï ¸¡Á¢Âõ 
 ¿¢îºÂ §¿¡¾ø ¦ºöÔõ 
À¡Ã¢É¢ ÄÀ¡É Å¡Ô 
 ÀñÒÈî §ºÕ Áý§È 
     -º¢ò¾ ÁÕòÐÅ¡í¸î ÍÕì¸õ 
Siddha maruthuvanga churukkam explained that urination is one of the 14 
natural urges. When one suppress this visceral reflex it don‟t pass urine regularly, it 
will cause obstruction in the urethral passage, ulceration in the urinary tract, pain in 
the joints and genitalia and distension of the lower abdomen, urinary tract infection 
with ulceration in the genitalia and deranged of keezh nokkungaal. This leads to the 
formation of calculus. 
The author also explains that ejaculation of semen is one of the 14 natural 
urges when one suppress this reflex it leads to fever, retention of urine which favours 
urinary calculi, chest pain, arthralgia, urinary infection, spermatorrhoea and white 
discharge. 
Íì¸¢Äó ¾¨É Â¼ì¸¢ý 
 ÍÃÓ¼É£÷ì ¸ð¼¡Ìõ 
Àì¸Á¡í ¨¸¸¡ø ºóÐ 
 À¡Ã§¿¡ö ÅÆ¢Â¢ÈíÌõ 
Á¢ì¸Á¡÷ §¿¡Ôñ¼¡Ìõ 
 Á¢Ìò¾¢Îõ À¢Ã§Á¸ó ¾¡ý 
¾ì¸§¾¡÷ §À¡ÐÁ¡¸¢ý 
 ¾Ã¢ò¾¢Îõ Å¡Ôì Ü§È 
                          - Å¢Â¡º À¸Å¡ý ºÃ£Ã Ýò¾¢Ãõ 
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According to T.V. Sambasivam pillai 
  
                     A urinary disease occasionally developed in the urinary bladder, which is 
called vesical calculus. It is said to be due to the deranged Vayu encircling or 
prevailing in the region of the abdomen arising from any of the following causes viz:- 
 Suppression of seminal discharge during sexual intercourse. 
 Retention of semen in the spermatic region in involuntary discharge during 
nocturnal emissions due to excessive heat in the body. 
 Prevention of discharge of semen induced by taking aphrodisiac preparations. 
 
According to Noi vilakkam 
 
"¸Õ ¿£Ã¼ì¸ø Å¢¨ÃÂ¢ø «ÊÀ¼ø 
 ¿£Ã¢Âó¾¡ì ¸ø º¢Ú¿£Ã¼ì¸ø 
ÅÇ¢§¿¡ö Á¢ÕìÌ Ó½×õ ´Øì¸Óõ 
 ¸¨¼ô À¢Êò¾¢Î¾ø §Á¸Ó¾ü ÀÄ 
À¢½¢ÔÈø ±ØÁ¢¨Å ÂÊôÀ¨¼Â¡¸ì 
 ¸øÄ¨¼ô ¦ÀýÛí ¸ÎõÀ¢½¢ Å¢¨ÇÔõ 
ÅÇ¢ÂÐ Á£È¢¨Â ¦Â¡Î ÁøÄ¡Ð 
 ¸Õ¿£ ¦Ã¡Îí ¸ÄóÐÈ ¿£Ã¸òÐî 
º¢Ú¿£÷ì ¸Æ¢× ¦¾¡Ìò¾Ä¡Öõ 
 «ýÉ¨Å ¸ø¦ÄÉò ¾¢ÃÙ ¦ÁýÀ" 
- §¿¡ö Å¢Çì¸õ 
 Derangement of humour in blood 
 Excessive indulgence in sexual activity or sexual perversion 
 Trauma on testis 
 Suppression of urine and semen 
 Inflammation of bladder 
 Syphilis (Mega noi) 
 Stagnation of urine in urinary tract 
 Dryness of semen causes the formation of stones 
 Increased intake of food that cause flatulence 
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Å¢ØÌ º¢Ä§ºÃõ Å¢ÎÀðÎ ¿£§Ã¡Îõ  
 ´Ø¸¢Â Å¡Ô× ¦Á¡Ð¸¢É¡ø §¿¡¸¡Ð 
ÅØ¸¢Â Áó¾ò¾¡ø Å¡ÔÅó§¾ Ò¸¢ø  
¸Ø¸¢ Ó¾¢÷ó¾¢Îõ ¸øÄ¨¼ôÀ¡Ì§Á 
                    -¾¢ÕãÄ÷ ¸Õì¸¨¼ ¨Åò¾¢Âõ 
Stone is formed by derangement of humours of vatham and Pitham. 
According to Saraga samhithai 
 º¢Ú¿£÷ô¨ÀÂ¢ø ¸ø §¾¡ýÚ¾ø: 
  Å¡¾õ º£üÈÁ¨¼óÐ º¢Ú¿£÷ìÌÆ¡Â¢ø §º÷óÐ «¾ý ÅÆ¢¨Â 
«¨¼òÐ º¢Ú¿£¨Ã ÁðÎ§Á¡ Å¢óÐ ¸Äó¾ º¢Ú¿£¨Ã§Â¡ 
¿£÷ò§¾¡üÈò¾¢Ä¢ÕìÌõ À¢ò¾òÐ¼ý ÜÊÂ º¢Ú¿£¨Ã§Â¡ ¸ÀòÐ¼ý ÜÊÂ 
º¢Ú¿£¨Ã§Â¡ ¯Ä÷óÐ §À¡¸î ¦ºöÔõ. «ùÅ¡Ú ÅÈñÎ§À¡É º¢Ú¿£Ã¢ø 
¸¨ÃóÐûÇ À¢ò¾õ, ¸Àõ «øÄÐ Å¢óÐ þ¨Å¸û ¯¨ÈóÐ §À¡Å¾¡ø ÀÍÅ¢ý 
À¢ò¾ò¾¢ø §¸¡§Ã¡ºÉõ §¾¡ýÚÅÐ §À¡ø ¸ÊÉÁ¡É ¦À¡Õû §¾¡ýÚõ. þÐ 
(«îÁÃ£) ¸ø ±ýÚ ÜÈôÀÎõ. 
                         -ºÃ¸ ºõ†¢¨¾ 3õ À¡¸õ  
º¢Ú¿£÷ô¨ÀÂ¢ø §¾¡ýÚõ ¸øÄ¢ý þÄì¸½õ 
 
     º¢Ú¿£÷ô¨ÀÂ¢ø §¾¡ýÚõ ¸ø ¸¼õÀÁÄ¨Ãô §À¡ø §¾¡üÈÓõ ¿¢ÈÓõ 
¦¸¡ñÎ ¸ø¨Äô§À¡ø ¸ÊÉÁ¡Ôõ ÅÆÅÆôÒ¼ý Óì§¸¡½ ÅÊÅ¢ø ãýÚ 
¦À¡¨È¸Ù¼Ûõ ¦Áý¨ÁÔ¼Ûõ þÕìÌõ. «Ð º¢Ú¿£÷ ÅÆ¢¨ÂÂ¨¼óÐ 
º¢Ú¿£÷ ¦ÅÇ¢ÅÃ¡Áø ¾ÎòÐ º¢Ú¿£÷ô¨ÀÂ¢ø ¦¸¡ÊÂ ÅÄ¢¨ÂÔõ Ìò¾¨ÄÔõ 
§¾¡üÚÅ¢ìÌõ. 
 
POTHU KURIKUNANGAL 
According to the text of Siddha Maruthuvam (pothu) 
 Gradual or sudden obstruction to flow of urine 
 Unbearable pain (agonizing pain) in the penis 
 Excruciating pain and swelling is experienced at tip of penis if the calculus attempts to expel. 
 Colicky pain radiating from loin to groin, lower abdomen, urethra and genitalia if the calculus 
is irregular with sharp projection. 
 Burning and scanty micturition and haematuria. 
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According to the text of Aruvai Maruththuvam 
 
 In starting stage, nausea with vomiting occurs 
 
 pain in and around the umbilicus and penis 
 Urine smelling like that of goat‟s urine 
 Sometimes, blood appears while passing urine 
 Sometimes urine passed from two ways. 
SYMPTOMS ASSOCIATED WITH KALLADAIPPU 
 ¯ì¸¡Ã Ý¨Ä 
"ÌòÐÓì ¸¡Ã Ý¨ÄÂ¢ý Ì½ó¾¡ý 
 §¸¡÷¨ÅÂ¡ö Å¢Ä¡Å¾É¢ø ÓÐ¸¢ø ¦¿ïº¢ø 
«ò¾¢Â¢ø ¿¡À¢Â¢É¢ ÄÀ¡É Ì¾ò¾¢ø 
 «¾¢¸òÐý Á¡í¸¢„ó¾¡ý ÅÇ÷óÐ §ÁÅ¢ô 
ÀòÐÁ½ü ÀÕì¨¸§À¡ü ºÄòÐ Å¡Ãô 
 À¾¢¦¿Õì¸¢ ãò¾¢ÃÁ¡í ¸¢Ã¢îº¢ Ôñ¼¡öò 
¾òÐº¼í ¸Îô¦ÀÎòÐ Á¾¢¸ Äí¸¢ò 
 ¾Ç÷îº¢¦Â¡Î ÁÂì¸Á¡öò ¾ûÙó ¾¡§É" 
      - ä¸¢ ¨Åò¾¢Âº¢ó¾¡Á½¢. 
 Excessive growth of muscles in chest region, back of trunk, umbilicus, anal 
and urethral orifice followed by stricture of urethral orifice, sand like crystals blocked 
in urethra. Dysuria, body pain, Impairment of conscious, tiredness and giddiness 
occur. 
CLASSIFICATION OF KALLADAIPPU 
§¾¡ýÈ¢É§¾¡÷ ¿¡Ä¢É¢¼ ¿¡Áí §¸Ç¡ö 
    ÍÕì¸¡É Å¡¾ò¾¢ý ¸øÄ ¨¼ôÒ 
âýÈ¢Â§¾¡÷ À¢ò¾ò¾¢ý ¸øÄ ¨¼ôÒ 
    ÒÃñ¼§¾¡÷ º¢§ÄðÎÁò¾¢ý ¸øÄ ¨¼ôÒ 
¾£ýÈ¢Â§¾¡÷ ¦¾¡ó¾Á¡í ¸øÄ ¨¼ôÒ 
    §¾¸ò¨¾ô ÀüÈ¢§Â º¢È¢Ð ¸¡Äõ 
¾¡ýÈ¢§Â ºÄô¨ÀÂ¢ø Åó¾¢ Æ¢óÐ 
    ºÕÅ¢§Â Ä¢í¸ò¾¢ü ÈÃ¢ìÌó ¾¡§É. 
              -ä¸¢ ¨Åò¾¢Â º¢ó¾¡Á½¢. 
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The most experienced of Siddhars, Yougi mamunivar who has studied the 
disease according to Regional and Humoral pathology classifies Kalladaippu into 4 
types, there are 
1. ÅÇ¢ì ¸øÄ¨¼ôÒ 
2. «Æø ¸øÄ¨¼ôÒ 
3. ³Âì ¸øÄ¨¼ôÒ 
4. ÓìÌüÈì ¸øÄ¨¼ôÒ 
 
ÅÇ¢ì ¸øÄ¨¼ôÒ (VALI KALLADAIPPU) 
“¾Ã¢òÐ¿¡ À¢ìÌí¸£úî ÍÕì¸¡öì Ìò¾¢î 
    ºÄÁÄó¾¡ý Å£Æ¡Áü ÈõÀ Á¡¸¢ 
ÅÃ¢òÐ§Á Ä¢í¸ò¾¢ø ÅÄ¢Ô Á¡¸¢ 
    ÁÕÅ¢Â§¾¡÷ ¦À¡ò¾¢¦ÂøÄ¡ï ÍÃóÐ ¸ðÊ 
¾¢Ã¢ò¾¢§Â ¸¢¼ì¦¸¡¼¡ô ÒÃð¼ Ä¡¸¢ò 
    §¾õÀ¢§Â ãîÍÁ¡ö ÅÂ¢Ú ÓôÒõ 
¯Ã¢ò¾§¾¡÷ º¨¾§À¡Ä ¯Å÷ôÒ Á¡Ìõ 
    µí¸¢Â§¾¡÷ Å¡¾ì¸ø Ä¨¼ôÒ ¾¡§É” 
    - ä¸¢ ¨Åò¾¢Âº¢ó¾¡Á½¢. 
 
Pain is felt just below the umbilical region and penis. 
 
It is characterized by, 
 Severe colic pain 
 Dyspnoea 
 Abdominal distension 
 Oliguria 
 constipation 
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«Æø ¸øÄ¨¼ôÒ (AZHAL KALLADAIPPU) 
“«¨¼ôÀ¡¸¢î ºÄó¾¡Û ÁÕÅ Ä¡¸¢ 
    «Âí¸¡öîº¢î ¦º¡Õ¸¢É¡ü §À¡§Ä 
Ò¨¼ôÀ¡¸¢ô ¦À¡ò¾¢¦ÂíÌõ ÒØì¸Á¡¸¢ô 
 âðÎ§À¡ø Å¢ÌÅ¡¸¢ô ÒÃð¼ Ä¡Ìõ 
Á¨¼ôÀ¡¸¢ ¯¾¢Ã¿¢È Á¡öì¸ø Ä¡¸¢ 
     Åó¾¢Æ¢óÐ Ä¢í¸ò¾¢ø Á¡ðÊì ¦¸¡ûÙõ 
Ì¨¼ôÀ¡¸¢ì ÌüÈÄ¡öì Üîº Ä¡¸¢ì 
Ì¾ðÎ§Á À¢ò¾ì¸ø Ä¨¼ôÒò ¾¡§É” 
    - ä¸¢ ¨Åò¾¢Âº¢ó¾¡Á½¢. 
 
In azhal kalladaippu, reduced urine output with characteristic burning 
sensation (similar to introducing a red-hot iron needle into the urethra), red blood 
coloured stones which blocks the ureter causing pricking pain and tenderness. 
³Âì ¸øÄ¨¼ôÒ (IYYA KALLADAIPPU) 
 
“¾¡É¡É ¦¾¡ôÒÇ¢§Ä Å¢øÖô §À¡Äî 
 ºÄ¢Â¡Áü ÍÃóÐ§Á ºü§È ÌòÐõ 
²É¡É ¸¡¦Ä¡Î ¨¸¸û ºóÐ 
 þÎôÒ¾¡ý Ì¨¼îºÄ¡ Â¢º¢× ¸¡Ïõ 
§ÅÉ¡É Ä¢í¸ò¾¢ý §Åý¨Á ¾ýÉ¢ø  
 Å¢ÚÅ¢¦Èý¦È ¸ÎôÀ¡¸¢ Å¢Â÷¨Å Â¡Ìõ  
§¾É¡É ¦ÅÙôÒì¸ø º¢Ú¸ø Ä¡¸î 
 º¢ì¸Ä¡ö Åó¾¢ÈíÌï º¢§ÄðÎÁó ¾¡§É” 
    - ä¸¢ ¨Åò¾¢Âº¢ó¾¡Á½¢. 
 
Iyya kalladaippu is characterized by excruciating pain in the umbilical 
region, pain in the joints of upper and lower extremities, low-backache, spasmodic 
pain, sweating and gradual passing out of white coloured stone granules in the urine. 
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ÓìÌüÈì ¸øÄ¨¼ôÒ (MUKKUTRA KALLADAIPPU) 
“Åó¾¢ÈíÌõ ¿£÷ò¾¡¨Ã «ÊÂ¢ü È¡Ûõ 
 Á¡ÅÕò¾ Óñ¼¡¸¢ ÅÄ¢Ô Á¡¸¢ 
¦¿¡ó¾¢Èí¸¢ ¿£÷¾¡Û ÁÕÅ¢ô À¡Ôõ 
 ¦¿¡ö¾¡É º¢ÚÁ½ü§À¡ø ¦¿¡Úí¸¢ì ¸øÄ¡ï 
ºó¾¢Èí¸¢ ¿£÷ÅÆ¢Â¢ø ÅóÐ Å£èõ 
 ¾¡ì¸¡É º¢Èí¨¸ì¸ø ¾¢É¦Á¡ýÚìÌ 
Ñó¾¢Èí¸¢ò ¾¢Éó¾¢ÉÓ Á¢Æ¢óÐ ¦¸¡øÖõ 
 ¦¾¡ó¾Á¡í ¸øÄ¨¼ôÒî ÝðÊð ¼¡§Â” 
    - ä¸¢ ¨Åò¾¢Âº¢ó¾¡Á½¢. 
 
In Mukkuttrak kalladaippu, severe pain is felt just below the urethral region 
with excess urination. It is characterized by disintegration of stones into small, sand 
like granules in the urine. 
 
CLASSIFICATION ACCORDING TO NOI VILAKKAM 
"ÅÇ¢ Ó¾ø ãýÈ¢Ûó §¾¡ýÈÄ¡Öõ 
¸Õ¿£÷ ¾ýÉ¢ü §¾¡ýÈÄ¡Öõ 
¸øÄ¨¼ ¿¡ø Å¨¸ô ÀÎ¦ÁÉ¦Á¡Æ¢§Â" 
    - §¿¡ö Å¢Çì¸õ 
There are four types of Kalladaippu according to Noi vilakkam 
1. Vali kalladaippu 
2. Anala kalladaippu 
3. Iyya kalladaippu 
4. Karuneer kalladaippu 
 
ÅÇ¢ì¸øÄ¨¼ôÒ (VALI KALLADAIPPU) 
 
"À¼÷Á¢¸ô ÀÎò¾ø Àü¸û ¸Êò¾ø 
 ¿Îí¸ø ¯ó¾¢Ôõ ÌÈ¢Ôõ À¢¨º¾ø 
¸ºÎ¸£ú ºÇ¢¦Â¡Î ¸ÆÄø «Ø¾ø 
 º¢Ú¿£÷ ÐÇ¢ò¾ø ±ýÀ×õ À¢È×õ 
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ÅÇ¢Â¢ý ¸øÄ¨¼ì ÌÈ¢¦ÂÉ ¦Á¡Æ¢Â 
 ¸ÚòÐï º¢ÅóÐõ Ó¨É¸û ÀÃóÐõ 
ÅÇ¢Â¢ý ¸øÄÐ ÅÊ×Û ¦ÁýÀ" 
    - §¿¡ö Å¢Çì¸õ 
 Tongue biting, palpitation and shivering 
 Crushing of the lower abdomen and genital organs 
 Dribbling of urine 
 The stones are blackish red colour 
 
 
«ÉÄì¸øÄ¨¼ôÒ(ANALA KALLADAIPPU) 
"Íð¦¼É ¿£Ã¢Âõ Á¢¸¦ÅõÀ¢Î¾Öõ 
 §¿¡¾Öõ «¨Åì ¸øÄ¨¼ìÌÈ¢§Â 
º¢ÅóÐí ¸ÚòÐ ÁïºÇ¡¸¢Ôõ 
 §ºíÌÕ ÅÊÅ¢ø ¸øÄÐ §¾¡ýÚõ" 
    - §¿¡ö Å¢Çì¸õ 
 Burning micturition 
 Dysuria 
 The stones are reddish black or yellow in colour and passing of small stones 
 
³Âì¸øÄ¨¼ôÒ (IYYA KALLADAIPPU) 
"¿£Ã¢Âí Ìò¾ø ¾¢½¢ò¾ø ÌÇ¢÷ò¾ø 
 ±ÛÁ¢¨Å ³Âì ¸øÄ¨¼ì ÌÈ¢§Â 
¦ÅÙòÐõ §¾É¢ÈÁ¡¸¢Â ¦Á¡Ç¢÷óÐõ 
 ¦ÀÕ ÅÊ×¨¼ò¾¡õ ³Â ¸øÄ¨¼ôÒ" 
    - §¿¡ö Å¢Çì¸õ 
 Pricking pain, forceful pain with severe intensity when passing urine 
 Fever with rigors 
 White or honey coloured shining or luminant large size stone expelled. 
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¸Õ¿£÷ ¸øÄ¨¼ôÒ (KARUNEER KALLADAIPPU) 
"¸Õ ¿£÷ì¸øÄ¢ý ÅÇ¢ º¢Éó¦¾ØóÐ 
 Å¢¨Ã¸Ç¢ ÉÎÅ¢ø «Ð¾¨Éò ¾Îò¾Ä¢ý 
¸Õ¿£÷ì ¸øÄ¨¼ ÁÕÅ¢Î ¦ÁýÀ 
 ¿£Ã¢Âõ §¿¡¾ø º¢Ú¿£÷ ¾¨¼À¼ø 
Å¢¨Ã Å£í¸¢Â¢Õò¾ø ±ÛÁ¢¨Å À¢È×õ 
 ¸Õ¿£÷ ¸øÄ¨¼ì ÌÈ¢¦ÂÉ ¦Á¡Æ¢Â 
¸Õ¿£÷ì ¸øÄ¢¨É ÅÇ¢ÂÐ ÓÎ¸¢î 
 º¢È¢Â×õ ¦ÀÃ¢Â×ó ÐñÎ¸Ç¡¸ ¦¿¡Úì¸¢Îõ 
«¨Å º¢Ú¿£÷ ÅÆ¢ ¦ÅÇ¢ôÀ¼Å¡Ìõ 
 «¨Å º¢Ú¿£Ã¢¨Éò ¾Îò¾ø ¿¢üÌõ 
º¡üÈ¢Â ¿£Ã¢¨Éò ¾ÎòÐ ¿¢üÀ¢ý 
 ¬üÈø Ì¨È¾ø ÅÂ¢Ú §¿¡¾ø 
Í¨Å¦¸¼ø ¦ÅÇ¢Ú ÁÚôÒ ¿£÷§Åð¨¸ 
 ¦ÅøÅÇ¢ ¦ÂÛÁ¢¨Å Å¢¨Çó¾¢Î ¦ÁóÀ 
º¢ÚÅ÷ì ¸¡Â¢ý ¸ø º¢È¢¾¡¾Ä¢ý 
 ¸ÕÅ¢Â¢ ¦ÉÎò¾ø ±Ç¢¾¡ ¦ÁýÀ 
¸Õ¿£÷ì ¸øÄ¨¼ º¢ÚÅ÷ì ¸¢ø¨Ä 
 Å¢¨ÃÔõ ¯ó¾¢Ôõ Á¢¨¸ôÀ¼ Å£í¸ø 
º¢Ú¿£÷ ¾¨¼ôÀ¼ø §¿¡× Á¢Ì¾ø 
 ±ýÀ¨Å Ð½¢¸ø Á½Ä¢¨¼ò §¾¡ýÈ¢ý 
À¢¨Æò¾ ÄÃ¢¦¾Éô §ÀÍÅ÷ ÒÄÅ÷" 
    - §¿¡ö Å¢Çì¸õ 
 Sudden or gradual obstruction to flow of urine 
 Excessive vali kutram breaks the stones into small and large size crystals and 
expels along with urine 
 Sudden stoppage of urine stream 
 Retention of urine 
 Abdominal pain 
 Loss of taste, excessive thirst 
 Pricking pain with swelling of abdomen and testis 
 Retention of urine or anuria may leads to renal failure and fatal 
 
 
 
22 
 
CLASSIFICATION IN DHANVANTHIRI VAITHYAM 
 
"¾¢Õó¾¢Â Å¡¾À¢ò¾î º¢§ÄüÀÉõ À¢Ã§¸¡Àò¾¡ø 
 ÅÕó¾ ÍÁÃ¢ò¾¡ É¡ýÌ Å¨¸ÀÎí¸ø¦ÄÃ¢ôÀ¡ý 
À¢Ã¢ó¾¢Îï º¢§ÄüÀÉ¡ ÍÁÃ¢ À¢ò¾¡À¢ýÛ 
 Á¢Õó¾¢Î Íì¸¢Ä¡ÍÁÃ¢ ¿¡ýÌ ¦ÁöÐ¦Áý§È" 
     -¾ýÅó¾¢Ã¢ ¨Åò¾¢Â¸¡Å¢Âõ 
In Dhanvanthiri vaithyam, Kalladaippu is classified into four types, they are 
1. ¸ø¦ÄÃ¢ôÀ¡ý 
2. º¢§ÄòÐÁ «îÁÃ¢ 
3. À¢ò¾ «îÁÃ¢ 
4. Íì¸¢Ä «îÁÃ¢ 
¸ø¦ÄÃ¢ôÀ¡ý (KALLERIPPAN) 
"¸òÐ¿£÷ ¿¡Çó¾ýÉ¢ø Íì¸¢Äó¾É¢ü º¢§ÄüÀõ 
 À¢ò¾Á£ ÐÅ÷ò¾ø ¸øÄ¡öô À¢º¸¢É£Ã¨¼òÐ ¦¸¡ûÙí 
¦¸¡òÐ¿£ Ã¢üÚÅ¢Øí ¦¸¡ôÒû§¿¡ Ì¼õÒ¸¡Ôï 
 º¢ò¾Á¡ ÂÕº¢Ôñ¼¡ï §º÷ó¾ ¸ø¦ÄÃ¢ôÀ¡§Á" 
    -¾ýÅó¾¢Ã¢ ¨Åò¾¢Â¸¡Å¢Âõ 
 Increased Iyyam and Azhal kutram dries the urine and semen forming calculi 
 Sudden or gradual obstruction in urinary tract 
 Dysuria 
 Pain in umbilicus 
 Fever 
 Anorexia 
º¢§ÄòÐÁ «îÁÃ¢ (SILETHUMA ACHMARI) 
"¿£÷ÅÕ ¿¡Çó¾ýÉ¢ø ¿¢ýÈ¿£÷ º¢ÕòÐì¦¸¡ñÎ 
 §º¡÷¾Õõ º¢ÄôÒ ¦Åñ¨Á Íì¸¢Äõ§À¡øÅ£Øõ 
§À÷¦ÀÈ ¿¡Ä¡ ¦ÁðÎô À¢ýÉÁ¡öì ¸øÖÅ£Øõ 
 ²÷¦ÀÚ º¢§ÄüÀÉò¾¢ý «ÍÁÃ¢ ±ýÉÄ¡§Á" 
    -¾ýÅó¾¢Ã¢ ¨Åò¾¢Â¸¡Å¢Âõ 
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 Calculus in the ureter or urethra causes hydronephrosis 
 Oliguria 
 Reddish white in colour and falls out like semen 
 Stones are expelled as 4 or 8 fragments 
 
À¢ò¾ «îÁÃ¢ (PITHA ACHMARI) 
"¦ºöÔõ¿£÷ ¿¡Çó¾ýÉ¢ø À¢ò¾ò¾¡ ¦ÄÃ¢ô¦ÀøóÐ 
¦ºöÔ×‰½ò¾¡ø ¦ÅóÐ §ºí¦¸¡ð¨¼§À¡ø ¸øÖñ¼¡õ 
¿öÂ§Å ¾¨É¸û ¦ºöÔõ ¿Å¢øÌ½õ À¢ò¾ó¾ýÉ¢ø 
±ö¾ÍÁÃ¢ ¦Âý§ÈÓý É¢ÂõÀ¢É ÃÈ¢Å¢ýÁ¢ì§¸¡÷" 
    -¾ýÅó¾¢Ã¢ ¨Åò¾¢Â¸¡Å¢Âõ 
 Burning sensation in urethra due to azhal kutram 
 Burning micturition 
 Formation of stone that appear like Semicarpus anacardium seeds 
 
Íì¸¢Ä «îÁÃ¢ (SUKKILA ACHMARI) 
"Íì¸¢Äõ ÅÕí¸¡Äò¾¢ø ¾õÀ¢ò¾¡ü Íì¸¢Äó¾¡ý 
Á¢ì¸ì¸ø Ä¡¸¢¦ÅÐõÀ¢ Å¢¾ÉÁ¡ö ¿£÷Å¢¼¡Áü 
º¢ì¸¢¿£÷ Å¢Æ¡ÁÄí§¸ Á½øÅ¢Øõ ¦ÅÙìÌõ§¾¸õ 
Á¢ìÌ½ï Íì¸¢Ä¡Í ÁÃ¢Âº¡ò¾¢Â ¦Áý§È¡§Ã" 
    -¾ýÅó¾¢Ã¢ ¨Åò¾¢Â¸¡Å¢Âõ 
 Suppressions of semen during ejaculation, develops on to stones and 
obstruction in the flow of urine 
 Sand like gravels are expelled 
 Pallor of the body 
 This is curable 
 
Classification of disease in Siddhar Aruvai Maruthuvam: 
1. Vali kalladaippu 
2. Azhal kalladaippu 
3. Iyya kalladaippu 
4. Venneer kalladaippu 
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Classification in Jeevaratchamirtham and Anubava vaithya devaragasium: 
Five types 
1. Vatha achmari 
2. Pitha achmari 
3. Kabha achmari 
4. Sukkila achmari 
5. Swargara achmari 
 
Classification of disease in North books: 
 
1. Vali kalladaippu 
2. Azhal kalladaippu 
3. Iyya kalladaippu 
4. Sukkira kalladaippu 
5. Sarkkarak kalladaippu 
                                        -Noi naadal and Noi muthal naadal part I 
 
MUKKUTRA VERUPADUKAL (PATHOLOGY) 
 
 The imbalance in one‟s diet and fluid intake increases the Azhal kutram. This 
raised azhal kutram dries up the body fluid and urine resulting in concentration of 
salts; this further affects the keezh nokku kaal. One of the functions of the keezh 
nokku kaal is to excrete urine. So when this keezh nokku kaal is affected the urine 
will be obstructed within urinary tract. This favors the deposition of urinary salts to 
develop into calculi anywhere in the kidney or urinary tract. 
 
Å¡Ô ÒÌóÐ ÁÄò§¾¡¼ À¡Éò¨¾ò 
§¾Ô ÜðÊò ¾¢ÃðÊî ÍÕìÌõ 
§¾Ôõ ÁÄõ ÅÃ¢ø ÍÕì¸¢ Óý§É 
 ¿¢ý§ÈÔ Ó¨É §À¡Ä À¡ÉÉ¢üÌõ 
                   - º¢ò¾ ÁÕòÐÅ¡í¸î ÍÕì¸õ 
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§¿¡ö ¸½¢ôÒÓ¨È (DIAGNOSIS) 
 In piniyarium muraigal the following principles are followed in siddha system. 
There are,  
1. Poriyal therthal 
2. Pulanal arithal 
3. Vinathal 
The Maruthuvar (physician) should observe the patient, palpate and 
interrogate the patient thouroughly. This is stressed also understood by this 
maxim. 
“Eyes first and most, Hands next and little, mouth last and never” 
PORIYAL THERTHAL & PULANAL ARITHAL 
 
 Poriyal therthal or understanding by the five organs of perception. 
 Pulanal arithal or understanding by the sense objects. There are, 
1. Mei - Ooru (somatic sense) 
2. Vaai  -Suvai (taste) 
3. Kan - Oli (vision) 
4. Mooku- Natram (smell) 
5. Sevi - Osai (sound) 
VINATHAL 
 An effective history taking helps one to diagnosis properly. By vinathal the physician 
should ask the patients native place, mode of living, food habits, complaints and duration of 
illness etc. if the patient is deaf or dump or if the patient is a child, the particulars should be 
obtained from his relatives or parents. 
 Poriyal therthal, pulanal arithal and vinathal are applied through eight special tools of 
investigation that is envagai thervugal. 
ENVAGAI THERVUGAL 
 
"¿¡ÊôÀÃ¢ºõ ¿¡¿¢Èõ ¦Á¡Æ¢Å¢Æ¢ 
ÁÄõ ãò¾¢ÃÁ¢¨Å ÁÕòÐÅÃ¡Ô¾õ" 
       -§¾¨ÃÂ÷ 
"¦ÁöìÌÈ¢¿¢Èõ ¦¾¡É¢ Å¢Æ¢¿¡ þÕÁÄõ 
            ¨¸ìÌÈ¢"            -§¾¨ÃÂ÷ 
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¸øÄ¨¼ôÒ ¿¡Ê ¿¨¼ 
 Aggravation of vali naadi produces symptoms of Kalladaippu. This is 
emphasized in Agathiar Naadi, Sathaga Naadi and Rathina churukka Naadi. 
"«¨Èó§¾¡õ Å¡¾§Ã¡¸¢Ô¼ø 
 «Êì¸ñ Ó¸Óõ ÀÄÁÄÓõ 
¿¢¨Èó¾ Å¢Æ¢Â¢ø ¿£÷ÅÊÔõ 
 ¿£ñ¼ ¿¡× ¸Úò¾¢¼×õ 
¿¢¨Èó¾ ÓûÇ¡ö ¾¡É¢ÕìÌï 
 º¢Ú¿£÷ ¦À¡ÕÁ¢ ¸ÕòÐ ÅÕõ 
¯¨Èó¾ ¿£Õí¸Õ ¸ÕòÐ 
 Ó¨ÈÂ¡ö §Ã¡¸Ó Óñ¼¡ö" 
    - «¸ò¾¢Â÷ ¿¡Ê 
"Å¡¾¦ÁÛõ ¿¡ÊÂÐ §¾¡ýÈ¢ø 
 º£¾Áó¾¦Á¡Î ÅÂ¢Ú¦À¡ÕÁø ¾¢Ãðº¢Å¡Ô 
º£¾ÓÕí ¸¢Ã¡½¢ Á§¸¡¾Ãõ ¿£Ã¡¨Á 
 ¾¢ÃûÅ¡Ô Ý¨Ä ÅÄ¢¸ÎôÒò¾£¨Ã 
¿£¾ÓÕí ¸¢ÕÁ¢ÌýÁõ «ñ¼ Å¡¾õ 
 ¿¢¨ÄÔ¿£÷ì ¸¢Ã¢îºÃí¸û ¾óÐ §Á¸õ" 
    -º¾¸ ¿¡Ê 
"§ÁÅ¢Â Å¡¾ï¦ºöÔõ Ì½ò¨¾ Å¢ÕõÀ¢ì§¸Ù 
 ¾¡Å¢Â ÅÂ¢ÕÁó¾ï ºóÐì¸¡ø ¦À¡ÕòÐ§¿¡Å¡õ 
§ºÅ¢Â ¾¡Ð¿¡ºî º¢ÚòÐ¼ý º¢Ú¿£÷ Å£Øõ 
 ¸¡Å¢Âí ¸ñ½£É¡§Ç ÁÄÁÐ ¸Õì¸¢¸¡Ïõ” 
    - þÃò¾¢Éî ÍÕì¸¿¡Ê 
 Aggravation of Azhal naadi produces symptoms of Kalladaippu, 
"²ÅÄ¡ö ÌÆÄ¡ö À¢ò¾¦ºöÌ½õ Å¢ÇõÀì§¸Ç¡ö 
 §¸¡Ä§Åø Å¢Æ¢º¢ÅóÐ ÌÇ¢÷ó¾¢ÕìÌ ÁøÄ¡ø 
º£Ä§Å ¿£÷¸ÕòÐ ¦¿¡óÐ ÍÕì¦¸É ÅóÐÅ¢Øõ 
 »¡Ä§Á ¸¢Ú¸¢¦ÈýÚ ¿¡×Ä÷ó¾¢ÕìÌó¾¡§É" 
"À¢ò¾§Ã¡¸¢ ¦ÀÕÓ¼ø Ý¼¡Ìõ 
 ¿¢ò¾Á¡ Ó¸õ§¿÷ Å¢Æ¢ ¿¡×Àø 
 Óò¾ ¿£Õ ÓÂ÷ó¾ º¢ÅôÀ¡Ìõ 
 Íò¾ ÁïºÇ¡öò §¾¡ýÈ¢¼ì ¸ñÊ§¼" 
    - þÃò¾¢Éî ÍÕì¸¿¡Ê 
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Derangement of Valiazhal naadi produces symptoms of Kalladaippu, 
"¦À¡ÕÇ¡É Å¡¾ò¾¢ø À¢ò¾ï §º÷óÐ 
 ¦À¡ÕóÐ Ì½í¸Ç¡ Ó‰½Å¡Ô ºò¾¢ 
¦ºÃ¢Â¡¨Á ÒÇ¢ò§¾ôÀõ ¦À¡ÕÁø ¿£Ã¢ü 
 º¢ÅôÒÁÄõ À¢Êò¾ÖÕó ¾¡Ð ¿ð¼õ" 
    - º¾¸ ¿¡Ê 
 
ŠÀÃ¢ºõ (Touch) 
 By sparism the temperature of skin (thatpam - cold or veppam - heat), 
sweating, dryness, smoothness, roughness, hard patches, swelling, abnormal growth 
of organs and tenderness can be felt. 
 In kalladaippu patients tenderness over the lower abdomen, lumbar region, 
renal angle and swelling can be felt (may be due to hydronephrosis). The patient‟s 
temperature is also increased in lower abdomen and sweating all over the body at the 
time of colic. 
¿¡ (Tongue) 
 By the examination of the tongue its colour, size, coating, moisture, ulcer, 
fissure, crust, movement and condition of teeth and gums can be examined. In 
kalladaippu if there were constipation, the tongue would seem to be coated. Loss of 
taste in Karuneer kalladaippu. 
"¸Õ¿£÷ì¸øÄ¢ý ÅÇ¢ º¢Éó¦¾ØóÐ 
Í¨Å¦¸¼ø ¦ÅÇ¢Ú ÁÚôÒ ¿£÷§Åð¨¸" 
    - §¿¡ö Å¢Çì¸õ 
¿¢Èõ (Colour) 
 Colour of the skin, conjunctiva, tongue, nail bed and hair etc. 
 Vali udal - Black colour 
 Azhal udal- Yellow or red colour 
 Iyya udal - White colour 
¦Á¡Æ¢ (Speech) 
 By examining mozhi (speech), characters, hoarseness, slurring speech and 
various disorders of speech such as dysarthria can be noted. In kalladaippu there is 
low pitch voice due to agonizing pain in lower abdomen and burning sensation. 
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Å¢Æ¢ (Eye) 
 Examine the colours of eye like reddish or yellowish discoloration and 
characters like dryness and lacrimation. Tiredness and redness due to pain is observed 
in patients with renal colic. In addition one has to be examine the patients acquit; 
there may be pallor of eyes due to gross haematuria. 
ÁÄõ (Stool) 
 By examining Malam, its nature, colour, quantity and presence of blood or pus 
can be noted. 
¿£÷ìÌÈ¢ (Urine examination) 
 Urine examination is good diagnosis method compare to other Envagai 
thervugal. Theraiyar mentions below as 
 ¿£÷ÌÈ¢î º¢ÈôÒ 
"¾÷ì¸º¡ò ¾¢Ã¢¸ Ç¡§É¡÷ 
 ¾í¸Ç¢ü §È÷óÐ ¿¡Ê 
Å÷ì¸Á¡õ ¿¡Ê ¾ýÉ¢ø 
 ÅÕÅÐ ÁÂì¸ ¦Áý§È 
¯üÈ¿£÷ô ÀÃ£¨‡ Â¡öó§¾ 
 Ô¨Ãò¾É Ã¢¾üÌ §¿Ã¡ö 
Áü¦È¡Õ Å¢¾¢á Ä¢ø¨Ä 
 ÁÕòÐÅì ¸¨ÄÅø§Ä¡÷ì§¸" 
   - º¢ò¾ ÁÕòÐÅ¡í¸î ÍÕì¸õ 
 Siruneer should be collected in early morning, patient should be eating six 
tastes of food with regular time and well sleeping overnight, urine should be examine 
within 3 3/4hrs. This is quoted as 
"«ÕóÐÁ¡ È¢Ã¾Óõ «Å¢§Ã¡ ¾Á¾¡ö 
«·¸ø «Ä÷¾ø «¸¡Äçñ ¾Å¢÷ó¾Æü 
ÌüÈÇ ÅÕó¾¢ ¯Èí¸¢ ¨Å¸¨È 
¬Êì ¸Äºò ¾¡Å¢§Â ¸¡Ð¦Àö 
¦¾¡ÕÓÜ÷ò ¾ì¸¨Äì ÌðÀÎ ¿£Ã¢ý 
¿¢ÈìÌÈ¢ ¦¿öìÌÈ¢ ¿¢ÕÁ¢ò¾ø ¸¼§É" 
   - º¢ò¾ ÁÕòÐÅ¡í¸î ÍÕì¸õ 
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º¢Ú¿£Ã¢ý ¦À¡Ðì Ì½õ 
"Åó¾¿£÷ì ¸Ã¢¦Â¨¼ Á½õ Ñ¨Ã ±ïº¦Äý 
¨Èó¾¢Â ÖÇ¨Å Â¨ÈÌÐ Ó¨È§Â" 
   - º¢ò¾ ÁÕòÐÅ¡í¸î ÍÕì¸õ 
1. ¿¢Èõ(Colour) 
2. ±¨¼(Specific gravity) 
3. ¿¡üÈõ(Smell) 
4. Ñ¨Ã(Froth) 
5. ±ïºø(Deposits) 
 
Above the five parameters by which each urine sample should be examined. 
¿¢Èõ (COLOUR) 
"À£¾õ ¦ºõ¨Á¨Àí ¸Õ¨Á ¦Åñ¨Á¦Âý 
§È¡¨¾í ¦¸¡Ø¨Á¨Â ¦Â¡òÐÌ ¿£§Ã" 
   - º¢ò¾ ÁÕòÐÅ¡í¸î ÍÕì¸õ 
1. Yellow 
2. Red 
3. Green 
4. Black 
5. White 
Urine may be any colour mentioned above. 
 
¸øÄ¨¼ôÒ ¿£Ã¢ý Ì½õ (Colour Indicating Renal stones) 
 The urine colour would look like flesh washing water; this is indicated in 
kidney diseases. 
"¾£ôÒÄ¡ø ¸Ø¿£÷î ¦ºÂ¦ÄÉ¢ü ÌñÊì 
 ¸¡öòÐ÷ô ÀÄò¾¡ø ¸¾¢ò¾ ¿£Ã¡Áò 
Ð÷ôÀÄì ¸ÀÓõ §º¡Ã¢Ôõ ¦¸¡¾¢ôÒÈô 
 ÀüÀ¸ Ä¡¸ô ¨ÀÂô À¾¢ó¾§¾" 
   - º¢ò¾ ÁÕòÐÅ¡í¸î ÍÕì¸õ 
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±¨¼ (SPECIFIC GRAVITY) 
 No thickness in urine is considered to be healthy. 
"Á¢¸ò¾Êô ÒõÁ¢¸ò §¾ÈÖõ þý¦ÈÉ¢ø 
Í¸ò¨¾ò ¾Õõ¦Áöî ÍÀ¡Å¿£÷ ¿ý§È" 
   - º¢ò¾ ÁÕòÐÅ¡í¸î ÍÕì¸õ 
 
 
Ñ¨Ã (FROTH) 
"Àó¾¦Áöô À¨ºÂ¢Ç ¸ôÀÎõ ÀÕÅò 
¾ó¾÷ô â¾Á¡ö «É¢Äãò ¾¢Ãò¾¢ø 
ºõÀó¾ô ÀÎõ ¾¾¢Ñ¨Ãô ÒÉ§Ä" 
   - º¢ò¾ ÁÕòÐÅ¡í¸î ÍÕì¸õ 
 Urine may be frothy in nature. If it is reduced, vali, azhal and iyyam are said 
to be deranged. 
 
 
¿¡üÈõ (SMELL) 
   Á½Å¢Äì¸½õ 
"µ¾Á½ò §¾¡¼ù §Å¡¾¦Á¡ò ¾¢ÈíÌõ 
 º£¾Çí ¸õÁ¢Â §¾¸¢¸ Ùì§¸" 
- º¢ò¾ ÁÕòÐÅ¡í¸î ÍÕì¸õ 
 
"¸¡¾¢½¢ø º£Øí ¸Äó¾¢Æ¢ Á½ÓÈ¢ý 
¸ÕôÀ ¿¡À¢¸Ù Ùí ¸¡Á ¿¡ÇòÐÙõ 
Å¢Ã½Óý Êý§Èø ±öÐ¸ø ÁÈ¢ÂÄ 
¾¢Õò¾§Ä ¾¢ñ½ ¦ÁÉÁÉò Ðý§É". 
                      - º¢ò¾ ÁÕòÐÅ¡í¸î ÍÕì¸õ 
      The presence of pus of an obnoxious odour suggests infections and ulcer of the 
genitalia. This also occurs in renal calculi. 
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±ïºø (DEPOSIT) 
 If urine excretion look like curd water, milk and sand like deposits in urine 
indicate stones in kidney. This is mentioned as follows, 
"¿¡÷ò¾¾¢ ¿£÷À¡ø §À¡Ä 
 ¿¨ÅÔüÈí ¸¢Æ¢Ô Á¡É¡ø 
Á¡ÃüÀ ÓüÈ ¿£Ã¢ 
 ÄÊÁñÊì ¸¢¼ó¾ ¾¡É¡ø 
À¡Ã¢ó¾ ¦ÁØÌ Á¡í¸¡ö 
 ÀüÈ¢Â ¸øÄ¢ É¡§Ä 
º£ÕüÈ ¦ºö¨¸ ¦ÂýÚ 
 ¦¾Ã¢×Èî ¦ºôÀ Ä¡§Á" 
   - º¢ò¾ ÁÕòÐÅ¡í¸î ÍÕì¸õ 
¦¿öìÌÈ¢ 
 The urine is kept in a bowl; a drop of oil gently with rod is dropped at the 
centre of urine bowl without any shake. It should be ensure that the sunlight falls on 
it, but is not disturbed by the wind. A keep observation of the oil drop suggests the 
condition of the patient.  
 
¿¢ÈìÌÈ¢ì ÌÃò¾ ¿¢ÕÁ¡½ ¿£Ã¢ü 
º¢Èì¸ ¦Åñ¦½ö§Â¡÷ º¢ÚÐÇ¢ ¿ÎÅ¢Îò 
¦¾ýÚÈò ¾¢Èó¦¾¡Ä¢ ²¸¡¾¨Áò¾¾¢ 
É¢ýÈ¾¢Å¨Ä §À¡õ ¦¿È¢Å¢Æ¢ÂÈ¢×õ 
¦ºýÈÐ Ò¸Öï ¦ºö¾¢¨Â Ô½§Ã 
- º¢ò¾ ÁÕòÐÅ¡í¸î ÍÕì¸õ 
If oil spreads like the shape of snake it indicates Vali neer, a ring indicates Azhal neer, 
if it stands like a pearl it indicates Iyya neer and sinks in urine indicates Mukkutram. 
 
"«Ã¦ÅÉ ¿£ñÊÊý «·§¾ Å¡¾õ" 
"¬Æ¢§À¡ü ÀÃÅ¢ý «·§¾ À¢ò¾õ" 
"Óò¦¾¡òÐ ¿¢ü¸¢ý ¦Á¡Æ¢Å¦¾ý ¸À§Á" 
   - º¢ò¾ ÁÕòÐÅ¡í¸î ÍÕì¸õ 
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¾£Õõ ¾£Ã¡¾¨Å (PROGNOSIS) 
“ÝðÊð¼ º¡ò¾¢Âò¨¾î ¦º¡øÄì §¸Ç¡ö 
    ÍÙì¸¡Ìõ Å¡¾ò¾¢ý ¸øÄ ¨¼ôÒ 
âðÊð¼ À¢ò¾ò¾¢ý ¸øÄ ¨¼ôÒ 
    Ò¸Æ¡É º¢§ÄðÎÁò¾¢ý ¸øÄ ¨¼ôÒ 
ãðÊð¼  þÐãýÚõ º¡ò¾¢Â Á¡¸¢ 
    Ó¨ÉÂ¡É ÁÕóÐ¸Ç¢ü ¦ºõ¨Á Â¡Ìõ 
§¾¡ðÊð¼ ¦¾¡ó¾Á¡í ¸øÄ ¨¼ôÒò 
    ¦¾¡ÎÍÈ§Å ¦¸¡øÖÁ¢Ð Ýðºó ¾¡§É” 
    - ä¸¢ ¨Åò¾¢Âº¢ó¾¡Á½¢. 
  
According to Yougi mamunivar, vali, azhal and iyya kalladaippu are curable 
whereas mukkutra kalladaippu is incurable. 
 
 
ÁÕòÐÅõ (LINE OF TREATMENT) 
"¨Åò¾¢Âî ¦ºÂø ¨Åò¾¢Â§Á" 
   - ¾¢ÕãÄ÷ 800 
 
The author of dissertation has selected trial drug Karpoora Silasathu Parpam, dose 
of 130mgs two times per day with Radish juice for 48 days. 
 In siddha system, treatment is not only for removable of disease but also the 
prevention and improving the body condition after removal of disease. This is said as 
kaappu, neekkam and thiraippu. 
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DIET 
 All patients are strictly advised to follow the following diet restriction. All the 
kalladaippu patients in this trial should avoid highly calcium and oxalate diet like,  
 
 
 
 
 
 
 
OXALATE FOODS LIKE CALCIUM FOODS LIKE 
 
 Spinach 
 Beans 
 Green pepper 
 Salt 
 lots of meat 
 soft drinks 
 cocoa 
 tea 
 
 Cabbage 
 cauliflower 
 Tomato 
 peanuts 
 Cashew nuts 
 Almond 
 Grapes 
 strawberry 
 
 milk 
 buttermilk 
 curd 
 butter 
 cheese 
 
 
 
 
 panneer 
 milkgova 
 chocolates 
 fish 
 egg 
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According to Siddha Maruthuvam  
§º÷ì¸§ÅñÊÂ¨Å: 
 ¿¡û ´ýÚìÌ 2 Ó¾ø 3 Ä¢ð¼÷ Å¨Ã ¾ñ½£÷ «Õó¾ 
§ÅñÎõ. 
 À¡÷Ä¢ «Ã¢º¢ì ¸ïº¢, ¿ýÉ¡Ã¢ §Å÷ìÌÊ¿£÷, þÇ¿£÷ ¬¸¢Â¨Å 
§º÷ì¸ §ÅñÎõ. 
 
¸¡ö¸û: ÓûÇí¸¢, «Å¨Ã, ¦Åñ¨¼, Í¨Ãì¸¡ö, ¦Åñâº½¢, ¸£¨Ãò¾ñÎ,  
Å¡¨Æò¾ñÎ, §¸Ãð, À£÷ì¸í¸¡ö.  
 
¸£¨Ã¸û: º¢Ú¸£¨Ã, ¾¡Ç¢ì¸£¨Ã, ¸¡º¢É¢ì¸£¨Ã, Ò¾¢É¡ì¸£¨Ã, ¸Õ§ÅôÀ¢¨Ä  
 
ÀÆí¸û: ¾÷âº½¢, ¦ÅûÇÃ¢ôÀ¢ïÍ, «ýÉ¡º¢ôÀÆõ, ÀôÀ¡Ç¢, Å¡¨ÆôÀÆõ, 
±ÖÁ¢î¨º  
 
¾¡É¢Âí¸û: ¸¼¨ÄôÀÕôÒ. ¯ÙóÐ, À¡º¢ôÀÂÚ, ¯Ä÷ó¾ Àð¼¡½¢  
 
¾Å¢÷ì¸ §ÅñÊÂ¨Å: 
 ¾ì¸¡Ç¢        Óð¨¼ì§¸¡Í     ¸¡Ç¢À¢ÇÅ÷            
 Á£ý             Óð¨¼           Á¡Á¢º ¯½× 
 ¸¡Ç¡ý¸û      ¸£¨Ã¸û           ÓÕí¨¸ì¸¡ö   
 ¾¢Ã¡ð¨º        ŠðÃ¡¦À÷Ã¢        º¡ì§Äð              
 ÁÐÀ¡Éõ        ¸¡À¢/Ë             º¨ÁÂø§º¡¼¡                           
 Ò¨¸Â¢¨Ä       ÒÇ¢                ¦ÅüÈ¢¨Ä/À¡ìÌ        
 
 À¾ôÀÎò¾ôÀð¼ ÌÇ¢÷ À¡Éí¸û 
 ¯ôÒ ¿¢¨Èó¾ ¯½×¸û ÁüÚõ ¿£÷  
 À¡Ä¢ø ¾Â¡Ã¢ì¸ôÀð¼ ¯½× Å¨¸¸û  
 ¦À¡Ã¢ì¸ôÀð¼ ÁüÚõ Áº¡Ä¡ §º÷ó¾ ¯½× Å¨¸¸û.  
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RENAL CALCULUS 
           
ANATOMY OF THE KIDNEY 
              The Kidneys are a pair of the major excretory organ in the body. Each kidney 
is bean shaped situated on the posterior abdominal wall, on either side of the lumbar 
vertebral column. The left kidney is a little longer and narrower than the right kidney. 
Each kidney weighs about 120 to150gms. It is a compound tubular gland covered by a 
connective tissue capsule. There is a depression on the medial border of kidney called 
hilum, through which renal artery, renal veins, nerves and ureter pass. The 
components of kidney arranged in three layers. 
1. Outer Cortex 
 This is dark and granular in appearance. It contains renal corpuscles and 
convoluted tubules.  At intervals, cortical tissue penetrates medulla in this form of 
columns which are called renal columns or columns of Bertini. 
2. Inner Medulla 
 This gives radially striated appearance as it contains tubular and vascular 
structures. Medullary mass is divided into 8 to 18 medullary or malpighian pyramids. 
Broad base of each pyramid is in contact with cortex and the apex projects into minor 
calyx. 
3. Renal Sinus 
 It consists of the following structures; 
 Upper expanded part of ureter called renal pelvis. 
 Subdivisions of pelvis - 2 or 3 major calyces and 8 minor calyces. 
 Branches of nerves and arteries and tributaries of veins. 
 Loose connective tissues and fat. 
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KIDNEY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
37 
 
 NEPHRON  
  Nephron is defined as the Structural and functional unit of the kidney. Each 
kidney has a million nephrons. Each nephron is formed by two parts called renal 
corpuscle or malpighian corpuscle and renal tubule. Each nephron begins in cortex as 
a funnel like 
dilatation called the Bowman‟s capsule, which encloses a tuft of capillaries, the 
glomerulus. The Bowman‟s capsule together with glomerulus is called the Renal 
corpuscle.  
              The renal tubule leaves the Bowman‟s capsules and becomes convoluted to 
form the proximal convoluted tubule (PCT). It then becomes straight and passes down 
the medulla as the descending limb of the loop of Henle, after varying distances 
before reaching the end of the papilla, it turns round in the form of U-shaped bend, 
forming loop of Henle, and passes upwards towards the cortex, parallel with its 
former course as the ascending limb of the loop of Henle.Each limb has an outer thick 
and inner thin portion. 
 Thick ascending limb approaches its own, glomerulus, and contact with the 
afferent and efferent arterioles to form the juxtaglomerular apparatus. It then becomes 
convoluted to form the distal convoluted tubule (DCT). The DCT then straightens out 
and joins by short connecting ducts to form the collecting tubules or collecting ducts 
(CD). They unit to form larger collecting ducts and descend parallel to loop of Henle 
and open in the papilla or the duct of Bellini in the renal pelvis. The length of the 
nephron varies from 4 to 6.5cms. 
RENAL CIRCULATION 
 
 Renal artery arises from the abdominalaorta, enters the kidney through the 
hilus and divided into an anterior and a posterior branch, which gives rise to about 
five segmental arteries. The segmental artery divided into interlobar arteries, which 
pass outward in the medulla between the pyramids to reach boundary zone between 
the medulla and cortex. Here they turn to take a horizontal course uniting with 
adjacent arteries to form arterial arches called arcuate arteries. Several straight arteries 
arise from these arches and run radially outward through the cortex. These are called 
interlobular arteries. From each interlobular artery, numerous afferent arteries arise, 
and enter the Bowman‟s capsule forming glomerular capillary tuft. The afferent 
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arterioles divide into 4 to 5 large capillaries, which form the loop, and capillary loop 
unite to form the efferent arteriole, which leaves the Bowman‟s capsule. 
 The efferent arterioles give rise to renal portal system. The efferent arterioles 
form a second capillary network surrounding the tubular portion of the nephron; the 
capillaries of second set are called peritubular capillaries. Thus the renal circulation 
forms a portal system by the presence of two sets of capillaries – glomerular 
capillaries and peritubular capillaries. 
 The tubular portion of juxtamedullary nephrons are supplied by some 
specialized capillaries called vasa recta.Vasa recta arise directly from the efferent 
arteriole of the juxtamedullary nephrons. The peritubular capillaries and vasa recta 
drain into the venous system, which include the peritubular venules, interlobular 
veins, arcuate veins, interlobar veins, segmental vein and finally the renal vein. Renal 
vein leaves the kidney through the hilus and join the inferior vena cava. 
NEPHRON
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URINE FORMATION 
 Kidney excretes the unwanted substances along with water and urine includes 
metabolic end products and those substances, which are present in excessive 
quantities in the body, through urine. Normally about 1 to 1.5 liters of urine is formed 
every day. The urine formation includes the following three processes: 
 1. Glomerular filteration 
 2. Tubular reabsorption 
 3. Tubular secretion 
 GLOMERULAR FILTERATION 
 When blood passes through the glomerular capillaries the plasma is filtered 
into the Bowman‟s capsule. All the substances of plasma are filtered except plasma 
proteins. The filtered fluid is called glomerular filtrate. During filtration the 
substances passes through the three layer of filtrating membrane such as, 
 1. The glomerular capillary membrane 
 2. Basement membrane  
 3. Endothelium of visceral layer of Bowmen‟s capsule. 
 The glomerular filtration is called ultrafiltration because even the minute 
particles are filtered, but the plasma proteins are not filtered due to larger molecular 
size than the size of the slit pores present in the endothelium of capillaries. The 
composition of glomerular filtrate is similar to that of plasma except in the absence of 
plasma proteins. 
 
GLOMERULAR FILTRATE RATE (GFR) 
 
 The total quantity of filtrate formed in all the nephron of both the kidneys in 
the given unit of time is called glomerular filtrate rate. The normal value of 
glomerular filtrate rate is 125ml/ minute or about 180liters/day. 
FILTRATION FRACTION 
 
 The fraction of the renal plasma, which becomes the filtrate is called filtration 
fraction. It is the ratio between renal plasma flow and glomerular filtration rate. It is 
expressed in percentage, as follows, 
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  Filtration fraction =     GFR   x 100 
        Renal plasma flow 
 
=    125ml/minute   x 100 
          650ml/minute 
          =    19.2% 
The normal filtration fraction values from 15 to 20% 
   
PRESSURES DETERMINING FILTRATION 
       Glomerular capillary pressure, colloidal osmotic pressure in the glomeruli 
and the hydrostatic pressure in the Bowman‟s capsule, which are determine the GFR. 
Among these pressures, the glomerular capillary pressure favors filtration the 
glomerular capillary pressure, is about 60mmHg and is the highest capillary pressure 
in the body. The colloidal osmotic pressure and hydrostatic pressure oppose the 
filtration. The colloidal osmotic pressure exerted by plasma protein in the glomeruli. 
The plasma proteins are not filtered through the glomerular capillaries, so increased 
concentration of proteins in glomerulus during filtration causes the development of 
colloidal osmotic pressure. It is about 25mmHg. Hydrostatic pressure in Bowman‟s 
capsule is exerted by the filtrate in Bowman‟s capsule during filtration. It is about 
15mmHg. 
NET FILTRATION PRESSURE 
 The balance between pressure favoring filtration and pressures opposing 
filtration is called net filtration pressure. It is very essential for the maintenance of 
GFR, so this is otherwise known as effective filtration pressure of essential filtration 
pressure. 
The net filtration pressure = Glomerular capillary pressure – colloidal osmotic 
pressure + Hydrostatic pressure in Bowman‟s capsule 
      = 60 – (25+15) 
      = 20mmHg 
 The normal net filtration pressure is about 20mmHg and it varies between 15 
to 20mmHg. 
 
 
 
 
41 
 
FILTRATION COEFFICIENT 
          It is the GFR per mmHg of net filtration pressure.  
The filtration coefficient      =         125ml 
                                                     20mmHg 
                                            = 6.25ml/mmHg 
FACTORS REGULATING GFR 
 Following are the various factors, which regulate or affect the GFR 
1. Renal blood flow 
              This is the most important factor necessary for glomerular filtration.  GFR is 
directly proportional to renal blood flow. Normal blood flow to both the kidneys is 
1300ml minute. The renal blood flow is controlled by autoregulation. 
2. Tubulo glomerular feedback mechanism 
 This is the process in which the GFR is constantly regulated by means of feed 
back from renal tubule. The macula densa of juxtaglomerular apparatus is responsible 
for this. When the glomerular filtrate passes through the end portion of thick 
ascending segment of renal tubule, the macula densa detects the concentration of 
sodium chloride and accordingly alters the GFR. If the concentration of sodium 
chloride is more, macula densa causes constriction of afferent arteriole and filtration 
rate decreases, the constriction of afferent arteriole may be due to the secretion of 
thromboxane A2 from macula densa. 
 
3. Glomerular capillary pressure 
   The GFR is directly proportional to glomerular capillary pressure. When 
glomerular capillary pressure is increased the GFR is also increased, in turn depends 
upon the renal blood flow and arterial blood pressure. Normal glomerular capillary 
pressure is 60mmHg. 
4. Colloidal osmotic pressure 
 The GFR is inversely proportional to colloidal osmotic pressure exerted by 
protein. During dehydration or increased plasma protein level, colloidal osmotic 
pressure is more and GFR is reduced. Normal colloidal osmotic pressure is 25mmHg. 
5. Hydrostatic pressure in Bowman‟s capsule 
 The GFR is inversely proportional to this. The hydrostatic pressure in 
Bowman‟s capsule is increased in conditions like obstruction of urethra and edema of 
kidney beneath renal capsule. Normally it is 15mmHg. 
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6. Constriction of afferent arteriole 
 This reduces the blood flow to the glomerular capillaries and this in turn 
reduces GFR. 
7. Constriction of efferent arteriole 
 If the efferent arteriole is constricted initially there is an increase in GFR 
because of stagnation of blood in the capillaries. 
8. Systemic arterial pressure 
 However, increase in mean arteriole pressure upto 180mmHg or reduction 
upto 60mmHg does not alter renal blood flow or GFR. This is due to autoregulatory 
mechanism. Variation in pressure above 180mmHg or below 60mmHg affects the 
renal blood flow and GFR because auto-regulating mechanism fails beyond this 
range. 
9. Sympathetic stimulation 
 The mild or moderate stimulation of sympathetic nerves does not causes any 
significant change either in renal blood flow or in GFR. This is due to auto regulation. 
Strong sympathetic stimulation causes severe constriction of the blood vessels needs 
to increase filtration initially, but later decreases.however, if the stimulation is 
continued for more than 30 minutes, there is recovery of both renal blood flow and 
GFR. It is because of reduction in sympathetic neurotransmitter.  
10. Surface area of capillary membrane 
 GFR is directly proportional to the surface area of the capillary membrane. If 
the glomerular capillary membrane is affected as in the case of some renal diseases, 
the surface area for filtration decreases. So, there is reduction in GFR. 
11. Permeability of capillary membrane 
               GFR is directly proportional to the permeability of glomerular capillary 
membrane. 
12. Contraction of glomerular mesangial cells 
            Contraction of these cells decreases surface area of capillaries resulting in 
reduction of GFR. 
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TUBULAR REABSORPTION 
             Tubular reabsorption is the process by which water and other substances are 
transported from renal tubules back to the blood. When the glomerular filtrate flows 
through the tubular portion of nephron, both quantitative and qualitative changes 
occur. The tubular epithelial cells reabsorb large quantity of water, electrolytes and 
other substances. The substances, which are reabsorbed, pass into the interstitial fluid 
of renal medulla, and from here, the substances move into the blood in peritubular 
capillaries. As the substances are taken back into the blood, the entire process is called 
tubular reabsorption. 
Selective reabsorption 
 The tubular cells of kidney selectively reabsorb the substances present in the 
glomerular filtrate, according to the needs of the body. So the tubular reabsorption is 
called the selective absorption.  
 
MECHANISM OF REABSORPTION 
The mechanisms involved in tubular reabsorption are of two types 
  1. Active reabsorption 
  2. Passive reabsorption 
 
1. Active Reabsorption 
    The movement of molecules is against the electrochemical gradient. This 
needs liberation of energy and the energy is derived from ATP. The substances 
reabsorbed actively from the renal tubule are sodium, calcium, potassium, phosphates, 
sulphates, bicarbonates, glucose, amino acids, ascorbic acid, uric acid and ketone 
bodies. 
 
2. Passive Reabsorption 
     In this process, the movement of molecules is more along the 
electrochemical gradients. This process does not need energy; the substances 
reabsorbed by passive transport are chloride, urea and water. 
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Site of Reabsorption 
     Substances reabsorbed from proximal convoluted tubule are glucose, amino 
acids, sodium, potassium, calcium, bicarbonates, chlorides, phosphates, uric acid and 
water. The substances reabsorbed from loop of Henle are sodium and chloride. The 
substances reabsorbed from distal convoluted tubule are sodium, calcium, bicarbonate 
and water. 
 
REGULATION OF TUBULAR REABSORPTION 
 
           Tubular Reabsorption is regulated by three factors. 
1. Glomerulotubular balance 
2. Hormonal factors 
3. Nervous factors 
GLOMERULOTUBULAR BALANCE 
 
              When GFR increases, the tubular load of solutes and water in the proximal 
convoluted tubule is increased.  It is followed by increase in the reabsorption of 
solutes and water.  
 
HORMONAL FACTORS 
 
           Several hormones are increases or decreases sodium reabsorption in structure 
of nephron. 
NERVOUS FACTORS 
           Activation of sympathetic nervous system increases the tubular reabsorption 
from renal tubules indirectly by stimulation of renin from the juxtaglomerular cell. 
THRESHOLD SUBSTANCES 
             Depending upon the degree of reabsorption, the various substances are 
classified into three categories. 
1. High threshold substances 
 The food substances like glucose, amino acid, acetoacetate ions and vitamins 
are completely reabsorbed do not appear in urine under normal condition. These 
substances can appear in urine, only if their concentration in plasma is abnormally 
high or in renal diseases. So these substances are called high threshold substances. 
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2. Low threshold substances 
 The substances such as urea, uric acid and phosphate are reabsorbed to little 
extend. These substances appear in urine even under normal conditions. Such 
substances are known as low threshold substances. 
 
3. Non- threshold substances 
 The metabolic end products like creatinine are not at all reabsorbed and are 
excreted in urine irrespective of their plasma level. These substances are called non-
threshold substances. 
 
MECHANISM OF REABSORPTION  
 
TUBULAR SECRETION 
Tubular secretion is the process by which the substances are transported from 
blood into renal tubules. Some substances secrete into the lumen from the peritubular 
capillaries through the tubular epithelial cells. These known as tubular secretion or 
tubular excretion. 
1. Potassium is secreted actively by sodium – potassium pump in distal 
convoluted tubules and collecting ducts. 
2. Ammonia is secreted in the proximal convoluted tubule. 
3. Hydrogen ions are secreted in the proximal and distal convoluted tubules. 
Maximum hydrogen ion is secreted in proximal tubule. 
 
Thus by the process of glomerular filtration, selective reabsorption and tubular 
secretion urine is formed in the nephron. It is also concentrated by counter current 
mechanism and anti- diuretic hormone. Finally it passes through the ureter into the 
urinary bladder and is stored there until it is voided out. 
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RENAL CALCULUS 
 
                         Renal calculi are formed by deposits of polycrystalline aggregates 
composed of varied amounts of crystalloid and organic matrix. They can vary in size 
and may be found anywhere in the urinary tract from the kidney to the bladder. 
Urinary stones have afflicted humans for centuries; the first reported cases are of 
bladder and renal calculi found in Egyptian mummies dated 4800BC. 
 
EPIDEMIOLOGY 
INTRINSIC FACTORS 
AGE AND SEX  
          The peak incidence of renal calculi occurs between 20 and 40 years of age. 
Males are affected 3 times as frequently as females. Testosterone may cause increased 
oxalate production in the liver (predisposing to calcium oxalate stones) and women 
have higher urinary citrate concentrations (citrate inhibits calcium oxalate stone 
formation). Renal Stones in childhood are usually predisposed to by urinary 
infections, a metabolic defect or an anatomical abnormality.  
GENETIC  
          Approximately 25% of patients with renal stones have a family history of stone 
disease and it is possible that urolithiasis is a polygenic defect with partial penetrance. 
Several disorders that have a clear genetic basis do predispose to stone formation 
(renal tubular acidosis, cystinuria, xanthinuria). 
 
                                                   EXTRINSIC FACTORS 
GEOGRAPHY  
         The prevalence of renal calculi disease is highest among those living in 
mountainous regions, deserts and tropical areas. However the capability of individuals 
to carry their stone risk from area to area suggests that the major tendency to stone 
formation resides in the individual.  
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CLIMACTIC AND SEASONAL FACTORS  
            There is an association between stone formation and environmental 
temperature with stone formation being more common in the summer months.  
This tendency may be due to relative dehydration and the subsequent 
production of concentrated, acidic urine. Alternatively some workers suggest the 
increased exposure to sunshine leads to increased urinary calcium excretion via the 
increased production of vitamin D leading to hypercalciuria. 
            Ureteric stones become more prevalent during the summer, the highest 
incidence occurring a month or so after peak summertime temperatures, presumably 
because of higher urinary concentration in the summer (encourages crystallization). 
Concentrated urine has a lower pH, encouraging cystine and uric acid stone 
formation. 
OCCUPATION 
            Sedentary occupations predispose to stones compared with manual 
workers.The risk of calcium oxalate and uric acid stones formation in Astronauts 
because of hypercalciuria, hypocitraturia, decreased pH and lower urinary volumes. 
WATER INTAKE 
             Low fluid intake (<1200ml/day) predisposes to stone formation. Increasing 
water hardness (high calcium content) may reduce risk of stone formation, by 
decreasing urinary oxalate. 
DIET  
           The dietary intake of certain food and fluid substances that lead to a higher 
urinary excretion of substrates that form stones increases the incidence of calculi. A 
high intake f oxalates, calcium, phosphates and other elements often lead to an excess 
excretion of them in urine. 
             High intake of animal protein causes high urinary oxalate, low pH, low 
urinary citrate, and High salt intake causes hypercalciuria.  However, a reduced 
calcium diet can increase the risks of further stone formation. It is therefore important 
that the diet is balanced and a relative excess or total abstinence of these constituents 
is avoided. 
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PHYSICAL CHEMISTRY 
                     Urinary stones occur when offending salt crystallises in the urine and 
this occurs when the urine is supersaturated with the substance. Calcium and oxalate 
crystallisation can be modified by the presence of so-called urinary inhibitors i.e. 
citrate, magnesium.  
                     The earliest phase of crystal formation is known as nucleation. Crystal 
nuclei usually form on the surfaces of epithelial cells or on other crystals. Crystal 
nuclei form into clumps a process known as aggregation. Citrate and magnesium not 
only inhibit crystallization but also inhibit aggregation.These include other inhibitors 
of crystallisation, and aggregation namely pyrophosphate, glyosaminoglycans, 
nephrocalcin and Tamm Horsfall proteins.  
                      Crystal aggregation and retention are necessary to lead to stone 
formation and therefore anatomical abnormalities such as medullary sponge kidney, 
pelviureteric junction obstruction and calyceal diverticulae increase the risk of stone 
formation.  
                       Bacterial infection is well known to predispose to stone formation by 
alteration of urinary PH, production of urease and perhaps by increasing urinary 
matrix production. Finally, abnormal intra and inter cellular calcium transport may 
lead to crystal retention in the tubules acting as foci for crystal aggregation, retention 
and eventual stone formation.  
Urinary supersarturation  
↓ 
Crystallization 
 
     Nucleation, growth, aggregation 
                             Renal tubular injury → ↓ 
Crystal–cell interaction 
↓ 
Crystal growth, crystal aggregation 
↓ 
Stone formation 
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TYPES OF CALCULUS 
      Basically the renal stones can be divided into two major groups 
I. Primary stones 
II. Secondary stones. 
 
(I) PRIMARY STONES 
            They appear in apparently healthy urinary tract without any antecedent  
inflammation. 
(a)   Calcium oxalate 
(b)  Uric acid calculi 
(c)   Cystine calculi 
(d)  Xanthine calculi 
(e)   Indigo calculi 
                  (f)  Struvitecalculi 
 
(II) SECONDARY STONES 
            They are usually formed as the result of inflammation. 
(a) Triple phosphate calculus 
(b)  Mixed stones 
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CALCIUM OXALATE STONES 
 
              Calcium oxalate stones are the most frequent renal stones containing 70–75% 
with Dumbbell shape. It develops as a multifactorial process in which an imbalance 
between crystallization - driving and - inhibiting forces plays a fundamental role. So 
are most certainly also sub epithelial calcifications (Randall‟s plaques), and it is of 
note that a large fraction of calcium oxalate containing stones also contain calcium 
phosphate.  
 
Calcium oxalate occurs in two different forms 
 
             Calcium oxalate monohydrate (COM) is compact and of brown or black 
color, varies in size and may have a spindle, oval, or dumbbell shape its formation is 
favored by high urinary oxalate concentrations. 
 
      High concentrations of calcium and magnesium result in Calcium oxalate 
dehydrate (COD) stone formation. These crystals are varying in size, colourless 
squares whose corners are connected by intersecting lines. They can occur in urine of 
any pH.  The recurrence risk is considered higher for COD than for COM stones.  
  
            Crystals of calcium oxalate form in supersaturated urine and then become 
anchored on the urothelium of the renal pelvis. Biochemical abnormalities that create 
supersaturation of the urine with respect to either calcium oxalate or calcium 
phosphate include hypercalciuria, hypocitraturia, hyperoxaluria, and hyperuricosuria. 
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SITE OF CALCULUS 
 
 
 
 
 
URETERIC CALCULUS 
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PATHOPHYSIOLOGY OF STONE FORMATION 
I. HYPERCALCIURIA 
             Hypercalciuria, or excessive urinary calcium excretion, occurs in about 5-
10% of the population. It can be found in as many as 60% of all calcium stone 
patients. It is defined as urinary excretion of more than 250 mg of calcium per day in 
women or more than 275-300 mg of calcium per day in men while on a regular 
unrestricted diet. It can also be defined as the excretion of urinary calcium in excess 
of 4 mg/kg of body weight per day or as a urinary concentration of more than 200 mg 
of calcium per liter. 
            An alternate definition of hypercalciuria is daily urinary excretion of more 
than 3 mg of calcium per kilogram of body weight or more than 200 mg of calcium 
per day while on a restricted (400 mg calcium and 100 milliequivalent [mEq] sodium) 
diet. 
             The mechanism resulting in precipitation and growth of calcium crystals in 
the urinary tract are multiple and not fully understood hypercalciuria is recognized as 
an important and reversible risk factor in stone formation. Calcium homeostasis 
reflects the balance between absorption in the intestine, excretion by the kidney, and 
exchange from bone, the three processes being tightly regulated by endocrine 
mechanisms. Accordingly, the pathophysiology of hypercalciuria has been classified 
into (i) primary renal leak; (ii) imbalance between bone resorption and formation; and 
(iii) gut hyperabsorption. In turn, these primary defects trigger compensatory 
mechanisms primarily mediated by parathyroid hormone (PTH) and 1, 25-dihydroxy-
vitamin D3 (1, 25(OH)2D3). 
 
TYPES OF HYPERCALCIURIA 
           The most common types of clinically significant hypercalciuria are absorptive, 
renal leak, resorptive. 
 
1. ABSORPTIVE HYPERCALCIURIA 
           Absorptive hypercalciuria is by far the most common cause of excessive 
urinary calcium. About 50% of all calcium stone formers have some form of 
absorptive hypercalciuria, which is caused by an increase in the normal 
gastrointestinal absorption of calcium, overly aggressive vitamin D supplementation, 
or excessive ingestion of calcium-containing foods (milk-alkali syndrome). Calcium 
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absorption occurs mainly in the duodenum and normally represents only about 20% of 
the ingested dietary calcium load. 
Increased intestinal calcium absorption produces a corresponding increase in serum 
calcium levels. Typically, serum parathyroid hormone (PTH) is low or in the low-
normal range in absorptive hypercalciuria, because the serum calcium level is 
generally high. Mild or moderate absorptive hypercalciuria can usually be controlled 
solely with dietary measures, but medical therapy is required in severe and resistant 
cases. 
Absorptive hypercalciuria can be categorized into the following 3 types: 
 Type I is relatively uncommon and is the most severe type of absorptive 
hypercalciuria. It is typically defined as the variant of absorptive 
hypercalciuria that is relatively unresponsive to dietary modifications, 
including severe dietary calcium restriction, but that normalizes urinary 
calcium excretion during periods of fasting. 
 Type II is the most common variety of absorptive hypercalciuria and usually 
responds to moderate dietary calcium restriction. 
 Type III also known as renal phosphate leak is a relatively uncommon cause 
of hypercalciuria. In this condition, the underlying etiology is a renal defect 
that causes excessive urinary phosphate excretion. This high urinary phosphate 
loss rapidly depletes the serum phosphate level, causing hypophosphatemia. 
The low serum phosphate increases the activation of vitamin D-3, which 
increases intestinal absorption of both phosphate and calcium. The 
unnecessary calcium absorbed is ultimately excreted in the urine, causing the 
hypercalciuria. Essentially, this is an absorptive vitamin D–dependent 
hypercalciuria due to inappropriate vitamin D-3 activation from 
hypophosphatemia. The hypophosphatemia is caused by the renal phosphate–
losing defect. 
2. RENAL LEAK HYPERCALCIURIA 
             Renal leak hypercalciuria is due to a specific defect in the kidneys that allows 
excessive obligatory urinary calcium excretion regardless of serum calcium levels, 
body stores, or calcium ingestion. The calcium/creatinine ratio is usually high (>0.20). 
The obligatory loss of serum calcium into the urine produces a mild hypocalcemia 
and secondary hyperparathyroidism, which is useful in diagnosing this condition. 
Renal leak hypercalciuria is far less common than absorptive hypercalciuria. 
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3. RESORPTIVE HYPERCALCIURIA (HYPERPARATHYROIDISM) 
              Resorptive hypercalciuria is due to the loss of calcium from the body's 
normal stores in the bony skeleton and is typically found in hyperparathyroidism. In 
this condition, calcium is released from bone in response to the increased activity of 
osteoclasts caused by excessive and inappropriate serum PTH levels. This causes 
significant hypercalcemia. Under normal conditions, PTH causes the kidney to limit 
calcium excretion, but, with the overwhelming serum calcium load produced with 
hyperparathyroidism, the kidneys are forced to excrete the extra calcium into the 
urine, causing the hypercalciuria. 
4. IDIOPATHIC HYPERCALCIURIA 
                  Idiopathic hypercalciuria is a familial disorder clinically associated with 
kidney stone production and reduced bone mineral content. An increase of intestinal 
Ca
2+
absorption and a reduction of tubular Ca
2+
 reabsorption are involved in the 
development of the disorder. 
 
II. HYPERCALCEMIA 
           Hypercalcemia is a condition in which the calcium level in blood is above 
normal. 
CAUSES OF HYPERCALCAEMIA  
1. Primary Hyperparathyroidism 
            The excess Para thyroid hormone triggers the release of too much calcium into 
the bloodstream. The bones may lose calcium, and too much calcium may be 
absorbed from food. The levels of calcium may increase in the urine, causing  renal 
stones. 
 
2. Malignancy associated hypercalcaemia 
                 Malignancy is a common cause of elevated blood calcium. Up to 20% of 
individuals withcancer will develop hypercalcemia at some point in their disease. 
                  Certain types of cancer, particularly lung cancer and breast cancer, as well 
as some cancers of the blood, such as multiple myeloma, increase the risk of 
hypercalcemia. Some malignant tumors produce a protein that acts like parathyroid 
hormone, stimulating the release of calcium from bones into blood. This is considered 
a paraneoplastic syndrome, the body's response to the presence of cancer or a 
substance the cancer produces. Spread of cancer (metastasis) to bones also increases 
the risk of hypercalcemia. 
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3. Familial hypocalciuric hypercalcemia  
                  Familial hypocalciuric hypercalcemia is a condition that can 
cause hypercalcemia, a serum calcium level typically above 10.2mg/dL. there is 
usually a family history of hypercalcemia which is mild, a urine calcium to creatinine 
ratio <0.01, and urine calcium <200mg/day. 
                   The perceived lack of calcium levels by the parathyroid leads to 
constitutively high levels of parathyroid hormone, and therefore hypercalcemia. 
Functionally, parathyroid hormone increases calcium resorption from the bone and 
increases phosphate excretion from the kidney which increases serum calcium and 
decreases serum phosphate. 
4. Granulomatous diseases 
                 Granulomatous diseases include tuberculosis, an infectious lung disease, 
and sarcoidosis, an inflammatory disease that usually begins in lungs. Elevated levels 
of calcitriol stimulate digestive tract to absorb more calcium, which raises the level of 
calcium in blood. Also, a rare genetic disorder known as familial hypocalciuric 
hypercalcemia causes an increase of calcium in blood because of faulty calcium 
receptors in body. 
5. Hypervitaminosis 
               An excess of vitamin D causes abnormally high blood concentrations of 
calcium produce hypercalcemia, which can cause over calcification of bones, soft 
tissues, heart and kidney.  It can also damage the kidney and produce renal stones. 
6. Hyperthyroidism  
                   Hypercalcemia occurs in up to 15 to 20 percent of patients with 
hyperthyroidism.T3 stimulatesbone resorption by the Activation of osteoclasts. 
7.Glucocorticoids 
              Administration of glucocorticoids   decreases bone resorption of calcium 
and intestinal calcium absorption and increases renal calcium excretion, leading to a 
substantial decrease in serum calcium concentration produce hypercalcemia.   
8.Milk-alkali syndrome 
 
          Milk alkali syndrome also called Burnett‟s syndrome is characterized 
by hypercalcemia caused by repeated ingestion of calcium and absorbable alkali such 
as calcium carbonate, or milk andsodium bicarbonate. If untreated, milk-alkali 
syndrome may lead to metastatic calcification and renal failure. 
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9. Pheochromocytoma 
              The increased catecholamines probably stimulated the parathyroid glands to 
produce excessive parathyroid hormone, resulting in hypercalcemia. 
10. Immobilization 
         Immobilization causes hypercalcemia in patients, whose underlying bone 
resorption is elevated, including children and adolescents, patients with Paget's 
disease, mild hypercalcemia of malignancy. These patients may diminish 
hypercalcemia and development of osteopenia, but resumption of weight-bearing is 
essential for resolution of hypercalcemia and hypercalciuria. 
11. Dehydration 
           A common cause of mild or transient hypercalcemia is dehydration, because 
when there is less fluid in blood, calcium concentrations rise. 
HYPEROXALURIA 
          Hyperoxaluria is a common abnormal finding in patients with calcium oxalate 
renal stones. Some degree of excessive urinary oxalate is found in 20-30% of all 
patients with recurrent calcium oxalate stones. It defined asurinary oxalate excretion 
that exceeds 40 mg/day. 
 Types of hyperoxaluria 
           Primary hyperoxaluria (types I and II), enteric hyperoxaluria, dietary 
hyperoxaluria, and idiopathic or mild hyperoxaluria 
Primary hyperoxaluria 
           This rare form of hyperoxaluria is due exclusively to a genetic defect that 
causes a loss of specific enzymatic activity. With the normal metabolic pathway 
blocked, the alternative pathway that leads to oxalate production as an end-product of 
glycolate metabolism becomes extremely active, resulting in extremely high oxalate 
production.  
 Type I it occurs in 1 per 120,000 live births and is transmitted as an autosomal 
recessive trait. In primary hyperoxaluria type I, the missing enzyme is alanine-
glyoxylate aminotransferase (ie, the AGTgene) and is normally found only in 
the hepatic peroxisomes. This enzyme is necessary to detoxify glyoxylate. 
When alanine-glyoxylate aminotransferase is lacking, oxalate production 
soars.  
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Pyridoxine (vitamin B-6) is a cofactor in this chemical pathway, which 
normally converts glyoxylic acid (C2 H2 O3) to glycine.
 
When the pathway is 
blocked because of a deficiency or absence of this enzyme, the result is high 
levels of glycolic and oxalic acid, which readily convert to oxalate. Oxalate is 
then excreted in the urine, which leads to nephrocalcinosis and the eventual 
development of end-stage renal failure, usually in childhood. 
 Type II the missing enzyme is D-glyceric dehydrogenase, which can be 
detected in leukocyte preparations. This deficiency promotes the conversion of 
glyoxylate to oxalate. 
The 2 types of primary hyperoxaluria result in approximately the same degree 
of hyperoxaluria. However, end-stage renal disease is slightly less common in 
patients with type II primary hyperoxaluria. Pyridoxine is generally not 
effective in patients with type II primary hyperoxaluria. 
 
Enteric hyperoxaluria 
            
  Enteric hyperoxaluria accounts for approximately 5% of all cases of 
hyperoxaluria. It is due to a gastrointestinal problem usually associated with chronic 
diarrhoea. Malabsorption from any cause can result in enteric hyperoxaluria. The 
basic mechanism is competition for the available ingested calcium, the leading 
intestinal oxalate-binding agent. Most of the bile acids produced during digestion are 
reabsorbed in the proximal intestinal tract.  
              
When this fails to occur, calcium and magnesium bind to these bile acids 
through saponification.This leaves very little free calcium available for absorption or 
binding with oxalate in the lower intestinal tract. Without the calcium necessary to 
adequately bind oxalate in the intestinal tract, additional oxalate is absorbed and then 
excreted in the urinary tract. 
 
Increased intestinal membrane oxalate transport and absorption may also 
occur through direct exposure of the intestinal lining to excess bile salts and fatty 
acids, which increase the oxalate permeability of the colonic mucosa. 
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 Hyperoxaluria has been reported to be the most common urinary metabolic 
abnormality in patients with stones who have undergone bariatric surgery.Oxalate 
absorption by the colon has been shown to increase up to 300-fold following small-
bowel bypass surgery; therefore, these individuals must be screened for enteric 
hyperoxaluria. In some severe cases, the bypass may need to be reversed to control 
the hyperoxaluria. The recent proliferation of bariatric surgery cases may result in an 
increased prevalence of enteric hyperoxaluria in the future. 
 
Dietary Hyperoxaluria 
              Dietary oxalate was thought to play a relatively minor role in hyperoxaluria 
and to account for only 10-20% of the total urinary oxalate produced. Recent evidence 
suggests that dietary oxalate plays a much more important role and may be 
responsible for 50% of the total urinary oxalate.
 
 
HYPERURICOSURIA 
              15-20% of patients with calcium stones have hyperuricosuria.80 and 90% of 
persons with hyperuricosuric calcium nephrolithiasis are men. It defined as urinary 
uric acid levels that exceed 800 mg/day in men and 750 mg/day in women. The most 
common cause of hyperuricosuria is increased dietary purine intake, but many other 
hereditary or acquired factors eg, gout may result in this condition. Hyperuricosuria 
may develop uric acid or calcium oxalate stones due to supersaturation of urine with 
monosodium urate.  It may initiate calcium oxalate stone formation by the induction 
of heterogeneous nucleation or by absorption of certain inhibitors. Patients with 
calcium oxalate stones have greater urinary pH than Patients with mixed uric acid and 
oxalate stones.   
HYPOCITRATURIA 
                  Hypocitraturia generally defined as urinary citrate excretion less than 320 
mg (1.67 mmol) per day for adults is a common metabolic abnormality in stone 
formers, occurring in 20% to 60%. It is more common in premenopausal women with 
stone disease than in postmenopausal stone-forming women. 
                   Citrate is a known inhibitor of stone formation, working through a variety 
of mechanisms. In the renal tubule citrate complexes with calcium, increasing its 
solubility and reducing the concentration of free calcium in the urine. This calcium-
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citrate complex limits calcium supersaturation and prevents nucleation of both 
calcium oxalate and calcium phosphate, at least partly through interactions with 
Tamm-Horsfall protein.The excretion of citrate in the urine is a function of filtration, 
reabsorption, peritubular transport, and synthesis by the renal tubular cell. Acidosis 
plays the important etiologic factor in hypocitraturiaPatients with chronic diarrhoea 
and inflammatory bowel disease frequently has hypocitraturia due to bicarbonate loss 
from the intestinal tract. Thiazide owing to hypokalemia with resultant intracellular 
acidosis may induce hypocitraturia.A diet rich in animal protein and strenuous 
physical exercisemay produce hypocitraturia.UTI with bacteria that degrade citrate 
lowers urinary citrate levels. 
 
HYPOMAGNESURIA 
            The most common cause of hypomagnesuria is chronic diarrhoeal syndrome 
and inflammatory bowel disease. Many of the patients with hypomagnesuria also have 
hypocitraturia. 
 
 
SEX HORMONES AND RENAL STONES 
             In males, Testosterone appears to promote stone formation by suppressing 
osteopontin expression in the kidneys and increasing urinary oxalate excretion.   
             Menopause and postmenopausal hormone (PMH) are associated with an 
increase in urinary calcium excretion, which may increase the risk for calcium-
containing stone formation in postmenopausal women compared with premenopausal 
women. Estrogen deficiency increases the sensitivity of bone to parathyroid hormone, 
leading to a net increase in bone resorption and increased urinary calcium excretion. 
 
CALCIUM PHOSPHATE STONES 
             Calcium phosphate stones constitute up to 10% of renal stones.  Calcium 
phosphate stones are less common than calcium oxalate with Elongate, narrow in 
shape. It precipitates in urine with an alkaline pH > 6.3. Calcium phosphate stones 
typically occur in patients with metabolic or hormonal disorders such as 
hyperparathyroidism and renal tubular acidosis. 
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CAUSES OF CALCIUM PHOSPHATE STONES 
               Patients with renal tubular acidosis, in addition to a high urinary pH, they 
also develop hypocitraturia because of the associated systemic acidosis, as well as 
hypercalciuria, probably due to effects of bone buffering of the acid load. All of these 
also favor calcium phosphate precipitation. Renal tubular acidosis significantly 
reduces urinary citrate as well as total urinary acid levels and can lead to stone 
formation, usually calcium phosphate. 
 
                 Hypercalciuria appears to be the primary abnormality, with calcium-
induced interstitial and tubular damage possibly responsible for the RTA. it is the 
initial condition with subsequent acidemia promoting stone formation both by 
increased calcium phosphate release from bone during bone buffering of retained acid 
and by direct reduction in the tubular reabsorption of these ions. The degree of 
hypercalciuria is roughly proportional to the severity of the acidemia. The persistently 
high urine pH, which favors the precipitation of calcium and reduced citrate excretion. 
Since acidemia enhances proximal citrate reabsorption. Urinary citrate is normally a 
potent inhibitor of calcium stone formation, both by forming a soluble complex with 
calcium and by inhibiting stone growth by agglomeration of calcium crystals.   
URIC ACID STONE 
              About 5–10% of all stones are formed from uric acid stones, normally show 
as brownish-white colour.Itform from high concentrations of uric acid in acidic 
urine.They also may form in association with conditions that 
cause hyperuricosuria with or withouthyperuricemia.   A diagnosis of uric acid stone 
is supported by the presence of radiolucent stone in the face of persistent urine 
acidity, in conjunction with the finding of uric acid crystals in fresh urine samples. 
Pathophysiology 
             When the concentration of uric acid in urine exceeds its solubility at the urine 
pH, uric acid changes from a compound dissolved in solution to an insoluble 
precipitate. Urate stones are formed by general mechanisms are overproduction, 
increased tubular secretion, or decreased tubular reabsorption, decreased urinary 
water content, or increased hydrogen ion concentration. 
               Uric acid results as a relatively insoluble end-product of purine metabolism. 
The concentration of uric acid in plasma depends on dietary ingestion, de novo purine 
synthesis, and uric acid elimination by the kidneys and intestine. 
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Causes 
              Urine pH from 6.0 to 5.0 has a greater influence on uric acid stone formation 
than the 24-hour urine excretion of uric acid. Uric acid stone formation is more 
determined by pH than by urine volume or urine uric acid concentrations. The normal 
range for uric acid excretion 500 to 600 mg per 24 hour, and excretions greater than 
750 mg for women and 800 mg for men are considered elevated. Clinically significant 
crystal and stone formation require persistent hyperuricosuria, dehydration, or marked 
reduction in urine pH.  
               The cause of the low urine pH in uric acid stone-formers is not completely 
understood, but reductions in urine ammonium excretion appear to play an important 
role. Dehydration, which reduces urine volume also promotes a decline in urine pH 
and thereby increases urine uric acid concentration. Stone formers who over-excrete 
uric acid do so either as a result of excess dietary purine ingestion and metabolic 
conversion to uric acid, or to excess production of uric acid. 
HYPERURICEMIA 
           Hyperuricemia, and particularly gouty arthritis, are far more common in men 
than in women. Only 5% of patients with gout are female, but uric acid levels increase 
in women after menopause. 
          Hyperuricemia is an excess of uric acid in the blood, above the level of 7 
mg/dL.  
Also important to blood uric acid levels are purines.    Purine breaks down into uric 
acid. Increased levels of uric acid from excess purines may accumulate in tissues, and 
form crystals. This may cause high uric acid levels in the blood. 
 
PATHOPHYSIOLOGY  
         Hyperuricemia is generally divided into 3 pathophysiologic categories, ie, uric 
acid underexcretion, uric acid overproduction, and combined causes. 
Uric acid underexcretion 
                 Most patients with gout are “underexcreters”, i.e. they have a defect in their 
renal handling of uric acid, as evidenced by a lower than normal ratio of uric acid 
clearance to glomerular filtration. Patients with gout excrete; on average 41% less uric 
acid than normal people for any have given plasma concentration of uric acid. This 
underexcretion is believed to be due mainly to decreased proximal tubular secretion. 
 
 
62 
 
Uric acid overproduction 
          The causes for hyperuricemia in overproducers may be either exogenous (diet 
rich in purines) or endogenous (increased purine nucleotide breakdown).  
 
Combined of underexcretion and overproduction 
            The most common cause under this group is alcohol consumption, which 
results in accelerated hepatic breakdown of ATP and the generation of organic acids 
that compete with urate for tubular secretion.  
 
STRUVITE STONES (INFECTION STONES) 
             About 9% of all stones are formed from Struvite stones with dirty-white 
colour. In worldwide the frequency of struvite calculi account for up to 30%. 
                 Struvite kidney stones are called triple phosphate stones because of their 
combination of magnesium, ammonium and calcium/phosphate. They are found 
predominantly in women with chronic urinary infections and people suffering from 
abnormal urinary tracts. They are most often associated with infections of the urinary 
tract.  
 
                 Struvite stones are more amorphous and spread out into the insides of the 
kidneys which give them their antler-like appearance.it can also form around calcium 
oxalate stones when the stone becomes infected. This is a potentially dangerous 
situation that can cause the stone to grow so big that it blocks the entire kidney. 
 
CAUSES 
             Struvite stones are almost always caused by urinry trct infections due to 
bacteri that prodce certain enzymes. These enzymes raise the concentration of 
ammonia in the urine. Ammonia makes up the crystals that form stuvite stones. The 
stone promoting bacteria are usually Proteus, but may also induce Pseudomonas, 
Klebsiella, Providencia, Serratia and staphylococci. Women are twice as likely to 
have struvite stones as men. 
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PATHOPHYSIOLOGY  
            Normal urine is undersaturated with ammonium phosphate, and struvite stone 
formation occurs only when ammonia production is increased and the urine pH is 
elevated more than 8, to decrease the solubility of phosphate.  
              Urease breaks down urinary urea into ammonia and carbon dioxide. The 
ammonia that is formed takes up a hydrogen ion to become an ammonium ion, 
increasing the PH of the urine so that it becomes more alkaline. Because phosphate 
levels are increased in alkaline urine and because magnesium always is present in the 
urine, struvite stones forms. 
CYSTINE STONES 
           Cystine stones are relatively rare, occurring in about 1% to 2% of persons who 
experience renal stone disease. Cystine stones are most common in young adults 
under age 40. Less than 3% of urinary tract stones are cystine stones. 
 
           Cystine crystals form hexagonal-shaped, that can be viewed upon microscopic 
analysis of the urine. The stones may be pink or yellow in colour, but later they turn 
to greenish due to exposure to air. Stones may be present in single, multiple, or large 
staghorn configurations. Pure cystine stones are not easily visible on plain x-rays due 
to their sulfur content. 
CYSTINURIA 
             Cystine kidney stones are due to cystinuria, a genetic disorder of the transport 
of an amino acid called cystine that results in an excess of cystine in the urine and the 
formation of cystine stones.  
                Cystinuria is characterized by the inadequate reabsorption of cystine in the 
proximal convoluted tubules after the filtering of the amino acids by the kidney's 
glomeruli, thus resulting in an excessive concentration of this amino acid in the urine. 
Cystine may precipitate out of the urine, if the urine is neutral or acidic, and 
form crystals or stones in the kidneys, ureters, or bladder. 
XANTHINE STONES 
             These stones are extremely uncommon and usually occur as a result of a rare 
genetic disorder.  Pure xanthine stones are radiolucent but patients with xanthinuria 
there may be a calcium salt mixture to render. These stones tend to be small, round or 
oval. 
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XANTHINURIA 
Pathophysiology 
                  
  The primary organs affected in xanthinuria are the kidney and, to a lesser 
extent, skeletal muscle and joints. Kidney complications are initiated by the formation 
of xanthine crystals in the tubules, leading to parenchymal deposition and/or 
radiolucent stone formation. Xanthine's high rate of renal clearance and low solubility 
in urine creates an environment in the urine favoring crystallization. Thus, patients 
with volume depletion who have xanthinuria are at particular risk of forming xanthine 
crystals.  
 
INVESTIGATION 
BLOOD TEST  
                  Createnine, Blood Urea, Uric acid, calcium, phosphorus, Electrolytes and 
complete blood count. 
URINE ROUTINE  
 Crystals in urine. 
 Blood cells in urine 
 Pus cells in urine. 
URINE CULTURE COLONY COUNT & SENSITIVITY TEST  
24-HOUR URINE TEST 
Urine is collected during a 24-hour period and analyzed for calcium, citrate, 
uric acid, magnesium, phosphate, sodium, oxalate, pH (acid level), and total 
volume. 
STONE ANALYSIS OF THE RETRIEVED CALCULUS 
IMAGING TESTS 
 X-Ray KUB 
 Ultrasonograpy of kidney, ureter, and bladder 
 Intravenous pyelogram (IVP), 
 Retrograde pyelogram,  
 Computed tomography (CT) scan. 
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PROPERTIES OF THE TRIAL DRUG 
¸üâÃî º¢Ä¡ºòÐ - ASPHALT 
ACTION:   Diuretic, Lithotriptic, Astringent, Styptic, Nutrient. 
¦À¡ÐìÌ½õ: 
      ¸øÄ¨¼ôÒ §Á¸í ¸ÉàÄõ Å¢ò¾¢Ã¾¢ 
      ¦º¡øÄ¨¼ìÌ ¿£ÃÕ¸ü §º¡½¢¾ì¸¡ý - ¦ÁøÄ¢¨¼Â¡÷ì 
      ¸¢øÄ¸îºò ¾¢ø¨Ä¦ÂÛ Á¢ó¾¢Ã¢Â ¿ð¼ÓÁ¡í 
      ¸øÄ¸îºò ¾¢ø¨Ä¦ÂÛí ¸¡ø. 
INDICATION:  Renal calculus, gonerrhoea, ascitis, Burning micturition, 
oligospermia. 
                       Ref: Gunapadam Thathu- Jeeva Vagupu, 2
nd
, 3
rd
 edition, p.no:529, 530. 
 
KARPOORA SILASATHTHU 
                                          (Crystallised foliated gypsum) 
 
                Shilajit is known to give the physical power and actually reducing the 
apparent age of a person. Shila means Rock and shilajit means Rock Borne or Rock 
like. 
                Karpoora silasaththu, which is combination of alum and iron available in 
nature and plenty in Nepal. It is taken out from the earth as thick sheets. 
                                                                   Ref: siddha material medica, page no: 404 
Constituents: 
 Silajit contains an oil which when distilled is known as ichthyol. Benzoic acid 
and benzoates are present in large quantities. It contains,  
 Urea - 65p.c. 
 Water - 8.85p.c. 
 Organic matter - 56.20p.c. 
 Mineral matter - 34.95p.c. containing 
 Nitrogen -1.03p.c. 
 Lime - 7.80p.c. 
 Potash - 9.07p.c. 
 Phosphoric acid - 0.16p.c. 
 Silica - 1.35p.c.  
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Uses: 
 Silajit is specially employed in genito-urinary diseases. 
 It is used in gallstones, renal and bladder calculi, anuria, jaundice, enlarged 
spleen etc. 
 It diminishes phosphaturia and is useful in phosphatic calculus. 
                                                                    Ref: Indian Materia Medica Vol – 2 
 
 
  
BEFORE PURIFICATION PURIFY WITH TENDER COCONUT 
 
 
                                        AFTER PURIFICATION 
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¦Åí¸¡Ãõ - SODIUM BIBORATE 
 
§ÅÚ¦ÀÂ÷: ¦À¡Ã¢¸¡Ãõ, ¸¡Ãõ, ¯Õì¸¢Éõ, ¯ÕìÌÁ¢ò¾¢Ãý, ¼í¸½õ,  
àÁò¨¾Â¼ì¸¢ 
 
Taste:    Sweet with Astringent 
 
Potency:  Veppam (hot) (¦Åí¸¡Ãõ ¦Åö¦¾É¢Ûõ §¿¡ö ¾£÷ìÌõ) 
 
Action:     Diuretic, Lithotriptic, Refrigerant, Emmenogouge, 
 
 
¦À¡ÐÌ½õ:        
¦º¡È¢Ò¨¼¦Âñ ÌýÁ¿¨Á §º¡Ã¢ Â¡ºõ 
            ÀÈ¢¸¢Ã¸½¢ ¸ø ¸øæÉõ Àý§É¡ö- ¦¿È¢¨Âò 
¾¼í¸½í¸ Àí¸¢ÕÁ¢ º÷ôÀÅ¢¼ï ºó¿¢ 
Â¢¼í¸½í¸ Äì¸¢ü§À¡ ¦Áñ. 
 
Indication: renal calculus, all types of ulcers, bleeding piles, Burning micturition, 
Delirium, Itching, Dysentery. 
 
                      Ref: Gunapadam Thathu- Jeeva Vagupu, 2
nd
, 3
rd
 edition, p.no: 434, 435. 
 
 
 
 
CHARACTERS: 
 
Borax: Na2B4O7 10H2O; Na2O-16.2%, B2O3-36.6%, H2O-47.2%,  
specific gravity: 1.7 
              Borax, also known as a hydrated sodium tetraborate, is one of the most 
important ofboron compound, a mineral, and a salt of boric acid. It is a soft and light 
crystalline substance. The colour is greyish white. Exposed to the air it becomes 
opaque or dirty white. 
                                                     Ref: The wealth of India raw materials volume 2: B 
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USES: 
 A mixture of powdered borax and honey is used externally for urethritis to the 
urethra and soreness of mouth. 
 Borax is given internally in doses varying from 10- 30 grains (650mgs-2gm) 
in acidity of the stomach, amenorrhoea, menorrhagia, and puerperal 
convulsions. 
 
                                                    Ref: Indian Materia Medica Vol – 2 
 
 
 
  
BEFORE PURIFICATION AFTER PURIFICATION 
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ÀÕò¾¢ - Gossypium herbaceum, Linn. 
 
§ÅÚ¦ÀÂ÷: ¬îº¡¾¿À¨Ä, ÀÃ¢, ¯ò¾¢Ã¢, ¸¡üÀ¡ºõ, ÀýÉø 
Part used: leaves, flower, tender, seed, bark, root bark 
Taste:      Sweet, Astringent 
Potency:    Veppam (hot) 
Division:    pungent 
Action:    
           Leaves, Flower:   Astringent, Nutrient 
           Seed:                    Laxative, Expectorant. 
           Bark, Root bark:    Diuretic, Emmenogouge. 
 
¦À¡ÐÌ½õ:  
 
ÀÕò¾¢Â¢¨Ä ¦Á¡ì¸¢Ãñ¨¼ô À¡Ä¢Ä¨Ãò Ðñ½ 
ÅÕòÐ¸¢ýÈ §Á¸¦ÁøÄ¡õ Á¡Úõ - ÀÕò¾ 
Å¢Ãò¾À¢ò¾ò §¾¡Î Å¢Ã½Å£ì ¸õ§À¡õ 
«Ãò¾Å¢¾ú Á¡§¾! Â¨È. 
Indication: Leucorrhoea, Hypertension, Wound, Swelling. 
                                    Ref: «¸ò¾¢Â÷ Ì½Å¡¸¼õ 
 
BOTANICAL ASPECT: 
             At the central institute for cotton research, Nagpur, over 6000 accessions of 
germplasm in all the four cultivated species og gossypium have been assembled and 
evaluated. These include 390 in g.herbaceum linn. 
                                               Ref: The wealth of India, Raw materials, vol: 3: D-I 
 
Botanical name: Gossypium herbaceum, linn. 
Family:               Malvaceae 
Habitate:            A small syrub, 60cm to 2.5m in height 
            Local name: eng - Indian cotton plant/ common cotton 
            Mal -parithi 
            San -karpasa 
             Hindi –kapas 
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PHYTOCHEMICALS: 
 Gossypetin 8-0- rhamnoside 
 Quercetin-3-0-glucoside 
 Gossypol 
 Strigol 
 Betaine 
 Choline 
 Salicylic acid 
                                                 Ref: Compendium of Indian Medicinal plants, vol: 4 
 
                                                          Indian Material Medica, vol: 1 
Medicinal uses: 
 It is useful in vitiated conditions of vatha, pitha, stangury, burning 
sensation of the stomach.  
                                                    Ref: Indian Medicinal plants, vol: 3 
 The leaves remove vatha, enrich the blood and increase the flow of 
urine. 
                                                    Ref: Indian Medicinal plants, vol: 1 
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Ðò¾¢ - Abutilon indicum 
§ÅÚ¦ÀÂ÷: ¸ì¸Ê, ¸¢ì¸º¢ 
Part used: leaves, flower, bark, root  
Taste:     Sweet  
Potency:   Thatpam (coolent) 
Division:   Sweet 
Action:    Diuretic, Nutrient, Laxative, Demulcent, Sedative. 
¦À¡ÐÌ½õ:  
ãÄ§¿¡ö ¸ðÊ Ó¨ÇÒØôÒñ Ïõ§À¡Ìï 
º¡ÄÅ¾ì ¸¢ì¸ð¼ò ¨¾Â§Ä!- §ÁÖÁ¨¾ 
±ôÀÊ§ÂÛõ Ò¸¢îº ±ôÀ¢½¢Ôõ º¡ó¾ÓÚõ 
þôÀÊÂ¢ü Úò¾¢ þ¨Ä¨Â. 
 
Indication: piles, wound. 
 
 The leave decoction with milk and sugar, it cures the Burning micturition. 
                                           Ref: «¸ò¾¢Â÷ Ì½Å¡¸¼õ 
BOTANICAL ASPECT: 
                  Botanical name: Abutilon indicum 
      Family:               Malvaceae 
      Habitate:             A syrub, 2-3 feet in height 
                 Local name:         Mal - thuththi 
                                              San - kanka-tila 
                                              Hindi -kanghi 
 
PHYTOCHEMICALS 
Leaves - Beta carotene 
Flower - Mucilage, tannin, organic acids, 
The essential oil contains,  
 Alpha pinene                             Geranylacetate 
 Caryophyllene                           Elemene 
 Caryophyllene – oxide              Eudesmol 
 Cineole                                      Farnesol 
 Geraniol                                     Borneol 
                                            Ref: The wealth of India, Raw materials, vol: 1: A-F 
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ROOTS- Asparagine, Gallic acid,  
                                                    Ref: The Indian Material Medica vol: 1 
                                                         Compendium of Indian Medicinal plants, vol: 4 
MEDICINAL USES: 
 The powder of seed have been taken, thus removes the burning sensation 
while passing urine. 
                                Ref: Tamil -English dictionary, t.v.sambasivam pillai, vol: 4 part2 
 Infusion of roots prescribed as a diuretic and demulcent in urethritis. Also 
used in relieving stangury and haematuria. 
 Decoction of leaves is used as internally for stone in the bladder. 
                                                Ref: The Indian Material Medica vol: 1 
 The milk of the plant cures urinary discharges. 
 The bark is good in stangury and haematuria. 
                                                 Ref: The Indian Medicinal plants, vol: 1 
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ÓûÇí¸¢ - Raphanus sativus 
Part used: leaves, seed, tuber. 
Taste:    pungent 
Potency:  Thatpam (coolent) 
Division:  Pungent 
Action:    Diuretic, Laxative, Stimulant, Aphrodisiac, Stomachic. 
 
¦À¡ÐÌ½õ: 
Å¡¾í ¸ÃôÀ¡ý ÅÂ¢ü¦ÈÃ¢× Ý¨ÄÌ¼ø 
Å¡¾í¸¡ º¨ÁÂõ Åý¾¨Ä§¿¡ö- §Á¡Ð¿£÷ì 
§¸¡¨ÅÀý§É¡ö Àøº¢Äó¾¢ ÌýÁÁ¢¨Ãô Òì¸ÎôÒï 
º¡×ÓûÇí ¸¢ì¸ó¾ò ¾¡ø. 
 
Indication: vatha diseases, eczema, ulcer, asthma. 
 
                                            Ref: «¸ò¾¢Â÷ Ì½Å¡¸¼õ 
 
 
 
BOTANICAL ASPECT: 
Habitate:            An annular herb with short condensed stem. 
Botanical name: Raphanus sativus, Linn. 
Family              : Brassicaceae 
Local name:  Eng- Radish 
             San- Moolika 
                       Mal- mullanki 
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PHYTOCHEMICALS: 
 
 Roots- amino acids, ornithine, citrulline, arginine, glutamic acid, aspartic acid 
                                  Ref: The Wealth of India, Raw Materials, vol: 5 R-Z 
 Fresh vegetable contains 91.00 p.c. moisture 
 Completely dried material contain :  
 Ether extract 4.00p.c. 
 Albuminoids 18.00 p.c. 
 Soluble carbohydrates 52.66 p.c. 
 Woody fibre 9.34 p.c. 
 Ash 16.00 p.c. 
                           Ref: Indian Materia Medica Vol - 1 
 Seeds- beta sitosterol, stearic acid 
                                       Ref: Compendium of Indian Medicinal plants, vol: 4 
Medicinal uses: 
 Radish leaves show broad spectrum antibiotic specific activity against 
streptococcus, pneumococcus, escherichia coli. 
                                         Ref: The Wealth of India, Raw Materials, vol: 5 R-Z 
 Roots are used for urinary disease. 
                                          Ref: The Indian Medicinal plants, vol: 1 
 Root juice is given for urinary complaints like dysuria and strangury. 
                                         Ref: Indian Materia Medica Vol - 1 
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§¸¡Æ¢ Óð¨¼ - EGG WHITE 
 
§ÅÚ¦ÀÂ÷: º¢üÈñ¼õ 
 
Action: Demulcent, Laxative, Nutrient. 
 
¦À¡ÐÌ½õ: 
Å¡¾À¢ò¾ï §º÷ôÀ¢ìÌõ Åý§È¡¼õ Òñ§À¡ìÌó 
¾¡Ð¨Å ¦Áò¾ ¾¨ÆôÀ¢ìÌ- §Á¡Ð 
¸Àò¨¾ Â¼ìÌí ¸ÃôÀ¡Ûñ¼¡ìÌ 
Á¢Àò¨¾ÔÚí §¸¡Æ¢Óð¨¼ ¦Âñ. 
 
Indication: vatha diseases, kaba diseases, wound. 
 
 §¸¡Æ¢ Óð¨¼ ¦Åû¨Çì¸Õ ¿£Ã¢ø ¸¨ÃÔõ.À¾¡÷ò¾í¸Ç¢ý «Øì¨¸ 
±Îì¸×õ §¾¸ò¾¢ø ±Ã¢îº¨Äò ¾½¢ì¸×õ ¦Åû¨Çì¸Õ ¯À§Â¡¸ôÀÎ¸¢ÈÐ. 
                     Ref: Gunapadam Thathu- Jeeva Vagup, 2
nd
, 3
rd
 edition, p.no: 634& 635 
 
 §¸¡Æ¢ Óð¨¼ Ì¼ø, Á¡÷Ò, º¢Ú¿£÷ô¨À þÅü¨È àö¨ÁÂ¡ìÌõ. º¢Ú¿£Ã¸õ, 
º¢Ú¿£÷ô¨À þÅüÈ¢ø §¾¡ýÚõ þÃ½ò¨¾ô §À¡ìÌõ. 
        À¡÷¨Å áø: «ìÉ¢§ÅºÃ¢ý ºÃ¸ ºõ†¢¨¾ 3õ À¡¸õ Àì¸ ±ñ: 187 
 
 
 
 
      
  
EGG WHITE 
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           PREPARATION OF THE TRIAL DRUG 
           KARPOORA SILASATHU PARPAM (INTERNAL MEDICINE) 
 
(Ref: Dr.K.Anbarasu, Agathiyar chendhooram - 300, moolamum uraiyum 1
st
 
edition, 1998, page no: 13 & 14) 
 
 
¸üâÃî º¢Ä¡ºòÐ ÀüÀõ 
 
§¸ÇôÀ¡ ¸üâÃ ºÄ¡ºò Ðò¾¡ý 
    ¦¸ÊÂ¡¸ ÀÄ¦Á¡ýÚ ¦À¡Ã¢¸¡ Ãó¾¡ý 
¿¡ÇôÀ¡ ÀÄ¦Á¡ýÚ ¦ÃñÎí ÜðÊ  
    ¿ÄÁ¡É ÀÕò¾¢ ¿£Ú Ðò¾¢ §Å÷ò§¾¡ø 
¿£ÇôÀ¡ À¡í¸¡¸ì ¸‡¡Âõ ¦ºöÐ  
    ¿¢ºÁ¡¸ Å¢ð¼¡ðÎ ´Õ ¿¡û ÁðÎõ 
Á¡ÇôÀ¡ «ï¦ºÕÅ¢ü Ò¼ò¨¾ §À¡Î 
    ¬È¢¦ÂÎ ¸øÅò¾¢ Ä¡ðÎ ¾¡§É 
 
 
¬ð¼òà Ç¡ÌÁ¼¡ ¦Åñ¸Õ¨Å Å¢ðÎ 
    «¨ÃòÐÅ¢ø¨Ä ¦ºöÐÃÅ¢ Â¢ÖÄ÷ò¾¢ì ¦¸¡ñÎ 
Á¡ð¼§Å «ï¦ºÕÅ¢ü Ò¼ò¨¾ô §À¡Î 
    Å¡¸¡¸ «¨ÃòÐ «ïÍ ¾ÃÓ Á¡É¡ø 
¿¡ð¼§Å ¦Åñ¦À¡ÊÂ¡õ À¾Éõ ÀñÏ 
    ¿ÄÁ¡É ¦ÀÕÅÂ¢Úõ Á§¸¡¾Ãí¸û 
°ð¼§Å ¿£÷î¦ºÃ¢ôÒ ¸øÄ¨¼ôÒ 
    µÎÁôÀ¡ ¦ÅÊÔôÒ ÍýÉ ¿£§Ã 
 
 
INGREDIENTS: 
 
 Purified karpoora silasathu     - 1palam(35gms) 
 Purified Vengaram                   - 1palam(35gms) 
 Ash of paruthi plant                - Required amount 
 Stem bark of Thutthi               - Required amount 
 Egg white                                 - Required amount 
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METHOD OF PURIFICATION  
 
 Karpoora silasathu: Purified by boiling it with tender coconut. Then it is washed  
in the water.
                        
 
 Vengaram: Purified by fried in a mud vessel until the water content of it 
evaporates
.
 
 
 Thutthi ver thol: Wash the root with running water and dry it. 
                                  
METHOD OF PREPARATION: 
 
Preparation of decoction: 
 
             A decoction is prepared by mixing ash of paruthi plant (Gossypium 
herbaceum) and the root bark of Thutthi (Abutilon indicum) in required amount of 
water. 
 
              Then, purified karpoora silasathu and Vengaram are taken and put into the 
Stone Martar and grinded by using the above said decoction for 24hrs. Then it is made 
into small Tablets (villai) and dried. Then it is subjected to pudam by using 5 cow 
dung cakes. The drug is again grinded by using egg white and made into small tablets 
(villai) and dried. Then it is again subjected into pudam by using 5 cow dung cakes. 
The above said procedure is repeated for 5 times. 
 
Dosage:          130mg (twice/day) after food 
 
Adjuvant:      Radish juice 
Indication:      Renal calculus, Ascitis. 
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ASH OF PARUTHI, THUTHI GRINDING WITH PARUTHI, 
THUTHI     DECOCTION 
 
 
PARUTHI DECOCTION + VILLAI EGG 
  
EGG WHITE GRINDING WITH EGG WHITE 
 
 
 
 
79 
 
KARPOORA SILASATHU PARPAM 
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PROTOCOL 
 
TITLE OF THE DISSERTATION PROJECT: 
 
      Pre clinical and clinical study on AZHAL KALLADAIPPU (Renal Calculi) 
and the drug of choice is “KARPOORA SILASATHU PARPAM” (Internal)   
 
 AIM: 
              To document the siddha drug  Karpoora Silasathu Parpam in the treatment 
of  Azhal Kalladaippu (Renal Calculi) by the standard process of evaluation of 
safety and efficacy of the drug. 
 
OBJECTIVE: 
  
1. Primary objective:  
             To evaluate the therapeutic efficacy of siddha drug Karpoora 
 
 Silasathu parpam (Internal) in the treatment of  Azhal Kalladaippu (Renal 
Calculi).  
  
   2. Secondary objective: 
 
             1. To evaluate the safety profile (acute, long term toxicity studies) of this 
drug. 
 
            2. To study the effect of other co-factors such as age, sex and siddha 
parameters. 
 
             
 STUDY DESIGN & CONDUCT OF STUDY:   
 
  Study type:        An open clinical trial.   
  Study place:       OPD and IPD of Ayothidass Pandithar Hospital, 
                               National Institute of siddha, 
                              Tambaram sanatorium, Chennai-47. 
Study period:    12 months. 
Sample size:      40 patients. 
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 TREATMENT: 
Medicine name: 
                                       Karpoora silasathu parpam (Internal) 
 
(Ref: Dr.K.Anbarasu, Agathiyar chendhooram - 
300, moolamum uraiyum 1
st
 edition, 1998, page 
no: 13 & 14) 
 
            Dosage:          130mg (twice/day) after food 
 
Adjuvant:      Radish juice 
Route of Administration:  Oral Route 
Duration of the Drug Administration:   48 days 
 
SUBJECT SELECTION: 
 
             As and when patients reporting at OPD of Ayothidoss Pandithar Hospital, 
NIS with symptoms of inclusion criteria will be subjected to screening test & 
documented using Screening Proforma.  
 
  SELECTION CRITERIA: 
 
         INCLUSION CRITERIA: 
          Patients who fulfilled any of the following criteria will be included in the study: 
 Age: 20- 60Yrs 
 Sex – Both male & female 
 Patients who are having the classical symptoms of  abdominal pain & distensión,  
pain from loin to groin, pain in urethra, agonizing pain, dysuria, oliguria, 
yellow coloured urination, burning micturition, haematuria, nausea & 
vomiting. 
 Stone size:  ≥4mm &≤10mm  
 Patient with renal calculus detected on X-ray KUB or USG abdomen. 
 History of Recurrence of Renal calculi.                                                                       
 Patient willing to sign the informed consent stating that he/she will conscientiously 
stick to the treatment during 48days but can opt out of the trial of his/her own 
conscious discretion. 
 Patients who are willing to take Ultrasonography Investigation (USG- abdomen / 
KUB) and provide blood for lab investigation. 
 Crystals, Blood cells, Pus cells in urine which can be detected in the urine test. 
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  EXCLUSION CRITERIA:  
 
         A potential subject who meets any of the following criteria will be excluded 
from participation in this study: 
 Stone size >10mm 
 Pregnancy and lactation 
 Presence of any associated severe systemic illness, e.g.CA  
 Patient taking any other lithotriptic agent 
 History of  Diabetes/ Hypertension 
 History of  Hepatic disease 
 History of  other Renal disease 
 History of  Cardiac disease 
 History of drug/alcohol abuse 
 History of taking treatment for any other ailments 
 
WITHDRAWAL CRITERIA: 
a. Intolerance to the drug & development of any serious adverse reactions 
during the trial period. 
b. Poor patient compliance & defaulters.  
 
c. Patient turned unwilling to continue in the course of clinical trial. 
 
d. Increase in severity of symptoms.  
 
e. Patient will not take medication regularly.  
 
 
ASSESSMENTS AND INVESTIGATIONS: 
 
a) clinical assessment 
    Siddha assessment 
b) Routine  investigations: 
1. Modern parameters 
2. Siddha parameters 
 
c) Specific investigations 
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a) CLINICAL ASSESSMENT: 
              
 Abdominal pain 
 Pain from Loin to groin 
 Agonizing pain 
 Pain in urethra 
 Yellow coloured urination 
 Burning Micturition 
 Oliguria 
 Dysuria 
 Abdominal distension 
 Nausea & vomitin 
 Haematuria 
 
SIDDHA ASSESSMENT: 
 
1. Thinai (Land): 
 Kurinchi (Hill areas) 
 Mullai (Forest) 
 Marutham (Fertile land) 
 Neithal (Costal area) 
 Paalai (Desert) 
 
 
 
2. Paruvakaalam (Season) 
 Kaar kaalam 
 Koothir kaalam 
 Munpani kaalam 
 Pinpani kaala 
 Elavenil kaalam 
 Muthuvenil kaalam 
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3. Poripulankal: 
 Mei (Skin) 
 Vaai (Tongue) 
 Kan (Eye) 
 Mooku (Nose) 
 Sevi (Ear) 
4. Kanmedriyam and Gnanenthiriyam: 
 Vaai (Buccal cavity) 
 Kaal (Lower limbs) 
 Kai (Upper limbs) 
 Eruvaai (Anorectal region) 
 Karuvaai (Uro-genital region) 
 
  5. Ezhu udal kaugal: 
 Saram 
 Senneer 
 Uoon 
 Kozhuppu 
 Enbu 
 Moolai 
 Sukkilam /suronitham 
 
6. Enn vagai thervu ( Eight types of Examination): 
 Naadi 
 Sparisam 
 Naa 
 Niram 
 Mozhi 
 Vizhi 
 Malam 
 Moothiram 
       -Neerkuri 
       -Neikuri 
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b) ROUTINE INVESTIGATIONS:   
 Modern parameters: 
 Hb  (gms/dl)                 
 
 Total RBC (million/cu.mm) 
 
 Total WBC (cubic mm) 
 Differential count: (%) 
 Polymorphs  
 Lymphocytes   
 Monocytes      
 Eosinophils       
 Basophils 
 ESR(mm/hr) 
 
 Blood sugar level    Fasting (mg/dl) 
                              Post prandial (mg/dl) 
                                   Random (mg/dl) 
 
 
 Lipid profile        Total cholesterol (mg/dl) 
                            HDL (mg/dl) 
                                        LDL (mg/dl) 
                                        VLDL (mg/dl) 
                                        TGL (mg/dl) 
 
 
 Bleeding time - /min 
 
 Clotting time - /min 
 
 Renal function test    -     Blood Urea (mg/dl) 
                                      Serum total Creatinine (mg/dl) 
                                       Uric acid (mg/dl) 
 
 
 
 Liver function test    -     Serum total bilirubin (mg/dl) 
                                                Direct bilirubin (mg/dl) 
                                                 Indirect bilirubin (mg/dl) 
                                                SGOT (IU/L) 
                 SGPT (IU/L) 
                Serum Alk.phosphotase (kingÅ units) 
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                 Serum calcium (mg/dl)  
                 Serum phosphorus (mg/dl)  
                                                Total protein (mg/dl)  
                                                Serum albumin (mg/dl)  
                                                 Serum globulin (mg/dl)  
                                                 Serum fibrinogen (g/dl) 
 
 Urine:                  Albumin 
        Sugar (fasting& post prandial) 
        Deposits 
        Bile salts 
        Bile pigments 
                                       Urobilinogen 
                                       Culture and sensitivity 
 
 Motion:               Ova 
       Cyst 
       Occult blood 
 Siddha parameters: 
 Malam         -  Niram: 
                     -  Elakal / Erukal: 
                     -  Muraigal (Times / day) kalappu: 
 
 Moothiram (urine): 
 Neerkkuri (urine signs):                                         neikkuri: 
i. Niram: 
ii. Edai: 
iii. Manam: 
iv. Nurai: 
v. Enjal 
 
C) SPECIAL INVESTIGATIONS: 
  
 Ultrasonography - Abdomen/ KUB 
 X-ray- KUB 
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  STUDY ENROLLMENT: 
 In this clinical trial, patients reporting at NIS OPD with the clinical symptoms 
of abdominal pain, pain from loin to groin, agonizing pain, pain in urethra, 
dysuria, oliguria, yellow coloured urination, burning micturition, abdominal 
distension, haematuria, nausea & vomiting will be examined clinically for 
enrolling in the study based on the inclusion(including USG/KUB) and 
exclusion criteria.  
 The patients enrolled in this study  will be informed (Form IV) about the 
objective of  
the study, trial drug, possible outcomes in their own language and terms 
understandable to them. 
 After ascertaining the patients willingness, informed consent will be obtained 
in the consent form (Form IV-A). 
 All these patients will be given unique registration card in which patients 
Registration number of the study, Address, Phone number and Doctors phone 
number etc. so as to report easily and any adverse reaction arise. 
 Complete clinical history, complaints and duration, examination findings-- all 
will be recorded in the prescribed Proforma in the history and clinical 
assessment forms separately. Screening Form- I will be filled up; Form I-A,  
      Form –II and Form –III will be used for recording the patients‟ history, 
clinical 
      examination of  signs and symptoms and laboratory investigations 
respectively. 
 Patients will be advised to take the trial drug and appropriate dietary advice        
(Form IV-D) would be given according to the patients perfect understanding. 
 
CONDUCT OF THE STUDY: 
 
       
          The trial drug “KARPOORA SILASATHU PARPAM” is given continuously 
for 48 days. For OP patients, they should visit the hospital once in 7days. At each 
clinical visit clinical assessment is done and prognosis is noted. For IP patients the 
drug is provided daily and prognosis is noted.  
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            Laboratory investigations & ultrasonography investigation are done 0
th
 day & 
49
th
 day of the trial. For IP patients, who is not in a situation to stay in the hospital for 
a long time is advised to attend the OPD for further continuation of the treatment. 
 
    During the course of the treatment, patient is advised not to take tamarind, tea, 
coffee, non-veg, tomato, cabbage, cauliflower etc., and advised to take the diet as 
given in Form IV- D. 
 
Follow-up: 
 
             After the end of the treatment, the patient is advised to visit the OPD for 
another 2months for follow-up.(medicines will not be given) If any of the trial patient 
who fails to collect the trial drug on the prescribed day but wants to continue in the 
trial, from the next day or two, he/ she will be allowed, but defaulters of one week and 
more will not be allowed to continue and be withdrawn from the study with fresh case 
being inducted.   
 
DATA MANAGEMENT: 
 
 After enrolling the patient in the study, a separate file for each patient will be 
opened and all forms will be filed in the file. Study No. and Patient No. will be 
entered on the top of file for easy identification.  Whenever the study patient 
visits OPD during the study period, the respective patients file will be taken 
and necessary recordings will be made at the assessment form or other suitable 
forms. 
 
 The screening forms will be filed separately. 
 
 The Data recordings will be monitored for completion by HOD, SRO 
(statistics) and the adverse event will be monitored by the members of the  
pharmacovigilance department of NIS . All forms will be further scrutinized in 
presence of Investigator by Sr.Research Officer (Statistics) for logical errors 
and incompleteness of data to avoid any bias. No modification in the results is 
permitted for unbiased reports. 
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 OUT COME OF TREATMENT: 
 
     Study Outcome is mainly assessed by, 
 
1. Clearance/ reduction in the size of renal calculus in X-ray KUB and 
USG abdomen. 
 
2. Complete reduction of clinical symptoms and improvement in the lab 
investigations. 
 
 
 
 ADVERSE EFFECT/SERIOUS EFFECT MANAGEMENT: 
  
          If the trial patient develops any adverse reaction (acute renal colic i.e. severe 
pain caused by the kidney stone and associated with nausea, vomiting and fever) 
he/she will be referred to the pharmacovigilance department of NIS. The members of 
this department will assess the adverse event and recorded in the prescribed adverse 
reaction form. For any AE the investigator will be given the proper management in 
NIS OPD with free of cost.  
 
STATISTICAL ANALYSIS: 
          All collected data will be entered into the computer and manually cross-
checked the correctness of the data entry. The clinical symptoms and size of the stone 
will be analyzed by comparing the two point of data (before and after treatment) 
paired test and chi-square test will be employed to study the efficacy of treatment. 
Further, the effect of age and sex will also be analyzed. 
 
 ETHICAL ISSUES: 
1. Informed consent will be obtained from the patient explaining in the 
understandable language to the patient. 
2. After the consent of the patient (through consent form) they will be enrolled in 
the study. 
3. Treatment will be provided free of cost. 
4.  USG- Abdomen will be taken in the NABL certified laboratories and charges 
will be borne by the Investigator. 
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5.  No other external or internal medicines will be used. There will be no 
infringement on the rights of patient.  
6.  To prevent any infection, while collecting blood sample from the patient, only 
   Disposable syringes, disposable gloves, with proper sterilization of lab 
equipments will be used.  
      7.  The data collected from the patient will be kept confidentially. The patient will 
be informed about the clinical trial, diagnosis, treatment and follow-up.  
 8. The patients who are excluded [as per the exclusion criteria] are given proper      
treatment, with full care at NIS.  
 9. All adverse events occurs during the trial period will be recorded by the 
Pharmacovigilance department team members.  If the event will be mild, the 
patient will be treated in NIS OPD. If the event will be severe the patient will be 
referred to the nearby Govt. hospital and take care of the patient until he/she will 
get recovery. The treatment will be provided free of cost. 
 
 
20.0 ASSESSMENT FORMS: 
 
Form - I             Screening and Selection Proforma 
Form - IA          History Proforma on enrollment 
Form - II            Clinical Assessment on enrollment  
Form - IIA         Clinical Assessment during and after the trial 
Form - III           Laboratory investigations on enrollment during and after the trial. 
Form - IV           Information sheet 
Form - IV A       Consent form 
Form - IV B       Withdrawal form 
Form - IV C       Drug Compliance form 
Form - IV D       Dietary Advice form 
Form - IV E       Adverse Reaction form  
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RESULTS AND OBSERVATIONS 
Results were observed with respect to the following criteria: 
1. Gender Distribution 
2. Age Distribution 
3. Gunam Distribution 
4. Kaalam Distribution 
5. Dietary Habits 
6. Seasonal Variation 
7. Thinai 
8. Occupational Status 
9. Treatment History 
10. Chronicity of Illness 
11. Clinical Features 
12. Disturbances in Vatham 
13. Disturbances in Pitham 
14. Disturbances in Kabam 
15. Kosangal 
16. Naadi 
17. Neerkuri 
18. Neikkuri 
19. Calculus in urinary system 
20. Hydrouretronephrosis 
21. Urine culture and sensitivity 
22. Outcome -  Result of USG abdomen 
23. Before after treatment of clinical features  
24. Result of Clinical features  
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DISTRIBUTION OF CASES BY GENDER 
GENDER NO. OF CASES  PERCENTAGE (%) 
MALE 28 70 
FEMALE 12 30 
TOTAL 40 100 
 
 
 
 
 
 
INFERENCE: 
 
         Among the 40 cases the prevalence of the disease was found to be higher in 
males. i.e. 70 % (28cases). 
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DISTRIBUTION OF CASES BY AGE 
 
   AGE (YEAR) NO. OF CASES    PERCENTAGE   % 
  21 to 30 9 22.5 
  31 to 40 16 40 
  41 to 50 9 22.5 
  51 to 60 6 15 
  TOTAL 40 100 
 
 
 
 
 
 
 
INFERENCE: 
The prevalence of the disease was found to be higher in the age group 31 - 40 
years. i.e, 16 cases (40%). 
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                DISTRIBUTION OF CASES BY GUNAM 
 
 
 
 
 
 
 
 
 
INFERENCE: 
All the 40 cases (100 %) were found to posses Rasatha gunam. 
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DISTRIBUTION OF CASES BY KAALAM (LIFE SPAN) 
 
KAALAM NO. OF CASES PERCENTAGE % 
Vatha kaalam (upto 33years) 15 37.5% 
Pitha kaalam (33 – 66 years) 25 62.5% 
Kaba kaalam (66 – 100 years) 0 0% 
 
 
 
 
 
INFERENCE: 
           Out of 40 cases, 25 cases (62.5%) were found to be in Pitha kaalam i.e. 
between 33 - 66 years and 15 cases (37.5%) were in vatha kaalam. 
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DISTRIBUTION OF CASES BY FOOD HABITS 
 
 
FOOD HABITS NO. OF CASES  PERCENTAGE  % 
Vegetarian 2 5 
Non- vegetarian 38 95 
Total 40 100 
  
 
 
 
 
 
 
INFERENCE: 
Among the 40 cases 38 cases (95%) were Non vegetarians and 2 cases (5%) 
were     vegetarians. 
  
vegetarian
5%
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DISTRIBUTION OF CASES BY PARUVAKAALAM (SEASON) 
 
PARUVA KAALAM NO. OF CASES PERCENTAGE % 
Kaar kaalam( Aug 17 - Oct 17 ) 4 10 
Koothir kaalam( Oct 18 - Dec 15 ) 0 0 
Munpani kaalam(Dec 16 - Feb 12 ) 0 0 
Pinpani kaalam(Feb 13 - Apr 13 ) 0 0 
Elavenil kaalam(Apr 14 - Jun 16 ) 9 22.5 
Muthuvenil kaalam(Jun 17 - Aug 16 ) 27 67.5 
Total 40 100 
 
 
 
 
      INFERENCE: 
 Among the 40 cases 27 cases (67.5 %) were admitted in Muthuvenil 
kaalam, 9 cases (22.5 %) were admitted in Elavenil kaalam and 4cases (10%) were 
admitted in kaar kaalam. 
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DISTRIBUTION OF CASES AS PER THINAI (LAND) 
 
THINAI (LAND) NO. OF CASES   PERCENTAGE   % 
Kurinji (Hill terrain) 0 0 
Mullai (Forest range) 0 0 
Marutham (Plain) 1 2.5 
Neithal (Costal belt) 39 97.5 
Paalai (Arid regions) 0 0 
Total 40 100 
 
 
 
 
 
 
INFERENCE: 
Among the 40 cases 39 cases (97.5%) were from Neithal thinai and 1 case 
(2.5%) was from Marutham thinai. 
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                   DISTRIBUTION OF CASES BY OCCUPATIONAL STATUS 
                                                                 
S. NO OCCUPATION NO. OF CASES PERCENTAGE % 
1. Sedentary work style 13 32.5 
2. Standing work style 2 5 
3. Field work style 8 20 
4. Home maker 10 25 
5. Coolie 1 2.5 
6 Cable Tv operator 1 2.5 
7. Fancy articles vender 2 5 
8. Sales executive 1 2.5 
9. farmer 1 2.5 
10. student 1 2.5 
Total 40 100 
 
 
 
 
 
INFERENCE:  
Among the 40 patients, 13cases (32.5%) were sedentary work style. 10cases (25%) 
were home maker. 8cases (20%) were field work and 2cases (5%) were standing work 
and fancy article vender. Rest of 1case (2.5%) were Coolie, Cable Tv operator, Sales 
executive and farmer. 
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             TREATMENT HISTORY (BEFORE ADMITTED TO THE TRIAL)     
                                                             
TREATMENT HISTORY NO. OF CASES PERCENTAGE (%) 
H/O Allopathy medicine taken 26 65 
No H/O any Medication 14 35 
Total 40 100 
  
 
 
 
 
INFERENCE:  
Among the 40cases, 26cases (65%) had taken allopathic treatment in the past 
and had discontinued the same. The rest of the 14cases (35%) had not taken any other 
drugs prior to enrolling for the study. 
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DISTRIBUTION OF CASES BY CHRONICITY OF ILLNESS 
 
DURATION IN MONTHS NO. OF CASES PERCENTAGE % 
0 to 3 29 72.5 
4 to 6 10 25 
7 to 9 0 0 
Above 9 1 2.5 
Total 40 100 
 
 
 
 
 
INFERENCE: 
Among the 40 cases majority of them were 0 to 3 months in their 
duration of illness, i.e, 29 cases (72.5%), 10cases (25%) had the illness in 4 to 6 
months and 1case (2.5%) was above 9 months. 
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DISTRIBUTION OF CASES AS PER CLINICAL FEATURES 
 
 
INFERENCE: 
               In clinical features, all the 40 cases (100%) had abdominal pain and pain 
from loin to groin region. 32cases(80%) had yellow coloured urination. 27cases 
(67.5%) had oliguria and burning micturition. 10cases (25%) were affected by 
dysuria. 9cases (22.5%) were affected by agonizing pain. 8cases (20%) had pain in 
urethra and 4cases (10%) had nausea and vomiting. 
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CLINICAL FEATURES NO. OF CASES PERCENTAGE % 
Abdominal pain 40 100 
Pain from loin to groin region 40 100 
Abdominal distension 0 0 
Pain in urethra 8 20 
Agonizing pain 9 22.5 
Dysuria 10 25 
Oliguria 27 67.5 
Burning micturition 27 67.5 
Yellow colored urination 32 80 
Nausea & Vomiting 4 10 
Haematuria 0 0 
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                                DISTURBANCES IN VATHAM 
 
 
VATHAM NO. OF CASES PERCENTAGE (%) 
Pranan 0 0 
Abanan 31 77.5 
Uthanan 4 10 
Viyanan 40 100 
Samanan 40 100 
Nagan 0 0 
Koorman 0 0 
Kirugaran 0 0 
Devethathan 0 0 
Dhananjeyan 0 0 
 
 
 
INFERENCE:  
                Out of 40 cases observed, viyanan was affected which resulted in abdominal 
pain and loin pain in all the 40 cases (100%) also samanan was affected in all the 40 
cases (100%) because it controls the other types of vathas. Abanan was affected 
which resulted in oliguria in 31cases (77.5%)  
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                                     DISTURBANCES IN PITHAM 
 
PITHAM    NO. OF CASES PERCENTAGE (%) 
Anarpitham 4 10 
Ranjagam  0 0 
Sathagam 40 100 
prasagam 0 0 
Alosagam 0 0 
 
 
 
 
INFERENECS: 
              Out of 40 cases, saathaga pitham was affected in all the cases (100%) as a 
result the patients were unable to perform their routine duties. Anarpitham was 
affected in 4 cases (10%) which resulted in nausea and vomiting. 
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DISTURBANCES IN KABAM 
                     
                                                       
KABAM 
 
   NO. OF CASES PERCENTAGE (%) 
Avalambagam 0 0 
kilethagam 0 0 
Pothagam 4 10 
Tharpagam 0 0 
santhigam 0 0 
 
 
 
 
 
INFERENECS: 
          Out of 40 cases pothagam was affected in 4cases (10%) which resulted in 
nausea and vomiting. 
 
 
 
 
 
0%
1%
2%
3%
4%
5%
6%
7%
8%
9%
10%
Avalambagam Kiletham Pothagam Tharpagam Santhigam
0% 0%
10%
0% 0%
C
A
SE
S%
DISTURBANCES IN KABAM
 
106 
 
                                                        KOSANGAL 
 
 
KOSAM NO. OF  CASES PERCENTAGE  (%) 
Annamaya kosam 4 10 
Pranamaya koosam 0 0 
Manomaya kosam 0 0 
Vignanamaya kosam 40 100 
Aananthamaya kosam 0 0 
 
 
 
 
 
INFERENECS: 
               Out of 40 cases, vingyanamayakosam was affected in all the 40 cases 
(100%) which resulted in abdominal pain and loin pain and 4cases (10%) was 
affected in Annamaya kosam which resulted in nausea and vomiting. 
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DISTRIBUTION OF CASES BY NAADI 
 
NAADI NO. OF CASES PERCENTAGE % 
azhal 1 2.5 
Valiazhal 21 52.5 
Azhalvali 18 45 
Total 40 100 
 
 
 
 
 
 
 
 
INFERENCE:  
  Among the 40 cases vali azhal naadi was felt in 21 cases (52.5 %), 
azhal vali naadi was felt in 18 cases (45 %); azhal naadi was felt in 1 case (2.5 %). 
 
 
 
 
0.00%
10.00%
20.00%
30.00%
40.00%
50.00%
60.00%
Azhal
Valiazhal
Azhalvali
2.50%
52.50%
45%
C
A
SE
S%
NAADI
 
108 
 
DISTRIBUTION OF CASES BY NEERKURI (URINE ANALYSIS) 
 
NEERKURI NO. OF CASES PERCENTAGE % 
Niram 
Yellow colour 32 80 
Straw colour 8 20 
volume  
reduced 27 67.5 
normal 13  32.5              
Manam 0 0 
Edai 0 0 
Nurai 0 0 
Enjal (Deposites) 12 30 
 
 
 
INFERENCE:  
Out of 40 cases, yellow coloured was observed in 32 cases (80%) and straw 
coloured was in 8cases (20%). The volume of urine was reduced amount in 27 cases 
(67.5%); rest of 13 cases (32.5%) had normal urine volume. Enjal was found to be in 
12 cases (30%) in the presence of bacterial infections. No other changes were 
observed in Manam, Edai and Nurai. 
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DISTRIBUTION OF CASES BY NEIKKURI (OIL SIGN IN URINE) 
 
NEIKKURI NO. OF CASES PERCENTAGE % 
Serpentine 3 7.5 
Annular/ring 10 25 
Pearl shape 27 67.5 
Total 40 100 
 
 
 
 
 
 
 
INFERENCE:  
Among the 40 cases, in 27cases (67.5%) the neikkuri was observed as 
pearl like. In 10cases (25 %) the neikkuri was observed as Annular like and in 3cases 
(7.5%) neikkuri was observed as serpentine like. 
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DISTRIBUTION OF CALCULUS IN URINARY SYSTEM 
 
SITE OF CALCULUS NO. OF CASES PERCENTAGE % 
Both kidneys 15 37.5 
Right kidney 7 17.5 
Left kidney 6 15 
 Ureter 12 30 
 
 
 
 
 
INFERENCE:  
Out of 40 cases, 15 cases (37.5%) had bilateral renal calculi, 13 cases (32.5%) 
had unilateral renal calculi, out of them 7cases (17.5%) in right kidney and 6 cases 
(15%) in left kidney. 12cases (30%) had ureteric calculi. 
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URINE CULTURE AND SENSITIVITY 
CULTUREAND SENSITIVITY 
 
NO. OF CASES 
 
PERCENTAGE (%) 
Before treatment 12 30 
 
After 
treatment 
No growth 5/12 41.7 
 
Grown in culture 7/12 58.3 
 
 
 
 
 
    INFERENCE: 
           Among the 40 cases, 12cases (30%) had Bacterial infections in urine culture 
before treated with trial drug. Out of them 5cases (41.7%) were found to be no 
bacterial infections in urine culture after the completion of the trial drug treatmen and 
7 cases (58.3%) had grown in culture. 
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           HYDROURETERONEPHROSIS 
 
HYDROURETERONEPHROSIS NO. OF CASES PERCENTAGE (%) 
 
Before treatment 12 30 
 
After 
treatment 
Relieved 7/12 58.3 
 
Not relieved 5/12 41.7 
 
  
 
 
 
 
INFERENCE:  
            Before treated with trial drug 12 cases (30%) had hydroureteronephrosis. 
Among them, 7cases (58.3%) were relieved from hydroureteronephrosis after the 
treatment with trial drug and 5 cases (41.7%) were not relieved. 
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OUTCOME MEASUREMENTS 
 
  1. PRIMARY OUTCOME OBSERVATION  
RESULT OF USG ABDOMEN AFTER TREATMENT 
RESULT NO. OF CASES PERCENTAGE % 
Normal study 15 37.5 
Reduced 20 50 
Increased 2 5 
No change 3 7.5 
Total 40 100 
 
 
 
INFERENCE:  
Out of 40 cases, 15 cases (37.5%) showed normal study, i.e. Stone completely 
dissolved. 20cases (50%) showed reduce its size and number. 2cases (5%) showed 
increase in size and 3cases (7.5%) showed no changes in size.  
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                                        IMPROVEMENT OF USG ABDOMEN 
 
RESULT NO. OF CASES PERCENTAGE % 
Good   35 87.5 
Poor   5 12.5 
Total  40 100 
 
 
 
Based on the above result of USG abdomen after treatment,  
               87.5% showed Good results and 12.5% showed poor results.  
Good -   Normal study (stone completely dissolved)  
               Reduced its number (more than 2 / multiple)  
               Reduced its size. 
Poor -    No change in size and increase in size 
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   2. SECONDARY OUTCOME OBSERVATION 
          CLINICAL FEATURES BEFORE AND AFTER TREATMENT 
 
 
 
 
 
 
 
 
 
 
 
 
CLINICAL FEATURES        BEFORE 
TREATMENT 
          AFETR 
  TREATMENT 
Abdominal pain 40 2 
Pain from loin to groin region 40 2 
Abdominal distension 0 0 
Pain in urethra 8 0 
Agonizing pain 9 0 
Dysuria 10 0 
Oliguria 27 0 
Burning micturition 27 0 
Yellow colored urination 32 0 
Nausea and Vomiting 4 0 
Haematuria 0 0 
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INFERENCE: 
            After treatment 38 cases (95%) had relieved from abdominal pain and loin 
pain. Rest of the other symptoms such as abdominal distension, pain in urethra, 
agonizing pain, dysuria, oliguria,  yellow coloured urination, burning micturition, 
nausea and vomiting, haematuria were relieved in 100% of cases. 
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RESULT OF CLINICAL FEATURES AFTER TREATMENT 
RESULT NO. OF CASES PERCENTAGE % 
Good   38 95 
Moderate     2 5 
Poor   0 0 
Total  40 100 
 
 
 
Good         - Symptoms completely relieved. 
Moderate - Symptoms reduced. 
Poor          - Symptoms not reduced. 
INFERENCE: 
Out of the 40 cases good improvement was observed in 38 patients (95%), 
moderate improvement in 2 patients (5 %).  
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STATISTICAL ANALYSIS 
 
                  Mean and Standard deviation was used to test the significance of treatment 
using before and after treatment data on Renal Calculi and Symptoms. 
       The level of significance probability 0.05 was used to test the treatment 
difference and the values are statistically significant. 
 
        Mean and Standard deviation of Renal calculi at before and after treatment 
 
variable    Mean  Std.Deviation Std.Error 
Mean 
    t 
VALUE 
p VALUE 
BTRLK 8.302 3.1685 .5010 6.092 P<0.001 
ATRLK 4.200 4.0324 .6376 
 
The mean± standard deviation of renal calculi at before and after treatment were 8.30 
± 3.16 and 4.2 ± 4.03 respectively which is statistically significant (t= 6.092 p<0.001). 
BTRLK – before treatment right left kidney 
BTRLK – after treatment right left kidney 
 
          Mean and Standard deviation of clinical Symptoms before and after 
treatment 
 
clinical 
Symptoms 
   Mean  Std.Deviation Std.Error 
Mean 
    t 
VALUE 
p VALUE 
Before 
treatment 
4.95 
 
1.894 0.299 7.525 
 
P < 0.0001 
After 
treatment 
2.93 0.656 0.104 
 
               The mean± standard deviation of symptoms score at before and after 
treatment were 4.95 ± 1.89 and 2.93 ± 0.66 respectively which is statistically highly 
significant (t= 7.5 p<0.0001) i.e. the symptoms have been reduced significantly after 
the treatment. 
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USG ABDOMEN REPORT BEFORE AND AFTER TREATMENT 
S. 
NO 
OPD/ 
IPD NO 
AGE/ 
SEX   
SIZE OF THE 
KIDNEY 
SITE OF THE 
CALCULUS 
NO OF 
CALCULUS 
SIZE OF THE 
CALCULUS 
HYDROURETERO 
NEPHROSIS 
1 C69642 24/F RT.KIDNEY BT 9.7 ×4.4cm lower calyx 2 3.2, 4.3mm nil 
        AT 105 ×42mm 
normal 
study 
    nil 
      LT.KIDNEY BT 
11.0× 
5.1cm 
- - - nil 
        AT 112× 40mm - - - nil 
2 C71045 31/M RT.KIDNEY BT 
10.5× 
4.7cm 
lower pole 1 4.8mm nil 
        AT 
10.9× 
4.4cm 
normal 
study 
    nil 
      LT.KIDNEY BT 
10.1× 
4.5cm 
- - - nil 
        AT 
10.3 
×5.2cm 
- - - nil 
3 C73030 43/M RT.KIDNEY BT 
91.3 
×61.4mm 
upper, middle 
calyx 
3 
3.0, 5.5mm, 
4.5mm 
nil 
        AT 
10.1 
×4.4cm 
upper pole 1 5.1mm nil 
      LT.KIDNEY BT 
98.8 
×54.4mm 
upper, middle 
calyx 
3 
3.0, 5.7mm, 
3.0mm 
nil 
        AT 
10.3× 
5.2cm 
lower pole 1 5.7mm nil 
4 C73050 43/M RT.KIDNEY BT 
102.8×  
53.6mm 
mid, lower 
pole 
4 
5.0mm, 
4.0,3.0mm 
nil 
        AT 
102.6 × 
53.6mm 
mid, lower 
pole 
3 
3.5mm, 
4.0,2.5mm 
nil 
      LT.KIDNEY BT 
87.5 × 
53.7mm 
upper, mid, 
lower pole 
4 
4.0,3.0mm, 
6.0,3.0mm 
nil 
        AT 
87.5×  
53.7mm 
upper, mid 
pole 
3 
4.0mm, 
6.0,4.0mm 
nil 
5 C72496 32/F RT.KIDNEY BT 9.4 ×2.9cm lower pole 1 4.0 mm nil 
        AT 9.0× 4.1cm 
normal 
study 
    nil 
      LT.KIDNEY BT 9.4× 4.8cm - - - nil 
        AT 9.5× 4.7cm - - - nil 
6 C74152 52/M RT.KIDNEY BT 
90.9×  
43.3mm 
inter polar 
calyx 
2 8.9, 8.3mm nil 
        AT 
89.6×  
36.7mm 
normal 
study 
    nil 
      LT.KIDNEY BT 
101.3×  
53.4mm 
pelvic 
calyceal 
system 
multiple 9.5mm nil 
        AT 
99.5 × 
57.6mm 
normal 
study 
    nil 
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S.# 
OPD/ 
IPD NO 
AGE/ 
SEX   
SIZE OF THE 
KIDNEY 
SITE OF THE 
CALCULUS 
NO OF 
CALCULUS 
SIZE OF THE 
CALCULUS 
HYDROURETERONEPH
ROSIS 
7 C73299 32/M RT.KIDNEY BT 
100.9× 
44.2mm 
- - - nil 
        AT 
104.0 
×44.5mm 
- - - nil 
      LT.KIDNEY BT 
107.6× 
52.5mm 
mid calyx 1 5.6mm nil 
        AT 
111.2× 
55.omm 
mid calyx 1 5.7mm nil 
8 C73332 42/F RT.KIDNEY BT 96 ×43mm lower pole multiple 4mm nil 
        AT 
10.7 
×4.7cm 
lower pole 3 3mm nil 
      LT.KIDNEY BT 92 ×49mm mid pole multiple 3.5mm nil 
        AT 
10.7 
×5.0cm 
upper, inter, 
lower pole 
3 3-4mm nil 
9 C75054 50/M RT.KIDNEY BT 
1o.2cm 
long 
- - - nil 
        AT 
1o.2cm 
long 
- - - nil 
      LT.KIDNEY BT 
11.0cm 
long 
mid calyx, 
mid ureter 
2 8mm, 12mm + 
        AT 
10.5cm 
long 
mid calyx 1 8mm nil 
10 C76543 24/M RT.KIDNEY BT 10cm long upper pole 1 6-7mm nil 
        AT 
102× 
46.6mm  
normal 
study 
    nil 
      LT.KIDNEY BT 
10.5cm 
long 
lower pole 1 3-4mm nil 
        AT 
97.8 
×53.2mm 
normal 
study 
    nil 
11 C74751 33/M RT.KIDNEY BT 
95.9 
×50.6mm 
middle calyx few 4.8mm nil 
        AT 
10.3 
×4.8cm 
upper, mid 
calyx 
2 
0.3,0.8 
×0.5mm 
nil 
      LT.KIDNEY BT 
97.3 
×55.3mm 
middle calyx 1 4.2mm nil 
        AT 
10.3 
×4.9cm 
normal 
study 
    nil 
12 C77242 34/M RT.KIDNEY BT 9.6×4.3cm 
inter polar 
calyx 
2 
6.4mm, 
7.2mm 
nil 
        AT 10.0×4.8cm 
inter polar 
calyx 
1 6.9mm nil 
      LT.KIDNEY BT 
10.1 
×5.3cm 
- - - nil 
        AT 
10.1 
×4.9cm 
- - - nil 
13 C77701 28/F RT.KIDNEY BT 
12.2× 
5.4cm 
dilated 
system 
few 8-10mm + 
        AT 
12.2× 
5.4cm 
dilated 
system 
few 8-10mm + 
      LT.KIDNEY BT 
11.3× 
5.4cm 
- - - nil 
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S. 
NO 
OPD/ 
IPD NO 
AGE/ 
SEX   
SIZE OF THE 
KIDNEY 
SITE OF THE 
CALCULUS 
NO OF 
CALCULUS 
SIZE OF THE 
CALCULUS 
HYDROURETERONEPH
ROSIS 
        AT 
11.3 
×5.0cm 
- - - nil 
14 C78713 53/M RT.KIDNEY BT 9.2 ×4.4cm mid pole 1 5.0mm nil 
        AT 8.6 ×4.2cm 
normal 
study 
    nil 
      LT.KIDNEY BT 9.2× 4.6 lower pole 1 3.0mm nil 
        AT 8.8× 4.8cm 
normal 
study 
    nil 
15 C79434 29/M RT.KIDNEY BT 8.9× 3.9cm upper calyx 1 5mm nil 
        AT 8.3× 3.5cm upper calyx 1 4mm nil 
      LT.KIDNEY BT 9.5× 3.8cm - - - nil 
        AT 9.1× 4.0cm - - - nil 
16 C78007 38/M RT.KIDNEY BT 
11.0× 
6.0cm 
mid ureter 1 10mm + 
        AT 
11.8 
×6.2cm 
mid ureter 1 8mm + 
      LT.KIDNEY BT 
11.0 
×5.5cm 
- - - nil 
        AT 
10.3× 
5.3cm 
- - - nil 
17 C80489 40/F RT.KIDNEY BT 10.0× 4.cm - - - nil 
        AT 
92.9× 
44.1mm 
middle calyx 1 4mm nil 
      LT.KIDNEY BT 
11.0 
×5.0cm 
VUJ 1 0.9,0.6cm + 
        AT 
97.5× 
54.0mm 
normal 
study 
    nil 
18 C80919 29/M RT.KIDNEY BT 9.6 ×4.3cm 
upper, lower 
pole 
2 
5.4, 
11.4×8mm 
nil 
        AT 9.4 ×4.5cm lower pole 1 11.4×7.7mm nil 
      LT.KIDNEY BT 
11.4× 
5.5cm 
- - - nil 
        AT 
11.2× 
5.8cm 
- - - nil 
19 C81353 60/M RT.KIDNEY BT 
117.0 
×51.7mm 
mid ureter 1 7.5mm + 
        AT   
normal 
study 
    nil 
      LT.KIDNEY BT 
104.8 
×55.4mm 
mid pole 1 2.5mm nil 
        AT   
normal 
study 
    nil 
20 C81148 36/M RT.KIDNEY BT 9.9× 5.4cm 
upper, inter, 
lower pole 
multiple 6.0mm nil 
        AT 
1o.4× 
6.2cm 
lower pole multiple 5.0mm nil 
      LT.KIDNEY BT 9.1×5.2cm 
inter, lower 
pole 
multiple 5.6mm nil 
        AT 
10.1 
×5.5cm 
mid pole multiple 3.0mm nil 
21 C82243 22/M RT.KIDNEY BT 9.3× 3.9cm - - - nil 
        AT 9.4 ×3.8cm - - - nil 
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S. 
NO 
OPD/ 
IPD NO 
AGE/ 
SEX   
SIZE OF THE 
KIDNEY 
SITE OF THE 
CALCULUS 
NO OF 
CALCULUS 
SIZE OF THE 
CALCULUS 
HYDROURETERONEPH
ROSIS 
      LT.KIDNEY BT 
10.2× 
3.7cm 
lower pole 1 4.5mm nil 
        AT 
10.0× 
4.4cm 
normal 
study 
    nil 
22 C81712 60/M RT.KIDNEY BT 
11.6 
×5.0cm 
proximal 
ureter 
1 10-15mm + 
        AT 9.8× 5.7cm lower ureter 1 8mm + 
      LT.KIDNEY BT 
10.7× 
5.0cm 
mid pole 1 5mm + 
        AT 
10.2× 
5.4cm 
mid pole 1 4mm + 
23 C82707 42/M RT.KIDNEY BT 
103.4× 
45.7mm 
- - - nil 
        AT 
109.2 
×43.6mm 
- - - nil 
      LT.KIDNEY BT 
116.6 
×61.4mm 
VUJ 1 6.6mm + 
        AT 
117.1 
×50.6mm 
normal 
study 
    nil 
24 C82990 27/M RT.KIDNEY BT 8.5× 3.7cm 
upper, mid 
pole 
multiple 5.0, 4.0mm + 
        AT 8.5 ×3.7cm 
upper, mid 
pole 
microliths   nil 
      LT.KIDNEY BT 9.0× 4.7cm lower pole 1 5.0mm nil 
        AT 9.0× 4.7cm lower pole microliths   nil 
25 C84030 38/M RT.KIDNEY BT 8.0× 3.7cm - - - nil 
        AT 
80.7× 
34.9mm 
- - - nil 
      LT.KIDNEY BT 9.6× 6.2cm 
proximal 
ureter 
1 10mm + 
        AT 
101.4× 
56.7mm 
normal 
study 
    nil 
26 C80753 48/M RT.KIDNEY BT 
100.1 
×45.2mm 
lower calyx 1 4.2mm nil 
        AT 
92.4 
×48.1mm 
normal 
study 
    nil 
      LT.KIDNEY BT 
84.1 
×96.6mm 
lower pole microliths   + 
        AT 
90.4 
×49.1mm 
normal 
study 
    nil 
27 C85766 32/M RT.KIDNEY BT 
103.8 
×49.8mm 
upper calyx 1 4.4mm nil 
        AT 
98.4 
×47.9mm  
normal 
study 
    nil 
      LT.KIDNEY BT 
100.8× 
46.7mm 
- - - nil 
        AT 
96.3 
×46mm 
- - - nil 
28 C85523 25/F RT.KIDNEY BT 
10.6 
×4.3cm 
  multiple 4mm + 
        AT 9.9 ×4.0cm   multiple 5-6mm  + 
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S. 
NO 
OPD/ 
IPD NO 
AGE/ 
SEX   
SIZE OF THE 
KIDNEY 
SITE OF THE 
CALCULUS 
NO OF 
CALCULUS 
SIZE OF THE 
CALCULUS 
HYDROURETERONEPH
ROSIS 
      LT.KIDNEY BT 
11.4× 
5.5cm 
  multiple 5-6mm + 
        AT 
10.8× 
4.7cm 
  multiple 5-6mm + 
29 C87868 42/M RT.KIDNEY BT 9.9× 4.1cm - - - nil 
        AT 
1o.0× 
4.1cm 
mid pole 1 microlith nil 
      LT.KIDNEY BT 
10.1 
×4.3cm 
mid pole 1 6.0mm nil 
        AT 
10.2 
×4.3cm 
mid pole 1 microlith nil 
30 C86025 40/M RT.KIDNEY BT 
10.2× 
4.9cm 
upper pole multiple 5.2mm nil 
        AT 10.5× 4.8 upper pole multiple <5.0mm nil 
      LT.KIDNEY BT 9.4× 5.5cm mid pole multiple 5.5mm nil 
        AT 10.3× 5.2 mid pole multiple <5.0mm nil 
31 C88682 45/F RT.KIDNEY BT 9.2× 4.2cm upper pole multiple 5.7mm nil 
        AT 9.1× 4.0cm upper pole multiple 5.2mm nil 
      LT.KIDNEY BT 
10.2 
×4.2cm 
lower pole multiple 4.9mm nil 
        AT 9.2 ×4.2cm lower pole multiple 4.0mm nil 
32 C89476 33/F RT.KIDNEY BT  9.6× 3.7cm               mid calyx 1 0.5cm nil 
        AT 9.9 ×3.9cm 
normal 
study 
    nil 
      LT.KIDNEY BT 
10.0× 
4.0cm 
lower calyx 3 0.4, 0.5, 1cm nil 
        AT 
10.2 
×5.2cm 
normal 
study 
    nil 
33 C95276 37/F RT.KIDNEY BT 
10.3 
×3.7cm 
- - - nil 
        AT 
10.1× 
3.9cm 
- - - nil 
      LT.KIDNEY BT 
10.7 
×4.7cm 
mid calyx 1 4mm nil 
        AT 
11.1× 
4.8cm 
normal 
study 
    nil 
34 3888 52/M RT.KIDNEY BT 
102.0 
×50.0mm 
middle calyx 2 6.0, 4.0mm nil 
        AT 9.2× 4.4cm 
inter polar 
region 
few 6mm nil 
      LT.KIDNEY BT 
100.2× 
49.0mm 
middle calyx 2 4.0, 3.0mm nil 
        AT 9.4× 5.3cm 
inter polar 
region 
microliths   nil 
35 4965 32/M RT.KIDNEY BT 8.5 ×4.3cm 
upper,middle 
lower calyx 
multiple 3.0, 5.0mm nil 
        AT 
109.7 
×44.2mm 
upper,middle 
lower calyx 
multiple 6mm nil 
      LT.KIDNEY BT 8.6 ×4.5cm 
upper,middle 
lower calyx 
multiple 3.0, 5.0mm nil 
        AT 
99.5 
×64.7mm 
middle calyx 1 4.0mm nil 
 
124 
 
S. 
NO 
OPD/ 
IPD NO 
AGE/ 
SEX   
SIZE OF THE 
KIDNEY 
SITE OF THE 
CALCULUS 
NO OF 
CALCULUS 
SIZE OF THE 
CALCULUS 
HYDROURETERONEPH
ROSIS 
36 5055 48/F RT.KIDNEY BT 
92.4× 
50.0mm 
- - - nil 
        AT 
98.8× 
37.0mm 
- - - nil 
      LT.KIDNEY BT 
94.2× 
50.4mm 
inter polar 
region 
2 3.8, 4.3mm nil 
        AT 
101.1× 
41.9mm 
lower calyx 1 4.1mm nil 
37 4061 32/F RT.KIDNEY BT 89× 40mm upper pole 2 3mm, 4mm nil 
        AT 
10.9× 
4.5cm 
lower pole 1 5mm nil 
      LT.KIDNEY BT 93 ×43mm lower pole 1 4mm nil 
        AT 
11.5× 
4.9cm 
inter polar 
region 
1 5mm nil 
38 4099 35/F RT.KIDNEY BT 
10.1× 
4.6cm 
- - - nil 
        AT 
10.1× 
4.6cm 
- - - nil 
      LT.KIDNEY BT 
11.5× 
4.7cm 
lower calyx 1 6mm nil 
        AT 
11.6× 
4.6cm 
lower calyx 1 4mm nil 
39 4156 55/M RT.KIDNEY BT 9.2× 3.2cm upper pole 1 2-4mm nil 
        AT 8.8 ×3.8cm upper pole 1 2-4mm nil 
      LT.KIDNEY BT 9.0× 3.6cm upper pole 1 2-4mm nil 
        AT 8.9× 3.5cm upper pole 1 2-4mm nil 
40 5115 27/M RT.KIDNEY BT 
97 
5×3.1mm 
middle calyx, 
lower ureter 
2 7.5, 8.5mm + 
        AT 96.2× 3mm middle calyx 1 5.1mm + 
      LT.KIDNEY BT 
99.3× 
58mm 
- - - nil 
        AT 99×56mm - - - nil 
 
BT – Before Treatment 
AT – After Treatment 
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RENAL CALCULUS 
 
OP No: C84030      Age: 38/M    Stone size: 5mm 
 
 
OP No: C85523     Age: 25 /M       Stone size: 5mm 
        
 
 
OP No: C73332    Age: 42 /M       
 Stone size: 3.5mm 
OP No: C77242    Age: 34/M       
 Stone size: 5mm 
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DISCUSSION 
 The main aim of the treatment was to evaluate the therapeutic effect of 
the drug Karpoora silasathu parpam (Internal) in the disease Azhal 
kalladaippu. The clinical features of Azhal kalladaippu can be correlated to Renal 
Calculus in Modern science. As per yougi vaithiya chinthamani text, Azhal 
kalladaippu is characterized by oliguria, urethral pain mimics a  pain caused by an 
insertion of  burning iron bar in the urethra,  sweating all over body, anuria, 
agonizing pain, blood stained calculus stagnated in urethra. 
 The safety of the trial drug usage and standardization of the trial drug 
through biochemical analysis were also ensured during the study. 
 The drug was prepared in the Gunapadam lab of National Institute of 
Siddha after the authentication of the raw drugs by the concerned 
department. The trial drug was prepared by the standard operating 
procedure as mentioned in the protocol. 
 The preclinical toxicity studies (Acute and sub acute toxicity) for the 
above said trial drug was conducted at National Institute of Siddha 
after getting the proper acceptance and permission from the 
Institutional Animal Ethical Committee (IAEC). The trial drug was 
proved to be safe for human beings from the observations made from 
the study. 
 The biochemical qualitative and quantitative analysis were done at the 
biochemistry lab of NIS and IIT Chennai respectively. It revealed the 
presence of effective minerals and the existence of the drug molecules 
at micro level. 
 The clinical study was conducted with a well defined protocol and a 
proper proforma after the approval of the Institutional Ethical 
Committee (IEC). After screening 60 cases reporting at the OPD of 
department of Maruthuvam, 40 cases were selected for induction to the 
trial. Before enrollment into the trial the informed consent was 
obtained from the patients. 
 The patients were treated for a period of 48 days with karpoora 
silasathu parpam (Internal medicine) at the dose of 130 mg, twice a 
day with the adjuvant of radish juice.  
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 Clinical assessment was done during each visit in OPD patients (7 days 
once) and daily for IPD patients and the data were noted in the 
prescribed proforma. 
 Laboratory investigations & USG Abdomen were done on the 0day, & 
48
th
 day of the trial for both OP & IP patients. For IP patients, who was 
not in a situation to stay in the hospital for a long time was advised to 
attend the OPD for the continuation of the treatment. All the patients 
were put under observation for 2 months follow up period without the 
trial drug treatment. 
 
THE OBSERVATIONS DISCUSSED BELOW: 
GENDER DISTRIBUTION 
             The majority affected sex was male i.e, 28 cases (70%) and female was 
12cases (30%).  
Inference:    
 Testosterone may cause increased oxalate production in men. 
 Women have higher urinary citrate concentrations.  
 
AGE DISTRIBUTION 
          This study showed that the highest incidence of Azhal kalladaippu was between   
31 -40 years of age, i.e. 16 cases (40%).  
Inference:    
          The peak incidence of renal calculi occurs between 20 and 40 years of age. As 
per the Rathina surukka naadi these period is mainly in pitha kaalam (33 – 66 years) 
of human life. 
GUNAM DISTRIBUTION 
           All the 40 cases under this analysis were predominantly of Rajo gunam 
assessed from interrogation and other observations. 
KAALAM DISTRIBUTION 
          Among the 40 patients, 25 cases (62.5%) were found to be in pitha kaalam (34-
66 yrs) and 15cases (37.5%) in vatha kaalam (upto 33 years). 
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DIET 
            Among the 40 cases 38 cases (95%) were non-vegetarians (mainly animal 
protein and fat substances).   
Inference:    
 
           Animal protein contains oxalates, calcium, phosphates and other elements 
often lead to an excess excretion of them in urine. High intake of animal protein 
causes high urinary oxalate, low pH, low urinary citrate, and High salt intake causes 
hypercalciuria.  However, a reduced calcium diet can increase the risks of further 
stone formation.      
 
DISTRIBUTION OF CASES BY PARUVAKAALAM (SEASONS)  
              In this study, 27 cases (67.5%) were reported in muthuvenil kaalam, 9cases 
(22.5%) in Elavenil kaalam and 4cases (10%) in Kaar kaalam. In Muthuvenil kaalam 
vatham is vitiated and Iyam comes to normal. In Elavenil kaalam Iyyam is vitiated.  
Inference:    
          Environmental temperature with stone formation being more common in the 
summer months. This tendency may be due to relative dehydration and the subsequent 
production of concentrated, acidic urine. Alternatively some workers suggest the 
increased exposure to sunshine leads to increased urinary calcium excretion. 
THINAI DISTRIBUTION 
            In this study, 90% of cases were reported from Neithal land.  
Inference:    
            In Siddha literatures, it was mentioned that Neithal is a land, which is 
responsible for vaatha diseases. Mineral contents of water in this Neithal land may 
contribute to the formation of kidney stone. 
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OCCUPATIONAL REFERENCES 
             Sedentary work style accounts for the highest number of 13cases (32.5%).   
Inference:    
             Sedentary occupations predispose to stones compared with manual workers. 
The risk of calcium oxalate and uric acid stones formation in Astronauts because of 
decreased pH and lower urinary volumes. 
TREATMENT HISTORY 
            26cases (65%) had taken allopathic treatment in the past and had discontinued 
the same. The rest of the 14cases (35%) had not taken any other drugs prior to 
enrolling for the study. 
 
DISTRIBUTION OF CASES BY CHRONICITY OF ILLNESS 
               Most of the cases (72.5%) were affected in the duration of upto 3 months. 
10cases (25%) were affected by the illness from 4 to 6 months, rest of 1case (2.5%) 
was affected by the illness above 9 months. 
 
CLINICAL FEATURES 
               Abdominal pain and pain from loin to groin region were present in almost all 
the 40 cases (100%). 32cases (80%) had yellow coloured urination. 27cases (67.5%)  
had oliguria and burning micturition. 10cases (25%) were affected by dysuria. 9cases 
(22.5%) were affected by agonizing pain. 8cases (20%) had pain in urethra. Only 
4cases (10%) were nausea and vomiting. 
DERANGEMENTS OF VATHAM 
           Viyanan and samanan were affected in all the 40 cases (100%) which resulted 
in abdominal pain and pain from loin to groin region. Abanan was affected in 31cases 
(77.5%) which resulted in burning micturition, dysuria and oliguria. 
DERANGEMENT OF PITHAM 
              Saathaga piththam was affected in all the cases (100%) as a result the 
patients were unable to perform their routine duties. Anarpitham was affected in 4 
cases (10%) which resulted in nausea and vomiting. 
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DERANGEMENT OF KABAM 
            Pothagam was affected in 4cases (10%) which resulted in nausea and 
vomiting. 
DERANGEMENT OF KOSANGAL 
            Vingyanamayakosam was affected in all the 40 cases (100%) which resulted 
in abdominal pain and loin pain and 4cases (10%) was affected in Annamaya kosam 
which resulted in nausea and vomiting. 
 
DISTRIBUTION OF CASES BY NAADI 
            Vali azhal naadi was felt in 21 cases (52.5 %), azhal vali naadi was felt in 18 
cases (45 %) and azhal naadi was felt in 1 case (2.5 %). 
DISTRIBUTION OF CASES BY NEERKURI  
           On examination by Envagai thervugal, the moothiram has been affected 
in all patients due to derangement of Vatham and pitham. Yellow coloured was 
observed in 32 cases (80%) and straw coloured was in 8cases (20%). The volume of 
urine was reduced the amount in 27 cases (67.5%), rest of 13 cases (32.5%) had norml 
urine volume. Enjal was found to be in 12 cases (30%) in the presence of bacterial 
infections. No other changes were observed in Manam, Edai and Nurai. 
DISTRIBUTION OF CASES BY NEIKKURI 
           In 27cases (68 %) oil was spread slowly like pearl shape.  In fastly spread, 
10cases (25 %) had annular/ring and 3cases (7%) had serpentine like. 
DISTRIBUTION OF CALCULUS IN URINARY SYSTEM 
          15cases (37.5%) had Bilateral renal calculi.12cases (30%) were affected by 
ureteric calculus. 7cases (17.5%) were affected by Right renal calculus. 6cases (15%) 
were affected by Left renal calculus. 
URINE CULTURE AND SENSITIVITY 
                  Among the 40 cases, 12cases (30%) had Bacterial infections in urine 
culture before treated with trial drug. Out of them 5cases (41.7%) were found to be no 
bacterial infections in urine culture after the completion of the trial drug treatmen and 
7 cases (58.3%) had grown in culture. 
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HYDROURETRONEPHROSIS 
          Before treated with trial drug 12 cases (30%) had hydrouretronephrosis. Among 
them, 7cases (58.3%) were relieved from hydrouretronephrosis after the treatment 
with trial drug and 5 cases (41.7%) were not relieved. 
OUTCOME 
PRIMARY OUTCOME OBSERVATION  
RESULT OF USG ABDOMEN AFTER TREATMENT 
        All the 40 patients were taken ultrasonography, after the completion of the trial 
drug treatment, 
 Among the 40 cases stone completely dissolved in 15 cases (37.5%) 
[Ureteric calculus, Renal calculus + Ureteric calculus] 
 Size and number of stone is reduced in 20 cases (50%) [Renal calculus].  
 In 5 cases (12.5%) there was no change in size of stone but clinical 
symptoms were completely relieved.  
Based on the above results, 
                         87.5% showed Good results and 12.5% showed poor results.  
Good -   Normal study (stone completely dissolved)  
               Reduced its number (more than 2 / multiple)  
               Reduced its size. 
Poor -    No change in size and increase in size. 
 
SECONDARY OUTCOME OBSERVATION 
RESULT OF CLINICAL FEATURES AFTER TREATMENT 
          Abdominal pain and loin pain were relieved in 38 cases (95%) other symptoms 
such as abdominal distension, pain in urethra, agonizing pain, dysuria, oliguria,  
yellow coloured urination, burning micturition, nausea and vomiting, haematuria were 
relieved in all the 40 cases (100%). 
IMPROVEMENT 
            Among 40 cases 38 cases (95%) had clinically good improvement (symptoms 
completely relieved) after treatment with trial drug, 2 cases (5%) had moderate 
improvement (symptoms reduced). 
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LABORATORY INVESTIGATIONS 
                Laboratory investigation of Blood, Urine and Stools were done for all 40 
cases.  
HAEMOGLOBIN: 
    Among 40 cases, 
 In 22 (55%) of cases there was improvement in HB after treatment 
ranging between   maximum 3.5gms% and minimum 0.3gms%. 
 1 (2.5%) cases remained in the same HB level after treatment. 
 In 17 (42.5%) of cases there was reduction in HB ranging between 
maximum   2.2gms% and minimum 0.2gms%. 
In the Haematological investigations other than Hb, all the reports i.e.  RBC, WBC,  
LFT,  RFT  and Blood Glucose were within the normal range before and after 
Treatment with the trial drug. 
 
BIOCHEMICAL ANALYSIS: 
 
 Qualitative analysis of Karpoora silasathu parpam done in NIS biochemical 
lab revealed that the trial drug contains minerals like Calcium, Sulfur, Silicate, 
Zinc, Phosphate, potassium etc. 
 Quantitative analysis  revealed that it contains chiefly, 
 
 458.885 mg/L Calcium 
 76.235 mg/L Sulfur 
 19.957 mg/L Silicate 
 23.745 mg/L Phosphate 
 25.124 mg/L potassium 
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TOXICITY STUDY: 
 
ACUTE ORAL TOXICITY STUDY 
Acute toxicity studies done in National Institute of Siddha, as per WHO guide 
lines revealed the safety of the drug at the dose of 4.68mg/kg/bw as it did not exhibit 
any mortality in mice. In necropsy there were no abnormalities detected in the internal 
organs such as, Liver, Heart, Lungs, pancreas Spleen, Stomach, Intestine, Kidney, 
Urinary bladder and Uterus.  
 
SUB ACUTE TOXICITY STUDY 
   
Sub acute toxicity studies done in National Institute of Siddha, as per WHO 
guide lines did not exhibit any mortality in rats. Animal behavior, metabolic functions 
(food and water intake, defaecation, urination etc) did not reveal any abnormality. 
Blood investigation parameters and histopathological examination did not show any 
abnormal variations. 
Hence it can be concluded from the study that up to maximum dose 
46.8mg/kg/bw (10X) the drug was proved to be safe. 
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SUMMARY 
 
 The aim of the study was to evaluate the therapeutic efficacy of the drug 
karpoora silasathu parpam (Internal) in Azhal kalladaippu. 
 Before initiating the clinical trial, approval was got from the Institutional 
Animal Ethical Committee (1248/ac/09/CPCSEA/4/04/2011 – 20/12/2011) 
and Institutional Ethical Committee (NIS/IEC/2011/3/04 – 24/12/2011) for 
conducting the pre clinical studies and clinical studies respectively by 
submitting the well defined protocol and proforma. 
 The raw drugs were authenticated by the concerned department and the trial 
drug was prepared by the investigator in the Gunapadam lab of National 
Institute of Siddha as per the Standard Operating Procedure mentioned in the 
protocol. 
 The medicine was then subjected to pre clinical toxicity studies (Acute and 
sub acute toxicity studies) as per the protocol and the safety of the drug was 
ensured. 
 From the Acute oral toxicity study, the trial drug was found to be safe even at 
higher dose level of 4.68mg/kg/bw.  
 From the sub acute toxicity study the trial drug at the dose of 46.8mg/kg/bw 
(10X) did not exhibit any mortality in rats. 
 The qualitative and quantitative bio chemical studies were done at the bio 
chemistry lab of National Institute of Siddha and IIT Chennai respectively. 
 The biochemical study of the trial drug reveals the presence of sulphate, 
potassium, phosphate and carbonate. 
 Among the 60 cases screened at the OPD of department of Maruthuvam NIS, 
40 cases were recruited for the trial as per the inclusion and exclusion criteria. 
 Clinical diagnosis of Azhal kalladaippu was made by Siddha and Modern 
methodology. 
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 Before inducement into the trial informed consent was obtained from the 
patients. Out of the 40 cases 33 cases were treated in OPD and 7 cases in IPD. 
 The patients were treated for a period of 48 days The trial medicine selected 
for  Internal  treatment were karpoora silasathu parpam (internal medicine)  at 
the dose of 130 mg  twice a day with  adjuvant of  Radish juice referred under 
Siddha literature Agathiyar chendhooram - 300, moolamum uraiyum 1
st
 
edition respectively. 
 Required lab investigations were carried out before and after the treatment and 
the concerned data was recorded in the proforma.  
 Clinical assessment was done daily in all the IP patients and in OP patients it 
was assessed once in 7 days. 
 During the study period, there was no event of any adverse reactions owing to 
the drug or disease. 
 Statistical analysis showed significant difference between before and after 
treatment in the kidney stone size (p < 0.001) and symptoms (p < 0.0001). 
 38 cases (95%) had clinically good improvement (symptoms completely 
relieved) after treatment with trial drug, 2 cases (5%) had moderate 
improvement (symptoms reduced). 
All the 40 patients were taken ultrasonography, after the completion of the trial drug 
treatment, 
 87.5% showed Good results and 12.5% showed poor results.  
Good -   Normal study (stone completely dissolved)  
               Reduced its number (more than 2 / multiple)  
               Reduced its size. 
Poor -    No change in size and increase in size. 
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CONCLUSION 
 The aim of the study was to evaluate the therapeutic efficacy of the drug 
karpoora silasathu parpam (Internal) in Azhal kalladaippu. 
 The safety studies (Acute toxicity and sub acute toxicity) studies conducted 
revealed that the trial drug was safe even at higher dosage of 46.8 mg/animal. 
There were no abnormalities found in blood investigation and 
histopathological examination. Hence it can be reasonably assumed that the 
drug is safe for human. 
    Clinical study revealed the therapeutic efficacy of the trial drug by showing,  
    In the result of USG ABDOMEN, 
 87.5% showed Good results and 12.5% showed poor results.  
 38 cases (95%) had clinically good improvement 2 cases (5%) had moderate 
improvement in clinical symptoms. 
 There were no adverse reactions complained during the trial. 
 Statistical analysis showed significant difference between before and after 
treatment in the kidney stone size (p < 0.001) and symptoms (p < 0.0001). 
 Because of the encouraging clinical outcome, the study may be further carried 
out with the same drug in a large number of cases.     
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TOXICOLOGICAL EVALUVATION OF KARPOORA SILASATHU PARPAM 
       ACUTE TOXICITY STUDY OF KARPOORA SILASATHU PARPAM 
              [WHO guidelines, 1993] 
Principle: 
    Acute toxicity was carried out in Swiss albino mice with a single 
exposure of 10 times of the recommended therapeutic dose of test compound the 
study duration will be 14 days. 
Animal species  : Swiss albino mice 
Age / Weight / Size  :  6 weeks.  Mice-20-25gms. 
Gender   :   Both male and female 
Number of Animals   : Mice: 20 
Acclimatization Period : 7 Days 
Clinical dose   : 260 mg\day 
S.No Group No of mice 
1 Vehicle control (radish juice) 10  (5 male, 5 female) 
 
2 
Toxic dose 
10X therapeutic dose 
(4.68mg) 
10  (5 male, 5 female) 
 
Test Animals  
       Test animals were obtained from the animal laboratory of the King 
institute, Chennai and stocked at National institute of siddha, Chennai. All the animals 
were kept under standard environmental condition (27+ or – 2 degree c).The animals 
had free access to water and standard pellet diet (Sai Durga foods pvt.ltd, 
Bangalore).The principles of laboratory animal care were followed and the  
Institutional ethical committee approved the use of animals and the study design. 
(1248/ac/09/CPCSEA/December/ 2011) 
 Route of administration: 
  Oral route was selected, because it is the normal route of clinical 
administration. 
Test substance and vehicle 
        The Karpoora silasathu parpam is ash in colour.  The test substance is 
insoluble in water, in order to obtain and ensure the uniformity in drug distribution the 
drug is dissolved by aqueous Tween 80 solution (10%).  
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Administration of doses 
            Karpoora silasathu parpam was suspended in aqueous Tween 80 
solution (10%), with uniform mixing and it was administered to the groups in a single 
oral dose .The control groups were received equal volume of the vehicle. The animals 
were weighed before giving the drug. The dose level was calculated according to 
body weight, and surface area. Since the clinical dose was 260mg\day it was 
converted to animal dose (4.68mg) and then administered. The principle of laboratory 
animal care was followed. 
Observations 
  Observations were made and recorded systematically and continuously 
observed as per the guideline after substance administration. Animals were observed 
individually (visual observations included skin changes, alertness, grooming, 
aggressiveness, sensitivity to sound, touch and pain ,restlessness, tremors, convulsion, 
righting reflex, corneal reflex, gripping reflex, pinna reflex, writhing reflex, papillary 
reflex, urination, salivation, lacrimation for first 4 hrs, then periodically during the 
first 24 hrs. Animals were observed for body weight and mortality for 14 days. If 
animals dying during the period of study, the animals were sacrificed.  At the end of 
the 14
th
 day all animals were sacrificed and necropsy was done. 
Body Weight 
  Individual weight of animals was determined before the test substance 
was administered and daily for 14 days. Weight changes were calculated and 
recorded. At the end of the test, surving animals were weighed and sacrificed. 
Results: karpoora silasathu param at the dose 4.68mg/animal did not exhibit any 
mortality in mice. 
  No behavior changes were noted for the first 4 hours and for the next 
24 hours and throughout the study period of 14 days. No weight reduction was noted 
before and after the acute study duration. Reflexes were found to be normal before 
and after the study. All other observations were found to be normal before and after 
the study. In Necropsy, the organs of the animal such as, Liver, Heart, Lungs, 
Pancreas, Spleen, Stomach, Intestine, Kidney, Urinary bladder, Uterus all appeared 
normal.  
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      SUB ACUTE TOXICITY STUDY OF KARPOORA SILASATHU PARPAM 
 
Animals             : Male and Female Wister albino rats 
Age                    : 6-8 weeks 
Weight   : 150-200 gms 
Gender   :  Both male and female 
Number of animals   : Rat: 40 
Acclimatization period : 7 Days 
Clinical dose   : 260mg\day 
Clinical duration  : 28 days 
 
Animal source:      
 Test animals were obtained from the animal laboratory of the King institute, 
Chennai, and stocked at national institute of siddha, chennai. All the animals were 
kept under standard environmental condition (27+ or – 2 degree c) .The animals had 
free access to water and standard pellet diet (Sai durga foods pvt.ltd, Bangalore). The 
principles of laboratory animal care were followed and the Institutional ethical 
committee approved the use of animals and the study design. 
(1248/ac/09/CPCSEA/December/2011) 
Identification of animal:  
 By cage number, animal number and individual marking on fur. 
Housing and Environment: 
 The animals were housed in polypropylene cages provided with bedding of 
husk. Dark and light cycle each of 12 hours. 
 
    S.No 
                 
             Group 
      
     No of Rats 
       1 Vehicle control (  radish juice ) 10 (5male,5 female) 
       2 1XTherapeutic dose (4.68 mg) 10 (5male,5 female) 
       3 5XTherapeutic dose (23.4mg) 10 (5male,5 female) 
       4 10XTherapeutic dose(46.8mg) 10(5male, 5 female) 
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Administration period: 
 The period of administration of the test substance to animals are depending on 
the expected period of clinical use. Since the clinical duration of the test drug is 28 
days and as per WHO guidelines the administration period is reported to be 1 month. 
 Dose selection: 
 The results of acute toxicity studies in Swiss albino mice indicated that 
karpoora silasathu parpam was non toxic and no behavioral changes, mortality was 
observed. On the basis of these results, the doses were selected for the study as per 
WHO guidelines.  
Preparation and administration of dose:        
 Karpoora silasathu parpam was suspended in aqueous twin 80 solution (10%). 
It was administered to animals at dose levels of 1X therapeutic dose (4.68mg/animal), 
5X Therapeutic dose (23.4mg/animal) and 10X Therapeutic dose 
(46.8mg/animal).The control animals were administered vehicle only. Administration 
was by oral (gavage) once a day for 30 days. 
 
METHODOLODY: 
Randomization, numbering and grouping of animal: 
 The animals were randomly divided into three groups for dosing up to 30 
days. Each group consist of 10 animals (5 per sex in each group) were allowed 
acclimatization period of 7 days to laboratory conditions prior to the initiation of 
treatment. Each animal fur was marked with picric acid. The females were nulliparous 
and non pregnant. 
 
OBSERVATION: 
 Experimental animals were kept under observation throughout the course of 
study for the following 
 
Body weight:  
 Weight of each rat was recorded on day 1 and at weekly intervals throughout 
the course of study and at termination to calculate relative organ weights. From the 
data mean body weights and percent body gain were calculated. 
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Food and water consumption: 
 The quantity of food consumed by groups consisting of an animal for different 
doses was recorded at weekly intervals. Food consumed per animal was calculated for 
control and the treated dose groups 
Clinical sings 
 All animals were observed daily for clinical sings. The time of onset intensity 
and duration of this symptom if any were recorded. 
Mortality: 
 All animals were observed twice daily for mortality during entire course of 
study. 
 
TERMINAL STUDIES: 
 
 LABORATORY INVESTIGATIONS: 
  Following laboratory investigations were carried out. On day 31 
animals fasted overnight. Blood samples were collected by cardiac puncture using 
sodium heparin (200IU\ml) for blood chemistry and potassium EDTA (1.5 mg/ml) for 
hematology anticoagulant. Blood sample were centrifuged at 3000 r. p .m for 10 
minutes. 
 
 BIOCHEMICAL INVESTIGATIONS: 
 
         The effect of karpoora silasathu parpam on certain biochemical parameters 
were examined and compared with those of the control group. The blood samples 
collected with heparinized bottles were centrifuged at 5000 rpm for 10 minutes to 
obtain clear serum for the following investigation. Glucose was estimated using 
commercial Glucose estimation kit (Span Diagnostics) by the method of Barham et 
al., (1972) and Tenscher. et al., (1971),Haemoglobin PCV, RBC, Erythrocyte  count 
was estimated by Hemocytometer method of Ghai (1995). Total Leukocyte Count was 
estimated by Hemocytometer method of John (1972).Total, (Bilirubin test kid-malloy 
and evelyn 1937) direct and indirect bilirubins were determined. Alkaline 
phosphatase, Alanine amino tranferase (ALT) and Aspartate amino transferase (AST) 
were measured by using ALT and AST test kit (kind & king) .Total protein TP 
concentration was determined. Albumin was determined based on its reaction with 
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bromocresol green (binding method). Urea was determined according to urease – 
berthelot method and plasma creatinine was estimated using jaffe reaction. Results of 
biochemical investigations conducted on day 31 revealed significant changes in the 
values of different parameters studied when compared with those of respective 
controls. 
Statistical analysis done for the above said biochemical investigations did not 
reveal any significant difference in values between the control groups and test groups 
stating that the provided test drug is non toxic. 
 
NECROPSY:  
          All the animals were sacrificed on day 31 under ether anesthesia. Necropsy of 
all animals was carried out and the weights of the organs including liver, kidneys, 
brain, heart, lungs and sex organs were recorded. 
 
HISTOPATHOLOGY: 
 
 Tissue samples of organs from control and treated animals were preserved in 
10% formalin for preparation of sections using microtome. The organs included brain, 
heart, lungs, stomach, liver, kidneys, spleen, intestine, pancreas and sex organs of the 
animals were preserved and they were subjected to histopathological examination. 
  The organ pieces (3-5 micron) were fixed in 10% formalin for 24 hours 
and washed in running water for 24 hours .Samples were dehydrated in tissue 
processor and then cleaned in benzene to remove absolute alcohol. Embedding was 
done by passing the cleared sample through three cups containing molten paraffin at 
50 degree c and then a cubical block of paraffin made by the L moulds it was 
followed by microtome and the slides were stained with haematoxylin–eosin stain. 
Stained sections of each organ were examined under light microscope at high (40X) 
power magnification. All the histo pathological slides were prepared at Vels 
University, pallavaram, Chennai. 
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RESULTS:  
                                 CONTROL ANIMALS 
Brain: Shows cerebral cortex with normal appearing glial cells. 
Heart: Shows normal appearing myocardial fibres with patent coronaries. 
Lung: Shows bronchioles, alveoli, widened alveolar septa and chronic 
inflammatory  cells. 
Stomach: Shows gastric mucosal glands lined by columnar cells. 
Liver: Shows central veins with rows of radiating hepatocytes, Portal triads 
and cells appear normal. 
Kidney: Shows glomeruli tubules, interstitial cells of normal histology 
Spleen: Section of spleen shows congested red pulp and lymphoid follicles 
with germinal centres forming the white pulp 
Intestine: Shows normal Intestinal mucosal lining with mild exudates. 
Pancreas:  Shows normal acini with islets of β-cells 
Ovary:  Shows ovarian stroma with follicles and corpus leuteum. 
Testis:  Shows normal tubules with spermatogenesis. 
 
IMPRESSION: NORMAL STUDY 
 
TEST GROUP ANIMALS 
1X THERAPEUTIC DOSE 
Brain:     Shows normal brain with nerve fibers and astrocytes. 
Heart:     Shows normal cardiac muscle bundles. 
Lung:      Shows normal alveoli. 
Stomach: Shows normal mucosal glands. 
Liver:       Shows almost normal hepatocytes and occasional binucleate cells. 
Kidney:    Shows normal renal tissue with glomeruli and tubules.  
Spleen:     Shows normal spleen with lymphoid aggregation. 
Intestine: Shows normal Intestinal mucosal lining with mild exudates. 
Pancreas:  Shows normal acini with islets of β-cells 
Ovary:     Shows ovarian stroma with follicles and corpus leuteum. 
Testis:     Shows normal tubules with spermatogenesis. 
 
IMPRESSION: NORMAL STUDY                           
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5X THERAPEUTIC DOSE 
Brain:   Shows brain with edema, microglial proliferation, shows brain with 
micro cystic change and astrocytic proliferation, shows brain with 
mononuclear infiltrate around vessel.  
Heart: Shows congestion and mild inflammatory infiltration in between 
cardiac muscle bundles. 
Lung: Shows congested alveolar wall with mild thickening and mild 
emphysematous changes.  
Stomach: Shows near normal mucosal gland with mild exudates. 
Liver:     Shows hepatocytes with focal mild fatty change. 
Kidney: Shows renal tissue with focal tubular damage, interstitial 
inflammatory collection. Glomeruli show epithelial proliferation.  
Spleen:    Shows congestion with lymphoid hyperplasia.  
Intestine:  Shows normal Intestinal mucosal lining with mild exudates. 
Pancreas: Shows pancreas with acini and normal islets.  
Testis:      Shows normal tubules with spermatogenesis. 
Ovary:     Shows ovarian stroma with follicles and corpus leuteum. 
 
IMPRESSION: NORMAL STUDY 
 
10X THERAPEUTIC DOSE 
 
Brain: Shows brain with edema. Astrocytes show degenerative changes. 
Shows brain with pyknotic irregular nucleus, shows brain with vesicular 
nuclei and micro cystic changes. 
 Heart: Shows hypertrophic cardiac muscle bundles.  
Lung:  Shows congestion, narrowed alveolar space and thickened alveolar 
wall. 
Stomach: Shows stomach with superficial erosion and congestion.  
Liver:  Shows marked dilatation of sinusoids, degeneration of hepatocytes, 
necrosis.   
Kidney: Shows renal tissue with tubular epithelial damage.  
Spleen:  Shows lymphoid hyperplasia. 
Intestine: Shows normal Intestinal mucosal lining with mild exudates. 
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Pancreas: Shows atrophic islet cells. 
Testis: Giant cells were formed in the lumen of the seminiferous tubules and 
the spermatogenic cells degenerated.  
Ovary: Shows ovarian follicles and corpus leuteum. 
 
IMPRESSION: NORMAL STUDY 
 
The histopathological studies did not reveal any abnormalities in the animals 
in both control and test groups stating that the drug is non toxic.  
 
RESULTS:  
 
 No weight loss, abnormal animal behaviours, metabolic functions [urination, 
lacrimation, defaecation etc.,] and mortality were noted. 
 In necropsy of the animal organs showed normal appearance and weight. 
 All Haematological and biochemical parameters were within normal limits. 
 The stastical report of the Haematological and Biochemical datas didnot show 
any significant difference, between the control and test groups.  
 In Histopathological studies, No abnormal findings were observed in the 
organs such as brain, heart, lungs, stomach, liver, kidneys, spleen, intestine, 
pancreas and sex organs in X, 5X and 10X compared with control group. 
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HISTOPATHOLOGY PHOTOS 
 
 
BRAIN(X) 
 
 
 
BRAIN(5X) 
 
 
BRAIN10(X) 
 
 
BRAIN(CONTROL) 
 
 
HEART(X) 
 
 
 
HEART(5X) 
 
 
HEART(10X) 
 
 
HEART(CONTROL) 
 
 
LUNGS(X) 
 
 
 
LUNGS(5X) 
 
 
LUNGS(10X) 
 
 
LUNGS(CONTROL) 
 
 
STOMACH(X) 
 
 
 
STOMACH(5X) 
 
 
STOMACH(10X) 
 
 
STOMACH(CONTROL) 
 
 
LIVER(X) 
 
 
 
LIVER(5X) 
 
 
LIVER(10X) 
 
 
LIVER (CONTROL) 
 
 
KIDNEY(X) 
 
 
 
KIDNEY(5X) 
 
 
KIDNEY(10X) 
 
 
KIDNEY (CONTROL) 
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SPLEEN(X) 
 
 
 
SPLEEN(5X) 
 
 
SPLEEN(10X) 
 
 
SPLEEN 
(CONTROL) 
 
INTESTINE(X) 
 
 
 
INTESTINE(5X) 
 
 
INTESTINE(10X) 
 
 
(INTESTINE (CONTROL) 
 
 
PANCREAS(X) 
 
 
 
PANCREAS(5X) 
 
 
PANCREAS(10X) 
 
 
PANCREAS(CONTROL) 
 
 
TESTIS(X) 
 
 
 
TESTIS(5X) 
 
 
TESTIS(10X) 
 
 
TESTIS(CONTROL) 
 
 
OVARY(X) 
 
 
 
OVARY(5X) 
 
 
OVARY(10X) 
 
 
OVARY (CONTROL) 
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BIO -CHEMICAL ANALYSIS OF KARPOORA SILASATHU PARPAM 
ANALYSED AT NATIONAL INSTITUTE OF SIDDHA 
 
 
 
S.No EXPERIMENT OBSERVATION INFERENCE 
1. Appearance of sample Ash in colour  
2. Solubility: 
a. A little (500mg) of the sample is 
shaken well with distilled water. 
b. A little (500mg) of the sample is 
shaken well with con. HCl/Con. H2So4 
Sparingly soluble 
 
 
Presence of Silicate 
3. Action of Heat: 
   A small amount (500mg) of the 
sample is taken in a dry test tube and 
heated gently at first and then strong. 
 No White fumes   
evolved 
Absence  of Carbonate 
 
4. Flame Test: 
  A small amount (500mg) of the 
sample is made into a paste with con. 
HCl in a watch glass and introduced 
into non-luminous part of the Bunsen 
flame. 
 No Bluish green 
flame appeared. 
Absence of Copper 
5. Ash Test: A filter paper is soaked into 
a mixture of sample and dil. cobalt 
nitrate solution and introduced into the 
Bunsen flame and ignited 
Yellow colour 
flame 
Presence of Sodium 
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PREPARATION OF EXTRACT: 
5gm of Karpoora silasathu parpam is weighed accurately and placed in a 
250ml clean beaker and added with 50ml of distilled water. Then it is boiled well for 
about 10 minutes. Then it is cooled and filtered in a 100ml volumetric flask and made 
up to 100ml with distilled water. 
 
S.No EXPERIMENT OBSERVATION INFERENCE 
 I. Test For Acid Radicals   
1. Test For Sulphate :  
2ml of the above prepared extract is 
taken in a test tube to this added 2ml 
of 4%dil. ammonium oxalate 
solution. 
 
  Cloudy     
appearance present 
 
Presence  
of Sulphate 
2. Test For Chloride: 
2ml of the above prepared extracts is 
added with 2ml of dil-HCl is added 
until the effervescence ceases off. 
 
 Cloudy appearance 
present. 
 
Presence  
of Chloride 
3. Test For Phosphate: 
2ml of the extract is treated with 2ml 
of ammonium molybdate solution and 
2ml of con.HNO3 
 Mild yellow  
appearance present 
 
 
Presence of 
phosphate  
4. Test For Carbonate:  
2ml of the extract is treated with 
2mldil. magnesium sulphate solution 
 
No of cloudy 
appearance 
 
Absence   
of  Carbonate 
5. Test For Fluoride & Oxalate: 
2ml of extract is added with 2ml of 
dil. Acetic acid and 2ml dil.calcium 
chloride solution and heated. 
Presence of cloudy 
appearance 
      
 Presence  of     
fluoride and   
oxalate 
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6. Test For Nitrate: 
1gm of the substance is heated with 
copper turning and concentrated 
H2SO4 and viewed the test tube 
vertically down 
 
No  Brown gas is 
evolved 
Absence of Nitrate 
7. Test For Sulphide:  
1gm of the substance is treated with 
2ml of con. HCL 
 Rotten Egg Smelling 
gas  evolved 
Presence  of   
Sulphide 
8. Test For Nitrite: 
  3drops of the extract is placed on a 
filter paper, on that-2 drops of 
dil.acetic acid and 2 drops of dil. 
Benzidine solution is placed. 
No   Characteristic    
changes 
Absence  of  
Nitrite 
9. Test For Borate: 
  2 Pinches (50mg) of the substance is 
made into paste by using dil.sulphuric 
acid and alcohol (95%) and 
introduced into the blue flame. 
Bluish  green  colour  
flame  not  appeared 
Absence   of   
Borate 
                                    
                                              II. TEST FOR BASIC RADICALS 
1. Test For Lead: 
        2ml of the extract is added with 
2ml of dil.potassium iodine solution. 
 Yellow Precipitate is 
obtained. 
Presence  of   Lead 
2. Test For Copper: 
 One pinch (50mg) of substance is 
made into paste with con. HClin a 
watch glass and introduced into the 
non-luminuous part of the flame. 
No blue colour    
precipitate formed. 
 
Absence  of  
Copper 
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3. Test For Aluminium: 
  To the 2ml of extract dil.sodium 
hydroxide is added in 5 drops to 
excess. 
No Characteristic    
changes 
 Absence of 
Aluminium 
4. Test For Iron: 
a. To the 2ml of extract add 2ml 
of thiocyanate ammonium solution 
b. To the 2ml of extract add 2ml 
of thiocyanate ammonium solution 
and 2ml  of con HNO3 . 
 
Mild red 
colour appear 
 
 
 
Presence of Iron 
 
 
5 5. Test For Zinc:  
      To 2ml of the extract dil.sodium 
hydroxide solution is added in 5 
drops to excess and dil.ammonium 
chloride is added.  
White  precipitate   is   
not formed 
  Absence of  Zinc 
6. Test For Calcium:  
      2ml of the extract is added with 
2ml of 4% dil.ammonium oxalate 
solution  
 Cloudy appearance 
and white precipitate 
is obtained 
Presence of  
Calcium 
7. Test For Magnesium:  
To 2ml of extract dil.sodium 
hydroxide solution is added in drops 
to excess. 
 
 
No White precipitate 
is obtained 
 
Absence  of 
Magnesium 
8. Test For Ammonium: 
  To 2ml of extract 1 ml of Nessler's 
reagent and excess of dil.sodium 
hydroxide solution are added. 
 
 No Brown colour 
appeared 
 
 
Absence  of 
Ammonium 
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9. Test For Potassium:  
   A pinch (25mg) of substance is 
treated off with 2ml of dil.sodium 
nitrite solution and then treated with 
2ml of dil.cobalt nitrate in 30% 
dil.glacial acetic acid. 
 
Yellowish 
Precipitate is obtained. 
 
Presence of  
Potassium 
10. Test For Sodium: 
    2 pinches (50mg) of the substance 
is made into paste by using HCl and 
introduced into the blue flame of 
Bunsen burner. 
  
Yellow  colour    
flame appeared 
   
Presence  of   
Sodium 
11. Test For Mercury:  
   2ml of the extract is treated with 
2ml of dil.sodium hydroxide solution.  
 
 No Yellow precipitate 
is obtained 
    
Absence of    
Mercury 
12. Test For Arsenic:  
   2ml of the extract is treated with 
2ml of dil.sodium hydroxide solution. 
 
No brownish red 
precipitate is obtained 
 
Absence  of   
Arsenic 
III. MISCELLANEOUS 
1.  Test For Starch:  
  2ml of extract is treated with weak 
dil.iodine solution  
 
  No Blue   colour 
developed 
 
  Absence of   
Starch 
2.  Test For Reducing Sugar: 
 
5ml of Benedict's qualitative solution 
is taken in a test tube and allowed to 
boil for 2 minutes and added 8 to 10 
drops of the extract and again boil it 
for 2 minutes. The colour changes are 
noted 
 
Brick   red  colour not 
developed 
 
 Absence of  
Reducing sugar 
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3.  Test For The Alkaloids: 
a) 2ml of the extract is treated with 
2ml of dil.potassium lodide solution. 
b)  2ml of the extract is treated with 
2ml of dil.picric acid. 
c)  2ml of the extract is treated with 
2ml of dil.phosphotungstic acid. 
 
 
  
Yellow   colour 
developed 
 
 
 
 Absence of  
Alkaloid 
4.  Test For Tannic Acid:  
  2ml of extract is treated with 2ml of 
dil.ferric chloride solution  
 
 No Black precipitate   
is obtained 
 
Absence of  
Tannic acid 
5.  Test For Unsaturated Compound: 
  To the 2ml of extract 2ml of 
dil.Potassium permanganate solution 
is added.  
 
Potassium 
permanganate is not 
decolourised 
 
Absence   of     
Unsaturated 
compound  
6.  Test For Amino Acid: 
    2 drops of the extract is placed on a 
filter paper and dried well. 20ml of 
Biurette reagent is added. 
 
Violet  colour 
developed 
 
Absence  of  
Amino acids 
7. Test For Type Of Compound: 
    2ml of the extract is treated with 2 
ml of dil.ferric chloride solution.  
  
No  Brown  colour 
developed 
Absence  of  Oay  
quinole, 
Pinephrine  and  
Pyro catechol 
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PRELIMINARY QUALITATIVE PHYTOCHEMICAL TESTS PROCEDURE AND  
INTERPRETATION OF RESULTS 
 
 
S.NO 
 
PROCEDURE 
 
INFERENCE 
1. Calcium    Presence  of  Calcium 
2. Sulphate    Presence  of  Sulphate 
3. Chloride    Presence  of  Chloride 
4. Carbonate    Absence  of  Carbonate 
5. potassium Presence of potassium 
6. Iron     Presence  of  Iron  
7. Phosphate    Presence  of  Phosphate 
8. Tannic acid    Absence  of  Tannic acid 
9. Aluminium    Absence  of  Aluminium 
10. Magnesium    Absence  of  Magnesium 
11. Ammonium    Absence  of   Ammonium 
12. Mercury    Absence  of  Mercury 
13. Alkaloids    Absence  of  Alkaloids 
14. Reducing Sugar    Absence  of  Reducing sugar 
15. Silicate    Presence  of  Silicate 
16. Copper    Absence  of  Copper 
17. Sodium    Presence  of  Sodium 
18. Lead    Presence  of  Lead 
    19. Fluoride And Oxalate    Presence  of  Fluoride and Oxalate 
20. Zinc   Absence of zinc 
21. Sulphide   Presence of sulphide 
22. Nitrate  Absence of nitrate 
23. Nitrite  Absence of nitrite 
24. Borate   Absence of borate 
25. Arsenic   Absence of arsenic 
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QUANTITATIVE ANALYSIS 
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COLOUR CHARACTERS AND PHYSICOCHEMICAL PROPERTIES OF 
KARPOORA SILASATHU PARPAM 
 
 
Table-1 
 
Colour characters of Karpoora Silasathu Parpam 
 
 
S No 
 
Solvent used 
 
Under ordinary light 
 
Under ultra violet light 
 
1 PM Ash Ash 
 
PM-Powdered material 
 
 
 
 
Table-2 
 
Physicochemical properties of Karpoora Silasathu Parpam 
 
 
S No. 
 
Parameters  
Values 
obtained 
(%w/w) 
Heavy/ toxic metals 
1 Total ash value  8.24 Lead BDL 
2 Acid insoluble ash  0.92 Cadmium BDL 
3 Water soluble ash  5.7 Mercury BDL 
4 Moisture content  10.11 Arsenic BDL 
 
 
 
 
 
Table-3 
 
Colour, nature and percent yields of extracts of Karpoora Silasathu Parpam 
 
 
S.no. 
 
Extract 
Solvents 
 
Colour 
 
Nature 
 
 
% 
Yield(w/w) 
 
SEM-Micro 
graph 
partical size 
range in 
micron 
 
pH 
1 Water ash Solid 46 1.5 -3 micron 8.8 -9.1 
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HR SEM-METHODOLOGY: 
An SEM is essentially a high magnification microscope, which uses a 
focussed scanned electron beam to produce images of the sample, both top-down and, 
with the necessary sample preparation, cross-sections. The primary electron beam 
interacts with the sample in a number of key ways:- 
 Primary electrons generate low energy secondary electrons, which tend to 
emphasize the topographic nature of the specimen.  
 Primary electrons can be backscattered which produces images with a high 
degree of atomic number (Z) contrast.  
 Ionized atoms can relax by electron shell-to-shell transitions, which lead to 
either X-ray emission or Auger electron ejection. The X-rays emitted are 
characteristic of the elements in the top few μm of the sample.  
SAMPLE PREPARATION: 
Sample preparation can be minimal or elaborate for SEM analysis, depending on the 
nature of the samples and the data required. Minimal preparation includes acquisition of a 
sample that will fit into the SEM chamber and some accommodation to prevent charge build-
up on electrically insulating samples. Most electrically insulating samples are coated with a 
thin layer of conducting material, commonly carbon, gold, or some other metal or alloy. The 
choice of material for conductive coatings depends on the data to be acquired: carbon is most 
desirable if elemental analysis is a priority, while metal coatings are most effective for high 
resolution electron imaging applications. Alternatively, an electrically insulating sample can 
be examined without a conductive coating in an instrument capable of "low vacuum" 
operation.  
 The SEM is carried out by using FEI-Quanta FEG 200-High Resolution 
Instrument. 
Resolution : 1.2 nm gold particle separation on a carbon substrate 
Magnification: From a min of 12x to greater than 1, 00,000 X 
Application : To evaluate grain size, particle size distributions, material 
homogeneity  and  inter metallic distributions 
   . 
Experimental Procedure: Done at SAIF, IIT Madras, Chennai-36 
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SEM – Micro graph partical size 
 
 KARPOORA SILASATHU PARPAM 
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NATIONAL INSTITUTE OF SIDDHA, CHENNAI – 47 
AYOTHIDASAR PANDITHAR HOSPITAL 
DEPARTMENT OF   MARUTHUVAM 
PRE CLINICAL AND CLINICAL STUDY ON “AZHAL KALLADAIPPU” (RENAL CALCULI) AND THE DRUG OF 
CHOICE IS “KARPOORA SILASATHU PARPAM” (INTERNAL) 
 
   FORM I  -  SCREENING AND SELECTION PROFORMA                Reg No:32101204/2012-13 
 
1. O.P No   ________      2.  I.P No  ________    3. S.No: ________    
 
4. Name: ________________ 5. Age (years):            6. Gender: Female/             Male 
 
7. Contact Nos:    ------------------------------------------ 
 
8.INCLUSION CRITERIA: 
 
 Age: 20- 60Yrs of both sex                                                                                       Yes/No                                                                                               
 Clinical symptoms of  abdominal pain & distension,  pain from loin to             Yes/No 
groin,  pain in urethra, agonizing pain, dysuria, oliguria, yellow 
 coloured urination, burning micturition, haematuria, nausea & vomiting. 
 Stone size:  ≥4mm &≤10mm                                                                                   Yes/No                                                                                    
 History of Recurrence of Renal calculi                                                                    Yes/No                                                                            
 Patient with renal calculus detected on X-ray KUB or USG abdomen.                   Yes/No                   
 Patient willing to undergo USG abdomen / X-ray KUB and   
blood investigations                                                                                                  Yes/No           
 Patient‟s willingness for consent to include in the trial                                            Yes/No 
9.EXCLUSION CRITERIA: 
Stone size >10mm yes No Hepatic disease Yes No 
Pregnancy and lactation   Other Renal disease   
Severe systemic illness (Eg:CA)        Cardiac disease   
Diabetes mellitus   Hypertension   
Patient taking any other lithotriptic agent   History of taking treatment for any 
other ailments 
  
History of drug/alcohol abuse      
 
10.ADMITTED TO TRAIL:    YES            NO            If Yes Serial No: 
Date:                                                                                                             
Station: 
Signature of the Investigator:  
                                         
Signature of the Lecturer:                                                  
                    
                                                                                   Signature of the HOD 
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NATIONAL INSTITUTE OF SIDDHA, CHENNAI – 47 
AYOTHIDASAR PANDITHAR HOSPITAL 
DEPARTMENT OF MARUTHUVAM 
PRE CLINICAL AND CLINICAL STUDY ON “AZHAL KALLADAIPPU” (RENAL CALCULI) AND 
THE DRUG OF CHOICE IS “KARPOORA SILASATHU PARPAM” (INTERNAL) 
 
FORM I-A HISTORY PROFORMA ON ENROLLMENT 
 
 
 REG NO: 32101204/2012-13 
 
1. Serial No of the case:   _______________         2. OP/IP No: ---------- 
       
3. Name: ________________    4. Gender:   Female/male 
 
 
5. Age (years): _________   DOB            
                                                                    Date       Month            Year 
 
6. Address:     -------------------------------------- 
                      ------------------------------------- 
                      ------------------------------------- 
 
 
7. A) Occupation: -----------------------------             B) Nature of work ----------------- 
  
8. Educational Status:   A) Illiterate                  B) Literate          
 
9. Height:  --------- cms                10.Weight: ---------- kg 
 
11. Complaints and Duration:   
 
________________________________________________________________________ 
 
________________________________________________________________________ 
 
________________________________________________________________________ 
 
________________________________________________________________________ 
 
 
12. Habit of 
          A) Smoking                  1. Yes; duration ________ years; Number-             2.No 
     B) Tobacco chewing      1. Yes; duration ________ years                            2.No                                         
                C) Betel chewing          1. Yes; duration ________ years                             2.No 
                D) Alcoholism              1. Yes; duration ________ years; Quantity-   ml     2.No 
 
 
13. Dietary style:  A. Pure vegetarian         B. Non-vegetarian            C. mixed diet 
 
 
14. Drug History: Had the patient been treated before with allopathic drug? 
 1) Yes              2) No 
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15 MARITAL STATUS:    1.Married   2.Unmarried  
 
 
                                               No of children:             male:          female: 
                                             
                               
                                                             
16. FAMILY HISTORY: 
 
      Whether this problem runs in family?                         1. Yes                               2.No   
  
       If yes, mention the relationship of affected person(s)        ------------------------- 
                                                                                     ------------------------- 
                                             
17. MENSTRUAL HISTORY:  
 
                                               
 
18. BOWEL HABITS & MICTURITION:  Normal  
 
            History of habitual constipation              1.Yes                      2.No                                                       
 
            History of frequent diarrhoea                  1.Yes                      2.No                                                         
 
            History of frequent dysuria                      1.Yes                      2.No                
 
 
19. PSYCHOLOGICAL STATE: 
                   
            Normal                                          Anxiety                                       Depression 
 
 
 
 
  Date:         
  Station: 
 
  Signature of the Investigator: 
 
 
  Signature of the Lecturer:                                                         
 
 
 
                                                                                    
                                                                                  Signature of the HOD 
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NATIONAL INSTITUTE OF SIDDHA, CHENNAI – 47 
AYOTHIDASAR PANDITHAR HOSPITAL 
DEPARTMENT OF MARUTHUVAM 
PRE CLINICAL AND CLINICAL STUDY ON “AZHAL KALLADAIPPU” (RENAL CALCULI) AND 
THE DRUG OF CHOICE IS “KARPOORA SILASATHU PARPAM” (INTERNAL) 
  FORM II AND II-A    CLINICAL ASSESSMENT ON ENROLLMENT AND ON VISITS   
 
1. S. NO -----------                    2. OP/IP NO ------------------     REG NO: 32101204/2012-13  
 
3.  NAME ---------------------------      4.GENDER M/F                         
 
5. WEEK OF ASSESSMENT   :    
 
                       0
th
 day            1
st
 week             2
nd
 week               3
rd
 week         
 
                       4
th
 week             5
th
 week            6
th
 week                7
th
 week  
 
 
SIDDHA SYSTEM OF EXAMINATION: 
 
6. ENVAGAI THERVU:[EIGHT-FOLD EXAMINATION] 
 
 I.NAADI: [PULSE PERCEPTION] 
 0th day 1st week 2nd week 3rd week 4th week 5th week 6th week 7th week 
Vali         
Azhal         
Iyyam         
Vali Azhal         
Azhal vali         
Iyya vali         
Vali Iyyam         
Azhal Iyyam         
Iyya Azhal         
 
 
II.NAA:[TONGUE] 
 0th day 1st week 2nd week 3rd week 4th week 5th week 6th week 7th week 
Colour normal/ Red 
pale/yellow 
normal/ Red 
pale/yellow 
normal/ Red 
pale/yellow 
normal/ Red 
pale/yellow 
normal/ Red 
pale/yellow 
normal/ Red 
pale/yellow 
normal/ Red 
pale/yellow 
normal/ Red 
pale/yellow 
Taste Sweet/Sour/ 
Pungent/ 
Bitter/None 
Sweet/Sour/ 
Pungent/ 
Bitter/None 
Sweet/Sour/ 
Pungent/ 
Bitter/None 
Sweet/Sour/ 
Pungent/ 
Bitter/None 
Sweet/Sour/ 
Pungent/ 
Bitter/None 
Sweet/Sour/ 
Pungent/ 
Bitter/None 
Sweet/Sour/ 
Pungent/ 
Bitter/None 
Sweet/Sour/ 
Pungent/ 
Bitter/None 
Coating Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Fissure Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Saliva Normal/ 
Increased/ 
Decreased 
Normal/ 
Increased/ 
Decreased 
Normal/ 
Increased/ 
Decreased 
Normal/ 
Increased/ 
Decreased 
Normal/ 
Increased/ 
Decreased 
Normal/ 
Increased/ 
Decreased 
Normal/ 
Increased/ 
Decreased 
Normal/ 
Increased/ 
Decreased 
Dryness Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Glossitis Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Baldness Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
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III.NIRAM:[COMPLEXION]    
0
th
 day 1
st
 week 2
nd
 week 3
rd
 week  4
th
 week 5
th
 week 6
th
 week 7
th
 week 
Dark/pale/ 
Yellow 
tinted/ 
wheatish 
brown 
Dark/pale/ 
Yellow tinted/ 
wheatish 
brown 
Dark/pale/ 
Yellow 
tinted/ 
wheatish 
brown 
Dark/pale/ 
Yellow tinted/ 
wheatish 
brown 
Dark/pale/ 
Yellow tinted/ 
wheatish 
brown 
Dark/pale/ 
Yellow tinted/ 
wheatish 
brown 
Dark/pale/ 
Yellow tinted/ 
wheatish 
brown 
Dark/pale/ 
Yellow tinted/ 
wheatish 
brown 
 
IV.MOZHI:[VOICE] 
0
th
 day 1
st
 week 2
nd
 week 3
rd
 week  4
th
 week 5
th
 week 6
th
 week 7
th
 week 
Medium/ 
High/ 
Low pitched 
Medium/ 
High/ 
Low pitched 
Medium/ 
High/ 
Low pitched 
Medium/ 
High/ 
Low pitched 
Medium/ 
High/ 
Low pitched 
Medium/ 
High/ 
Low pitched 
Medium/ 
High/ 
Low pitched 
Medium/ 
High/ 
Low pitched 
                     
V.VIZHI:[EYES] (Lower palpebral conjunctiva)     
0
th
 day 1
st
 week 2
nd
 week 3
rd
 week  4
th
 week 5
th
 week 6
th
 week 7
th
 week 
normal/ Red 
pale/yellow 
normal/Red 
pale/yellow 
normal/Red 
pale/yellow 
normal/ Red 
pale/yellow 
normal/ Red 
pale/yellow 
normal/ Red 
pale/yellow 
normal/Red 
pale/yellow 
normal/Red 
pale/yellow 
                                                   
 VI. MALAM:[BOWEL HABITS / STOOLS] 
 0
th
 day 1
st
week 2
nd
wk 3
rd
 week  4
th
 week 5
th
 week 6
th
 week 7
th
 week 
Colour Dark/pale/ 
yellow/ 
Red 
Dark/pale/ 
yellow/ 
Red 
Dark/pale/ 
Yellow/ 
Red 
Dark/pale/ 
yellow/ 
Red 
Dark/pale/ 
yellow/ 
Red 
Dark/pale/ 
yellow/ 
Red 
Dark/pale/ 
yellow/ 
Red 
Dark/pale/ 
yellow/ 
Red 
Consistency Solid/ 
Semisolid/
Watery 
Solid/ 
Semisolid/
Watery 
Solid/ 
Semisolid/
Watery 
Solid/ 
Semisolid/
Watery 
Solid/ 
Semisolid/
Watery 
Solid/ 
Semisolid/
Watery 
Solid/ 
Semisolid/
Watery 
Solid 
/Semisolid/
Watery 
stool  bulk                          Normal/
Reduced 
Normal/ 
Reduced 
Normal/ 
Reduced 
Normal/ 
Reduced 
Normal/ 
Reduced 
Normal/ 
Reduced 
Normal/ 
Reduced 
Normal/ 
Reduced 
Constipation   Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Diaarhoea Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
 
VII.MOOTHIRAM:[URINE EXAMINATION]     
Neerkkuri 0
th
 day   1
st
 
week 
 2
nd
 
week 
 3
rd
  
week  
 4
th
 
week 
 5
th
 
week 
 6
th
 
week 
 7
th
 
week 
Niram[Colour]   Yellow/ 
Red/ 
White/ 
Straw 
coloured/ 
Crystal clear 
Yellow/ 
Red/ 
White/ 
Straw 
coloured/ 
Crystal 
clear 
Yellow/ 
Red/ 
White/ 
Straw 
coloured/ 
Crystal 
clear 
Yellow/ 
Red/ 
White/ 
Straw 
coloured/ 
Crystal clear 
Yellow/ 
Red/ 
White/ 
Straw 
coloured/ 
Crystal 
clear 
Yellow/ 
Red/ 
White/ 
Straw 
coloured/ 
Crystal clear 
Yellow/ 
Red/ 
White/ 
Straw 
coloured/ 
Crystal 
clear 
Yellow/ 
Red/ 
White/ 
Straw 
coloured/ 
Crystal 
clear 
Manam[Odour] Present/ 
Absent 
 Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
 Present/  
Absent 
Present/ 
Absent 
Present/ 
Absent 
Nurai[Froth] Nil/ 
Reduced/ 
Increased 
Nil/ 
Reduced/ 
Increased 
Nil/ 
Reduced/ 
Increased 
Nil/ 
Reduced/ 
Increased 
Nil/ 
Reduced/ 
Increased 
Nil/ 
Reduced/ 
Increased 
Nil/ 
Reduced/ 
Increased 
Nil/ 
Reduced/ 
Increased 
Edai[Sp.gravity]                                Normal/
Increased/ 
Reduced  
Normal/ 
Increased/ 
Reduced  
Normal/ 
Increased/ 
Reduced  
Normal/ 
Increased/ 
Reduced  
Normal/ 
Increased/ 
Reduced  
Normal/ 
Increased/ 
Reduced  
Normal/ 
Increased/ 
Reduced  
Normal/ 
Increased/ 
Reduced  
Enjal[Deposits] Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Volume   Normal/ 
Increased/ 
Reduced 
Normal/ 
Increased/ 
Reduced 
Normal/ 
Increased/ 
Reduced 
Normal/ 
Increased/ 
Reduced 
Normal/ 
Increased/ 
Reduced 
Normal/ 
Increased/ 
Reduced 
Normal/ 
Increased/ 
Reduced 
Normal/ 
Increased/ 
Reduced 
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Neikkuri  0
th
 day 1
st
 week 2
nd
 week 3
rd
 week  4
th
 week 5
th
 week 6
th
 week 7
th
 week 
Serpentine 
fashion 
at___mints at___ mints at___ mints at___ mints at___ mints at__mints at__mints at___ mints 
Annular/Ringed 
fashion 
at___mints at___ mints at___ mints at___ mints at___ mints at__mints at__mints at___ mints 
Pearl beaded 
fashion    
at___mints at___ mints at___ mints at___ mints at___ mints at__mints at__mints at___ mints 
Mixed fashion at___mints at___ mints at___ mints at___ mints at___ mints at__mints at__mints at___ mints 
Other fashion at___mints at___ mints at___ mints at___ mints at___ mints at__mints at__mints at___ mints 
 
VIII. SPARISAM:[PALPATORY  PERCEPTION] 
0
th
 day 1
st
 week 2
nd
 week 3
rd
 week  4
th
 week 5
th
 week 6
th
 week 7
th
 week 
Warmth/Hot/ 
cold/ Sweat 
Warmth/Hot
/cold/ Sweat 
Warmth/Hot 
/cold/ Sweat 
Warmth/Hot/ 
cold/ Sweat 
Warmth/Hot/ 
cold/ Sweat 
Warmth/Hot/ 
cold/ Sweat 
Warmth/Hot/ 
cold/ Sweat 
Warmth/Hot/ 
cold/ Sweat 
 
 
7. THEGI:[ TYPE OF BODY CONSTITUTION]    
Vatham predominant  Kabam predominant  
Pitham predominant  Thondha udal  
 
8. NILAM:[ LAND WHERE PATIENT LIVED MOST]  
                
Kurinji               Mullai                 Marutham             Neithal              Palai   
 
(Hilly terrain)   (Forest range)         (Plains)               (Coastal belt)         (Arid regions)     
 
9. KAALAM: [SEASON] 
 
Kaarkalam   Pinpanikalam      
Koothirkalam   Ilavenil 
Munpanikalam   Muthuvenil 
 
10. GUNAM:[CHARACTER] 
 
Sathuvam                        Rasatham                       Thamasam    
 
 
11. IYMPORIGAL:[SENSORY ORGANS] 
 
 0
th
 day 1
st
 week 2
nd
 week 3
rd
 week  4
th
 week 5
th
 week 6
th
 week 7
th
 week 
 Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Mei [Skin]         
Vaai[Buccal 
cavity]  
        
Kan [Eyes]         
Mooku[Nose]         
Sevi [ear]         
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12. IYMPULANGAL: [MOTOR ORGANS] 
 0
th
 day 1
st
 week 2
nd
 week 3
rd
 week  4
th
 week 5
th
 week 6
th
 week 7
th
 week 
 Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Kai 
[upperlimb] 
        
Kal 
[lowerlimb] 
    
 
    
Vai[Buccal 
cavity] 
        
Eruvai  
[excretory 
organ] 
        
Karuvai[Rep
roduc-tive 
organ] 
        
 
 
13. KOSAM: [SHEATHS] 
 
 
0
th
 day 1
st
 week 2
nd
 week 3
rd
 week  4
th
 week 5
th
 week 6
th
 week 7
th
 week 
 Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Annamaya kosam 
 
        
Pranamaya 
kosam 
        
Manonmayakosam 
 
        
Vingyanamaya 
kosam 
        
Anandhamaya 
kosam 
        
 
14. MUKKUTRAM:[AFFECTION OF THREE HUMORS] 
 
A) VATHAM:                                                                          
 0
th
 day 1
st
 week 2
nd
 week 3
rd
 week  4
th
 week 5
th
 week 6
th
 week 7
th
 week 
 Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Praanan         
Abaanan         
Samaanan         
Udhaanan         
Viyaanan         
Naahan         
Koorman         
Kirukaran         
Devathathan         
Dhananjeyan         
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B) PITHAM:               
 0
th
 day 1
st
 week 2
nd
 week 3
rd
 week  4
th
 week 5
th
 week 6
th
 week 7
th
 week 
 Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Analapitham         
 Prasakam         
Ranjakam         
Aalosakam         
Saathakam         
C) KABAM:                        
 0
th
 day 1
st
 week 2
nd
 week 3
rd
 week  4
th
 week 5
th
 week 6
th
 week 7
th
 week 
 Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Avalambagam         
Kilethagam         
Pothagam         
Tharpagam          
Santhigam         
                
15. SEVEN DHATHUS: [SEVEN SOMATIC COMPONENTS]                                      
  
 0
th
 day 1
st
 week 2
nd
 week 3
rd
 week  4
th
 week 5
th
 week 6
th
 week 7
th
 week 
 Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Saaram[chyme]         
Senneer[Blood]          
Oon[Muscle]         
Kozhuppu[Fat]         
Enbu[Bones]         
Moolai[Bonemarrow]         
Sukkilam/Suronitham  
[Genital discharges] 
        
 
16. SYSTEMIC EXAMINATION: 
 0
th
 day 1
st
 week 2
nd
 week 3
rd
 week  4
th
 week 5
th
 week 6
th
 week 7
th
 week 
CardioVascular System          
Respiratory  System            
Gastrointestinal System         
CentralNervous System          
Endocrine System         
 
UROGENITAL SYSTEM 0
th
 day 1
st
 week 2
nd
 week 3
rd
 week  4
th
 week 5
th
 week 6
th
 week 7
th
 week 
Nephrotic syndrome         
Glomerulo Nephritis         
Acute/chronic 
Interstitial Nephritis 
        
Acute/chronic Renal 
failure 
        
Polycystic 
kidneydisease 
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17. GENERAL EXAMINATION: 
 0
th
 day 1
st
 week 2
nd
 week 3
rd
 week  4
th
 week 5
th
 week 6
th
 week 7
th
 week 
Height (cms)         
Weight (kg)         
Temperature(°F)            
Pulse rate (per 
min) 
        
Heart rate (per 
min) 
        
Respiratory 
rate(per min) 
        
Blood 
pressure(mm/Hg) 
        
Pallor         
Jaundice         
Cyanosis         
Lymphadenopathy         
Pedal edema         
Clubbing         
Jugular vein 
pulsation 
        
 
18. CLINICAL SYMPTOMS: 
 
 0th day 1st week 2nd week 3rd week  4th week 5th week 6th week 7th week 
Abdominal pain 
 
        
 Pain from loin to groin 
 
        
 Agonizing pain 
 
        
 Pain in urethra 
 
        
 Yellow coloured    
urination 
        
 Burning micturition 
 
        
 Oliguria 
 
        
 Dysuria 
 
        
 Abdominal distention 
 
        
 Nausea & Vomiting 
 
        
 Haematuria 
 
        
                   
Date: 
Station: 
Signature of the Investigator: 
 
Signature of the Lecturer:                                                       
                                                                                                   
                                                                                             
                                                                                             Signature of the HOD 
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NATIONAL INSTITUTE OF SIDDHA, CHENNAI – 47 
AYOTHIDASAR PANDITHAR HOSPITAL 
DEPARTMENT OF MARUTHUVAM 
 
PRE CLINICAL AND CLINICAL STUDY ON “AZHAL KALLADAIPPU” (RENAL CALCULI) AND 
THE DRUG OF CHOICE IS “KARPOORA SILASATHU PARPAM” (INTERNAL) 
 
 
FORM III   LABORATORY PARAMETERS-CHART 
 
1. OP/IP No: ________                          2.S. No:                          3.Reg no:  32101204/2012-13 
4. Name: ________________                  5. Age:   _______ years    6. Gender: M/F 
    
BLOOD INVESTIGATION 
0th DAY 
Date: 
49th DAY 
Date: 
NORMAL VALUES 
HB ( gms%)   M:14-18 ;W:11-15 
T.RBC(milli/cu.mm)   M:4.5-6.5 ;W:3.5-5.5 
 
ESR (mm) 
½ hr.    
1 hr.   M:0-10 ;W:0-20 
T.WBC (cu.mm) 
 
 
DIFFERENTIAL 
COUNT (%) 
                       
4000-11,000 
 
Polymorphs   40-75 
Lymphocytes   20-35 
Monocytes   2-10 
Eosinophils   1-6 
 Basophils   0-1 
 
BT (per min)   2-6 
Clotting time   3-8 
Blood 
glucose 
(mg/dl) 
Fasting   80-120 
PP   <130 
Random   <140 
Lipid 
profile 
(mg/dl) 
Serum cholesterol   150-250 
HDL   30-60 
LDL   Upto 130 
VLDL   40 
TGL   Upto 160 
RFT 
(mg/dl) 
Blood urea   16-50 
Serum creatinine   0.6-1.2 
Serum Uric acid    M:3-9 ;W: 2.5-7.5 
LFT 
(mg/dl) 
Total bilirubin   0.3-1 
Direct bilirubin   0.1-0.3 
Indirect bilirubin   0.2-0.8 
Serum total protein   6-8 
Serum Albumin   3.5-5.5 
Serum globulin   2-3.5 
Fibrinogen(g/dl)   0.2-0.4 
Serum calcium   9-11 
Serum phosphorous   2-5 
SGOT (IU/L)   6-18 
SGPT (IU/L)   3-26 
Alkaline phosphatase (kingÅ 
units) 
  3-12 
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URINE 
INVESTIGATION 
Before TMT 
Date: 
After TMT 
Date: 
Neerkkuri   
Niram   
Manam   
Nurai   
Edai   
Enjal   
Neikkuri   
Albumin   
Fasting sugar   
PP sugar   
Random Sugar   
Deposits   
Bile salts   
Bile pigments   
Urobilinogen   
Culture & sensitivity   
MALAM   
Ova   
Cyst   
Occult blood   
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SCAN: USG ABDOMEN 
 
 
Specific 
investigation 
 
Size of the 
kidney 
 
site of the 
calculus 
 
No of 
calculus 
 
Size of the 
calculus 
 
 
Hydro 
nephrosis 
 
 
 
Rt 
kidney 
Before 
treatment   
(0
th
 day) 
 
     
After 
treatment 
(49
th
 day) 
 
     
 
 
 
 
Lt 
kidney 
Before 
treatment   
(0
th
 day) 
 
     
After 
treatment 
(49
th
 day) 
     
 
 
X RAY CHANGES: 
 Before treatment   (0
th
 day) 
 
After treatment (49
th
 day) 
 
X RAY – KUB 
 
  
 
 
 
Date: 
 
Station: 
 
 
Signature of the Investigator: 
 
 
Signature of the Lecturer:                                                        
 
 
                                                                                                                   
                                                                                                           Signature of the HOD 
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NATIONAL INSTITUTE OF SIDDHA, CHENNAI – 47 
AYOTHIDASAR PANDITHAR HOSPITAL 
DEPARTMENT OF   MARUTHUVAM 
PRE CLINICAL AND CLINICAL STUDY ON “AZHAL KALLADAIPPU” (RENAL CALCULI) AND THE DRUG OF 
CHOICE IS “KARPOORA SILASATHU PARPAM” (INTERNAL) 
 FORM IV A (DRUG COMPLIANCE FORM) 
S. NO: ---------   OPD/IPD NO: ---------------  NAME :-----------------------        REG NO: 32101204/2012-13 
Name Of The Drug: karpoora silasathu parpam, 130mg, twice a day with Radish juice 
On 1
st
 week
 
-Date:                ; Drugs issued:  (Nos)   /   Drugs returned:    (Nos) 
On 2
nd
 week-Date:                ; Drugs issued:  (Nos)   /   Drugs returned:    (Nos) 
On 3
rd
 week -Date:               ; Drugs issued:  (Nos)   /   Drugs returned:    (Nos) 
On 4
th
 week-Date:                ; Drugs issued:  (Nos)   /   Drugs returned:    (Nos) 
On 5
th
 week
 
-Date:                ; Drugs issued:  (Nos)   /   Drugs returned:    (Nos) 
On 6
th
 week-Date:                ; Drugs issued:  (Nos)   /   Drugs returned:    (Nos) 
On 7
th
 week -Date:               ; Drugs issued:  (Nos)   /   Drugs returned:    (Nos)  
Day  Date/ §¾¾¢  Morning/ ¸¡¨Ä Evening/ Á¡¨Ä Day Date/§¾¾¢ Morning/ ¸¡¨Ä Evening/ Á¡¨Ä 
Day 1    Day25    
Day2    Day26    
Day3    Day27    
Day4    Day28    
Day5    Day29    
Day6    Day30    
Day7    Day31    
Day8    Day32    
Day9    Day33    
Day10    Day34    
Day11    Day35    
Day12    Day36    
Day13    Day37    
Day14    Day38    
Day15    Day39    
Day16    Day40    
Day17    Day41    
Day18    Day42    
Day19    Day43    
Day20    Day44    
Day21    Day45    
Day22    Day46    
Day23    Day47    
Day24    Day 48    
 
Date:                                     Station: 
Signature of the Investigator: 
Signature of the Lecturer:                                                 
                                                                                                     Signature of the HOD      
 
 
 
 
 
172 
 
NATIONAL INSTITUTE OF SIDDHA, CHENNAI – 47 
AYOTHIDASAR PANDITHAR HOSPITAL 
DEPARTMENT OF   MARUTHUVAM 
PRE CLINICAL AND CLINICAL STUDY ON “AZHAL KALLADAIPPU” (RENAL 
CALCULI) AND THE DRUG OF CHOICE IS “KARPOORA SILASATHU PARPAM” 
(INTERNAL) 
 
FORM IV-B INFORMATION SHEET 
 
Name of the Principal Investigator: Dr.S.Raja Rajeswari 
 
Name of the Institution                   :  National Institute of Siddha 
                                                              Tambaram Sanatorium 
                                                              Chennai- 47. 
 
 I, Dr.S.Raja Rajeswari studying M.D (Siddha) in National Institute of Siddha, Chennai. The 
disease called Azhal kalladaippu (Renal calculi) is formed by the sedimentation of 
crystalline mineral materials within the kidney or urinary tract. It includes the symptoms like, 
pain in the back region, radiating towards the groins and lower abdomen, painful urination, 
scanty urination, nausea, vomiting and may also pass the urine with blood. This condition is 
being treated in NIS with many siddha formulations. As a part of M.D(S) research programme 
and developing new efficacious medicine, we propose to study the karpoora silasathu 
parpam formulation for treating the condition. This formulation has been mentioned in siddha 
literature and empirical evidence with contemporary tools is required for documentation. You 
can receive medicines free of cost. The duration of treatment period is 48 days. You have to 
visit NIS every week and collect drugs for 7 days. The diagnosis tests will be carried out free 
of cost. However, a particular test USG Abdomen has to be taken from outside lab and 
charges to be borne by you. We will assess the effect of treatment after completion of 48 days 
of treatment using clinical and lab parameters. 
 In this regard, we need to ask you few questions. We will maintain confidentiality of your 
comments and data obtained from you. There will be no risk of disclosing your identity and no 
physical, psychological or professional risk is involved by taking part in this study. 
 Taking part in this study is voluntary. No compensation will be paid to you for taking part in 
this study. You can choose not to answer any specific question. There is no specific benefit for 
you if you take part in the study, but you will be under our clinical monitoring and specific 
attention will be given for your health. Taking part in the study may be of benefit to the 
community, as it may help us to develop medicine for Azhal kalladaippu. In case of any 
adverse symptoms during the treatment viz, acute renal colic i.e. severe pain caused by the 
kidney stone and associated with nausea, vomiting and fever which are expected in few 
patients during the treatment, shall be reported to PIs and care will be taken in NIS for relief. 
You can withdraw from the study at the midst of treatment period, if you are not interested to 
continue and you will receive our usual treatment without condition. 
 The information we will collect in this study, will remain between you and the principal 
investigator. We will ask you a few questions through questionnaire. We will not write your 
name on different forms which sent to different investigating/analysis sections and we will use 
a code instead given by the principal investigator. Only the principal investigator will know 
the key to this code which will be kept in safe custody. If you agree to be a participant in this 
study, you will be screened as per the study protocol.  
 If you wish to find out more about this study before taking part, you can ask me all the 
questions you want or contact Dr.S.Raja Rajeswari, PG scholar cum principal investigator of 
this study, attached to the National Institute of Siddha, Chennai (Mobile phone 
no:9486770094). You can also contact the Chairman/Member-secretary of Ethics committee, 
National Institute of Siddha, Chennai – 600047, Tel no: 91-44-22411611, for rights and 
participation in the study. 
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§¾º¢Â º¢ò¾ ÁÕòÐÅ ¿¢ÚÅÉõ, ¦ºý¨É 47 
«§Â¡ò¾¢¾¡º÷ ÀñÊ¾÷ ÁÕòÐÅÁ¨É 
«Æø ¸øÄ¨¼ôÒ §¿¡öì¸¡É º¢ò¾ ÁÕó¾¢ý (¸üôâÃº¢Ä¡ºòÐ ÀüÀõ)  ÀÃ¢¸Ã¢ôÒò ¾¢È¨Éì ¸ñ¼È¢Ôõ 
ÁÕòÐÅ ¬öÅ¢ü¸¡É ¾¸Åø ÀÊÅõ. 
 
FORM IV-B ¾¸Åø ÀÊÅõ 
 
Ó¾ý¨Á ¬Ã¡öîº¢Â¡Ç÷ ¦ÀÂ÷ :  Dr. ¦ºÇ.Ã¡ƒÃ¡§ƒŠÅÃ¢ 
 ¿¢ÚÅÉò¾¢ý ¦ÀÂ÷                  :  §¾º¢Â º¢ò¾ ÁÕòÐÅ ¿¢ÚÅÉõ 
                                                  ¾¡õÀÃõ º¡Éð§¼¡Ã¢Âõ 
                                                  ¦ºý¨É 47 
 
              Dr.¦ºÇ.Ã¡ƒÃ¡§ƒŠÅÃ¢ ¬¸¢Â ¿¡ý §¾º¢Â º¢ò¾ ÁÕòÐÅÁ¨ÉÂ¢ø Àð¼ §ÁüÀÊôÒ ÀÂ¢ýÚ 
ÅÕ¸¢§Èý. ¸øÄ¨¼ôÒ ±ýÛõ §¿¡Â¡ÉÐ º¢Ú¿£Ã¸õ ÁüÚõ º¢Ú¿£Ã¸ôÀ¡¨¾Â¢ø ¯ôÒì¸û ÀÊóÐ 
Óð¸û§À¡ø Á¡È¢ º¢Ú¿£÷ À¡¨¾¨Â «¨¼òÐ ÅÄ¢¨ÂÔõ º¢Ú¿£÷ ¾¨¼¨ÂÔõ ¯ñÎ ÀñÏõ ´Õ 
§¿¡Â¡Ìõ. þó§¿¡ö þÎôÀ¢¨Éî ÍüÈ¢ì Ìò¾ø, ÅÄ¢, º¢Ú¿£÷ ¦ºøÖõ§À¡Ð ÅÄ¢, ±Ã¢îºø, 
º¢ÄºÁÂí¸Ç¢ø º¢Ú¿£Õ¼ý þÃò¾õ ¸ÄóÐ ¦ÅÇ¢Â¡¾ø §À¡ýÈ ÌÈ¢Ì½í¸¨Çò §¾¡üÚÅ¢ìÌõ. 
þó§¿¡öìÌ §¾º¢Â º¢ò¾ ÁÕòÐÅÁ¨ÉÂ¢ø ÀÄ º¢ò¾ ÁÕóÐ¸û ÀÂýÀÎò¾ôÀðÎ ÅÕ¸¢ýÈÐ. º¢ò¾ 
ÁÕòÐÅ Àð¼ §ÁüÀÊôÀ¢ø, ¬öÅ¢ý ´Õ ÀÌ¾¢Â¡¸ Ò¾¢Â ÁÕóÐ¸¨Ç ÀÂýÀÎòÐõ §¿¡ì¸¢ø ¸üôâÃ 
º¢Ä¡ºòÐ ÀüÀõ ÁÕó¾¢¨É þó§¿¡öìÌ ÅÆí¸ ÀÃ¢óÐ¨Ã ¦ºö¸¢§È¡õ. þó¾ ÁÕó¾¢ý ¦ºöÓ¨È, 
«Ç×, «ÛÀ¡Éõ ÁüÚõ ÁÕòÐÅ ÀÂý¸û «¨ÉòÐõ «í¸£¸Ã¢ì¸ôÀð¼ º¢ò¾ ÁÕòÐÅ áÄ¢ø 
ÜÈôÀðÎûÇÐ. ±ó¾Å¢¾ ¸ð¼½ÓÁ¢ýÈ¢ ¾¡í¸û þó¾ ÁÕó¾¢¨É ¦ÀüÚì¦¸¡ûÇÄ¡õ. þó¾ ¬öÅ¢ø 
ÁÕóÐ ¯ð¦¸¡ûÙõ ¸¡Äõ 48¿¡ð¸û ¬Ìõ. Å¡Ãõ ´ÕÓ¨È §¾º¢Â º¢ò¾ ÁÕòÐÅÁ¨ÉìÌ §¿Ã¢ø 
ÅóÐ 7¿¡ð¸Ùì¸¡É ÁÕó¾¢¨É ¦ÀüÚì¦¸¡ûÇ §ÅñÎõ. þó¾ ¬ö× ºõÀó¾Á¡É ¬öÅ¸ 
ÀÃ¢§º¡¾¨É¸û ¸ð¼½Á¢ýÈ¢ ¦ºöÂôÀÎõ. §ÁÖõ þó§¿¡öì¸¡É, ÌÈ¢ôÀ¢ð¼ USG ABDOMEN 
ÀÃ¢§º¡¾¨É ¦ÅÇ¢ ¬ö×ìÜ¼ò¾¢ø ¾í¸û ¦ºÄÅ¢§Ä§Â ¦ºöÐ ¦¸¡ûÇ §ÅñÎõ. 48¿¡ð¸û ÁÕóÐ 
¯ð¦¸¡ûÙõ ¸¡Äõ ÓÊó¾ À¢ÈÌ §¿¡öì¸¡É ÌÈ¢Ì½í¸û ÁüÚõ ¬öÅ¸ ÀÃ¢§º¡¾¨É¸û þÅüÈ¢ý 
ÓÊ×¸Ç¢ý «ÊôÀ¨¼Â¢ø ÁÕó¾¢ý ÀÃ¢¸Ã¢ôÒò¾¢Èý ¸ñ¼È¢ÂôÀÎõ.  
        
þó¾ ¬ö× ºõÀó¾Á¡¸ º¢Ä §¸ûÅ¢¸¨Ç ¾í¸Ç¢¼õ §¸ð¸ þÕì¸¢§Èý. ¾í¸Ç¢¼Á¢ÕóÐ ¦ÀÈôÀÎõ 
¸ÕòÐì¸û ÁüÚõ ÌÈ¢ôÒ¸û «¨ÉòÐõ ¿õÀ¢ì¨¸Â¡¸ À¾¢× ¦ºöÂôÀÎõ.þó¾ ¬öÅ¢ø ¾í¸¨Ç 
¯ðÀÎò¾¢ì¦¸¡ûÅ¾¢ý ãÄõ ±ó¾ Å¨¸Â¢Öõ À¡¾¢ôÒìÌûÇ¡¸ Á¡ðË÷¸û ±É ¯Ú¾¢ «Ç¢ì¸¢§Èý. 
        
±ó¾Å¢¾ ÅüÒÚò¾ÖÁ¢ýÈ¢, þó¾ ¬öÅ¢ø Àí§¸ü¸×õ, þó¾ ¬ö× ºõÀó¾Á¡¸ §¸ð¸ôÀÎõ 
§¸ûÅ¢¸ÙìÌ À¾¢ø ÜÈ×õ ¾í¸ÙìÌ ÓØ Í¾ó¾¢Ãõ «Ç¢ì¸ôÀÎ¸¢ÈÐ. þó¾ ¬öÅ¢ø Àí§¸üÀ¾üÌ 
±ó¾ ºýÁ¡ÉÓõ ÅÆí¸ôÀ¼Á¡ð¼¡Ð.  ¬É¡ø, ¬ö× ÓØÅÐõ ±ÉÐ §ÁüÀ¡÷¨ÅÂ¢Öõ, ¾í¸û 
¯¼ø¿Äý ÌÈ¢ò¾ ¾É¢ ¸ÅÉò¾¢Öõ ¬ö× §Áü¦¸¡ûÇôÀÎõ.¸øÄ¨¼ôÒ §¿¡öì¸¡É Ò¾¢Â ÁÕó¾¢ý 
ÀÃ¢¸Ã¢ôÒò¾¢È¨É ºã¸ò¾¢üÌ ¯½÷òÐõ Å¨¸Â¢ø þó¾ ¬ö× §Áü¦¸¡ûÇôÀÎ¸¢ÈÐ. þó¾ ¬öÅ¢ø, 
ÁÕóÐ ¯ð¦¸¡ûÙõ ¸¡Äò¾¢ø º¢ÄÕìÌ þÎô¨ÀîÍüÈ¢Öõ ¾¡í¸ÓÊÂ¡¾ ÅÄ¢Ô¼ý ÌÁð¼ø, Å¡ó¾¢, 
ÍÃõ §À¡ýÈ Á¡ÚÀð¼ ÌÈ¢Ì½í¸û ¦¾¡¼÷óÐ þÕìÌõ Àðºò¾¢ø, Ó¾ý¨Á ¬Ã¡öîº¢Â¡ÇÃ¡É 
±ýÉ¢¼õ ¦¾Ã¢Å¢ì¸ôÀðÎ, §¾º¢Â º¢ò¾ ÁÕòÐÅÁ¨ÉÂ¢ø «¾üì¸¡É ¾£÷× ÅÆí¸ôÀÎõ. þó¾ 
¬öÅ¢¨Éò ¦¾¡¼Ã ¾í¸ÙìÌ Å¢ÕôÀõ þø¨Ä¦ÂÉ¢ø, ±ô¦À¡ØÐ §ÅñÎÁ¡ÉÖõ ¬öÅ¢ý þ¨¼Â¢ø 
Å¢Ä¸¢ì¦¸¡ûÇ×õ, þõÁÕòÐÅÁ¨ÉÂ¢ø ÅÆí¸ôÀÎõ þó§¿¡öì¸¡É ÅÆì¸Á¡É ÁÕóÐ¸¨Ç 
¦ÀüÚì¦¸¡ûÇ×õ «È¢×Úò¾ôÀÎ¸¢È£÷¸û. 
        
þó¾ ¬öÅ¢ø §º¸Ã¢ì¸ôÀÎõ Å¢ÀÃí¸û «¨ÉòÐõ ¾í¸ÙìÌõ Ó¾ý¨Á ¬Ã¡öîº¢Â¡ÇÃ¡É ±ÉìÌõ 
þ¨¼Â¢ø þÃ¸º¢ÂÁ¡¸ ¨Åì¸ôÀÎõ. §¸ûÅ¢ À¾¢ø ÅÊÅò¾¢ø ¾í¸Ç¢¼õ §¸ûÅ¢¸û §¸ð¸ôÀÎõ. 
«¨ÉòÐô ÀÊÅí¸Ç¢Öõ ¾í¸Ç¢ý ¦ÀÂ÷ ¾Å¢÷ì¸ôÀðÎ ¬öÅ¡ÇÃ¡ø ¾í¸Ùì¦¸É ¾É¢ì ÌÈ¢Â£Î 
ÅÆí¸ôÀÎõ. «ó¾ì ÌÈ¢Â£Î ¬öÅ¡ÇÕìÌ ÁðÎ§Á ¦¾Ã¢ó¾¾¡¸ þÕìÌõ. ¿£í¸û þó¾ ¬öÅ¢ø 
Àí§¸ü¸ Å¢ÕôÀôÀð¼¡ø, ¾¢ð¼ Å¨Ã× ÀÊ §¾÷× ¦ºöÂôÀÎÅ£÷¸û. 
         
¿£í¸û þó¾ ¬öÅ¢ø Àí§¸üÌõ Óý, þó¾ ¬öÅ¢¨Éô ÀüÈ¢Â §ÁÖõ Å¢ÀÃí¸û ¦ÀÈ §ÅñÎ¦ÁÉ 
Å¢ÕôÀôÀð¼¡ø, þó¾ ¬öÅ¢ý Ó¾ý¨Á ¬Ã¡öîº¢Â¡Ç÷ ÁüÚõ §¾º¢Â º¢ò¾ ÁÕòÐÅÁ¨É, Àð¼ 
§ÁüÀÊôÒòÐ¨È Á¡½Å÷ Dr.¦ºÇ.Ã¡ƒÃ¡§ƒŠÅÃ¢ ¬¸¢Â ±ý¨É 9486770094 ±ýÈ ±ñ½¢ø ¦¾¡¼÷Ò 
¦¸¡ûÇÄ¡õ. §ÁÖõ, ¿£í¸û þó¾ ¬öÅ¢ø, ¯í¸ÇÐ Àí§¸üÒ ÁüÚõ ¯Ã¢¨Á ÀüÈ¢ ¦¾Ã¢óÐ ¦¸¡ûÇ 
§¾º¢Â º¢ò¾ ÁÕòÐÅÁ¨É, ¾¨ÄÅ÷/¦ºÂüìÌØ ¯ÚôÀ¢É÷ «Å÷¸¨ÇÔõ  
91-44-22411611 ±ýÈ ±ñ½¢ø ¦¾¡¼÷Ò ¦¸¡ûÇÄ¡õ.   
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NATIONAL INSTITUTE OF SIDDHA, CHENNAI – 47 
AYOTHIDASAR PANDITHAR HOSPITAL 
DEPARTMENT OF MARUTHUVAM 
 
PRE CLINICAL AND CLINICAL STUDY ON “AZHAL KALLADAIPPU” (RENAL 
CALCULI) AND THE DRUG OF CHOICE IS “KARPOORA SILASATHU PARPAM” 
(INTERNAL) 
  
FORM IV-C CONSENT FORM 
CERTIFICATE OF CONSENT 
 
“I have read the foregoing information, or it has been read to me. I have had the 
opportunity to ask questions about it and any questions I have asked have been answered to 
my satisfaction.  
            I   consent voluntarily to participate as a participant in this study and understand 
that I have the   right to withdraw from the study at any time without in any way it affecting 
my further medical care”. 
 
"I have received a copy of the information sheet/consent form". 
 
 
In case of illiterate participant 
 
             “I have witnessed the accurate reading of the consent form to the potential 
participant, and the individual has had the opportunity to ask questions. I confirm that the 
individual has given consent freely.”                                                   
 
 
 
Date: 
 
 
 Signature of a witness  
         Left thumb Impression of 
the                        Participant    
  
           (Selected by the participant bearing no connection with the survey team) 
 
Date:    
Station:                                                                                  
Signature of participant:                                                 
 
Signature of the Investigator: 
 
                                  
Signature of the Lecturer:                                                      
 
 
 
 
                                                                                                                 Signature of the HOD 
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§¾º¢Â º¢ò¾ ÁÕòÐÅ ¿¢ÚÅÉõ 
«§Â¡ò¾¢¾¡º ÀñÊ¾÷ ÁÕòÐÅÁ¨É, ¦ºý¨É - 47. 
Àð¼ §ÁüÀÊôÒ ÁÕòÐÅòÐ¨È 
 
«Æø ¸øÄ¨¼ôÒ §¿¡öì¸¡É  º¢ò¾  ÁÕó¾¢ý (¸üôâÃ º¢Ä¡ºòÐ ÀüÀõ)  ÀÃ¢¸Ã¢ôÒò 
¾¢È¨Éì ¸ñ¼È¢Ôõ ÁÕòÐÅ ¬öÅ¢ü¸¡É  ´ôÒ¾ø  ÀÊÅõ 
 
FORM IV- C ´ôÒ¾ø ÀÊÅõ 
 
                ¿¡ý §ÁüÜÈ¢Â  ¾¸Åø  ÀÊÅò¨¾ ÀÊòÐ «øÄÐ ÀÊì¸ §¸ðÎ 
¦¸¡ñ§¼ý. -Ð ¦¾¡¼÷À¡É Å¢Çì¸í¸¨ÇÔõ §¸ðÎ ¦¾Ã¢óÐ ¦¸¡ñ§¼ý. ±ó¾ Å¢¾ 
ÅüÒÚò¾Ä¢ýÈ¢, ±ý ¦º¡ó¾ Å¢ÕôÀò¾¢ý §ÀÃ¢ø ±ý¨É -ó¾ ¬Ã¡öîº¢ìÌ ¯ðÀÎò¾ 
±ý ÓØÁÉ§¾¡Îõ ÍÂ¿¢¨É§Å¡Îõ ºõÁ¾õ ¦¾Ã¢Å¢ì¸¢§Èý. ±ÉìÌ Å¢ÕôÀÁ¢øÄ¡¾ 
Àðºò¾¢ø ó¾ ¬Ã¡öîº¢Â¢ø ÕóÐ ±ý¨É ±ô§À¡Ð§ÅñÎÁ¡É¡Öõ Å¢ÎÅ¢òÐ 
¦¸¡ûÙõ ¯Ã¢¨Á¨Â ¦ÀüÚû§Çý ±ýÀ¨¾Ôõ «È¢§Åý. 
 
 
  §¾¾¢:                                                       ¨¸¦Â¡ôÀõ: 
 
  ¼õ:                                                      ¦ÀÂ÷     : 
 
 
  §¾¾¢:                                                        º¡ðº¢ì¸¡Ã÷ ¨¸¦Â¡ôÀõ: 
  ¼õ:                                                        ¦ÀÂ÷                : 
                                                                  ¯È×Ó¨È         :      
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NATIONAL INSTITUTE OF SIDDHA, CHENNAI – 47 
AYOTHIDASAR PANDITHAR HOSPITAL 
DEPARTMENT OF MARUTHUVAM 
 
PRE CLINICAL AND CLINICAL STUDY ON “AZHAL KALLADAIPPU” (RENAL CALCULI) AND 
THE DRUG OF CHOICE IS “KARPOORA SILASATHU PARPAM” (INTERNAL) 
 
FORM IV- D DIETARY ADVICE FORM 
 
The following diet to be taken: 
 
 For a day, drink 2- 3 liters of water. 
 Should take Barley rice kanji, kol kudineer and tender coconut. 
 Vegetables:  
Radish, Indian butter bean, Lady‟s finger, Bitter bottle gourd, White 
pumpkin,  Green‟s stem, Plantain stem, Ribbed gourd, Carrot. 
 Greens: 
                     Brown Indian hemp, Marsh mint, Curry leaf. 
 Fruits: 
                     Watermelon, Cucumber, Pineapple, Lemon, Papaya, Banana. 
 Grains: 
                    Bengal gram, black gram, green gram, pea. 
 
 
The following food should be avoided: 
 
 Tomato                               Cabbage 
 Mushrooms                         fish 
 Cauliflower                        drumstick                        
 Chocolate                            Meat 
 Greens                                 Egg 
 Licker                                  Grapes 
 Strawberry                           baking  soda 
 Tamarind                              Betel leaf 
 betel-nut                               Tobacco  
 Coffee/Tea  
 
 preserved cool drinks 
 excessive intake of salt content 
 milk products 
 fried and spicy foods  
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§¾º¢Â º¢ò¾ ÁÕòÐÅ ¿¢ÚÅÉõ 
«§Â¡ò¾¢¾¡…÷ ÀñÊ¾÷ ÁÕòÐÅÁ¨É,¦ºý¨É-47 
Àð¼§ÁüÀÊôÒ ÁÕòÐÅòÐ¨È 
«Æø ¸øÄ¨¼ôÒ §¿¡öì¸¡É  º¢ò¾  ÁÕó¾¢ý (¸üôâÃ º¢Ä¡ºòÐ ÀüÀõ)  ÀÃ¢¸Ã¢ôÒò ¾¢È¨Éì ¸ñ¼È¢Ôõ 
ÁÕòÐÅ ¬öÅ¢ü¸¡É ¯½× «È¢×¨Ã ÀÊÅõ 
 
FORM IV- D ¯½× «È¢×¨Ã ÀÊÅõ 
§º÷ì¸§ÅñÊÂ¨Å: 
 ¿¡û ´ýÚìÌ 2 Ó¾ø 3 Ä¢ð¼÷ Å¨Ã ¾ñ½£÷ «Õó¾ §ÅñÎõ. 
 À¡÷Ä¢ «Ã¢º¢ì ¸ïº¢, ¦¸¡ûÙ «Å¢ò¾ ¿£÷, þÇ¿£÷ ¬¸¢Â¨Å §º÷ì¸ 
§ÅñÎõ. 
 ¸¡ö¸û: 
ÓûÇí¸¢, «Å¨Ã, ¦Åñ¨¼, Í¨Ãì¸¡ö, ¦Åñâº½¢, ¸£¨Ãò¾ñÎ, Å¡¨Æò¾ñÎ, 
§¸Ãð, À£÷ì¸í¸¡ö, ¬¸¢Â¨Å §º÷ì¸ §ÅñÎõ. 
¸£¨Ã¸û:
º¢Ú¸£¨Ã, ¾¡Ç¢ì¸£¨Ã, ¸¡º¢É¢ì¸£¨Ã, Ò¾¢É¡ì¸£¨Ã, ¸Õ§ÅôÀ¢¨Ä ¬¸¢Â¨Å §º÷ì¸ 
§ÅñÎõ. 
ÀÆí¸û:  
¾÷âº½¢, ¦ÅûÇÃ¢ôÀ¢ïÍ, «ýÉ¡º¢ôÀÆõ, ÀôÀ¡Ç¢, Å¡¨ÆôÀÆõ, ±ÖÁ¢î¨º ¬¸¢Â¨Å 
§º÷ì¸ §ÅñÎõ. 
 ¾¡É¢Âí¸û: 
¸¼¨ÄôÀÕôÒ. ¯ÙóÐ, À¡º¢ôÀÂÚ, ¯Ä÷ó¾ Àð¼¡½¢ ¬¸¢Â¨Å  §º÷ì¸ §ÅñÎõ. 
 
¾Å¢÷ì¸ §ÅñÊÂ¨Å: 
 ¾ì¸¡Ç¢               Óð¨¼ì§¸¡Í 
 ¸¡Ç¢À¢ÇÅ÷            ¸¡Ç¡ý¸û 
 ¸¡À¢/Ë                Á£ý 
 º¡ì§Äð              Á¡Á¢º ¯½× 
 ¸£¨Ã¸û               ÓÕí¨¸ì¸¡ö 
 Óð¨¼                ÁÐÀ¡Éõ              
 ¾¢Ã¡ð¨º              ŠðÃ¡¦À÷Ã¢                         
 º¨ÁÂø§º¡¼¡         ÒÇ¢                    
 ¦ÅüÈ¢¨Ä/À¡ìÌ       Ò¨¸Â¢¨Ä 
 
 À¾ôÀÎò¾ôÀð¼ ÌÇ¢÷ À¡Éí¸û 
 ¯ôÒ ¿¢¨Èó¾ ¯½× ÁüÚõ ¿£÷  
 À¡Ä¢ø ¾Â¡Ã¢ì¸ôÀð¼ ¯½× Å¨¸¸û  
 ¦À¡Ã¢ì¸ôÀð¼ ÁüÚõ Áº¡Ä¡ §º÷ó¾ ¯½× Å¨¸¸û.  
 
Å¡úì¨¸ Ó¨È Á¡üÈí¸û: 
 
 ´§Ã þ¼ò¾¢ø ¦ÅÌ§¿Ãõ ¿¢ýÚ «øÄÐ «Á÷óÐ ¦ºöÔõ §Å¨Ä¸¨Çò ¾Å¢÷ì¸×õ. ÓÊÂ¡¾ 
Àðºò¾¢ø ´Õ Á½¢ §¿Ãò¾¢üÌ ´ÕÓ¨È§ÂÛõ ºü§È ±ØóÐ ¿¼ôÀÐ «Åº¢Âõ. 
 º¢Ú¿£¨Ã ¦ÅÌ§¿Ãõ «¼ìÌ¾ø Ü¼¡Ð. º¢Ú¿£÷ ¸Æ¢ì¸ §ÅñÎõ ±ýÈ ¯óÐ¾ø ²üÀð¼ 
¯¼§É «¨¾ ¸Æ¢òÐ Å¢¼ §ÅñÎõ. 
 ¦ÅÂ¢Ä¢ø ÍüÚÅ¨¾ì Ì¨ÈÔí¸û. ÒØì¸Á¡É þ¼í¸Ç¢ø «¾¢¸ §¿Ãõ ¦ºÄÅ¢¼ §Åñ¼¡õ. 
 ¿£ñ¼ àÃ ÀÂ½í¸¨Çò ¾Å¢÷ôÀÐ ¿øÄÐ. 
 µö×õ àì¸Óõ Á¢¸ Á¢¸ «Åº¢Âõ. 
 ÁÉ «Øò¾õ, ÁÉ þÚì¸õ §À¡ýÈ¨Å þÕó¾¡ø §Â¡¸¡, ¾¢Â¡Éõ §À¡ýÈ Ó¨È¸¨Çì  
 ¸üÚì¦¸¡ñÎ «¨¾ì Ì¨Èì¸×õ. 
 ÀÃÀÃôÀ¡É, µöÅ¢øÄ¡¾ Å¡úì¨¸ Ó¨È þÕó¾¡ø «¨¾ ¯¼ÉÊÂ¡¸ Á¡üÈ¢ «¨Áì¸×õ. 
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PRE CLINICAL AND CLINICAL STUDY ON “AZHAL KALLADAIPPU” (RENAL CALCULI) AND 
THE DRUG OF CHOICE IS “KARPOORA SILASATHU PARPAM” (INTERNAL) 
 
 
FORM IV -E (WITHDRAWAL FORM) 
 
 
1)S. NO: -----------             2) OPD/ IPD NO: ---------------                 3)REG  NO: 
32101204/2012-13 
 
4)NAME:------------------------------    5) AGE: ---------                     6) GENDER: M/F-------- 
 
 
Date of trial commencement:  
 
Date of withdrawal from trial:  
 
 
REASONS FOR WITHDRAWAL: 
 
 Long absence at reporting :                              Yes/ No 
 Irregular treatment:                                           Yes/ No 
 Shift of locality :                                               Yes/No 
 Increase in severity of symptoms:                    Yes/No 
 Complication/Adverse reactions if any:       Yes/No 
 Poor patient compliance:                            Yes/No 
 
 
 
 
Date: 
      
Station: 
 
Signature of the Investigator: 
 
Signature of the Lecturer:                                                     
 
 
 
                                                                                         Signature of the HOD 
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FORM IV F 
 
ADVERSE REACTION FORM 
 
Name:  
Age: 
Gender:  Male/Female    
  
Serial No:                                              Op/Ip No: 
 
Reg No: 32101204/2012-13 
 
Date of trial commencement: 
 
Date of the adverse reaction occur: 
Time: 
 
Description of Adverse reaction:  
 
 
 
Date:                                                                              
Station:  
Signature of the Investigator: 
 
Signature of the Lecturer:                                                            
 
 
                                                                          Signature of the HOD   
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PATIENT USG ABDOMEN SCAN REPORT BEFORE TREATMENT 
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PATIENT USG ABDOMEN SCAN REPORT AFTER TREATMENT 
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PATIENT  ABDOMEN SCAN REPORT BEFORE TREATMENT 
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PATIENT USG ABDOMEN SCAN REPORT AFTER TREATMENT 
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PATIENT URINE CULTURE AND SENSITIVITY BEFORE TREATMENT 
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PATIENT URINE CULTURE AND SENSITIVITY AFTER TREATMENT 
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PATIENT URINE CULTURE AND SENSITIVITY BEFORE TREATMENT 
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PATIENT URINE CULTURE AND SENSITIVITY AFTER TREATMENT 
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BT AT BT AT BT AT BT AT BT AT BT AT BT AT BT AT BT AT BT AT BT AT
1
C69642 24/F + -
+ - - - - - - - + -
+ - + - - - + - - -
2
C71045 31/M
+ - + - - - + - + - - - + - + - + - - - - -
3
C73030 43/M
+ - + - - - + - + - - - + - + - + - - - - -
4
C73050 43/M
+ - + - - - + - + - - - + - + - + - + - - -
5
C72496 32/F
+ - + - - - + - + - + - + - + - + - - - - -
6
C74152 52/M
+ - + - - - + - + - + - + - + - + - - - - -
7
C73299 32/M
+ - + - - - + - + - - - + - + - + - - - - -
8
C73332 42/M
+ - + - - - + - + - + - + - + - + - + - - -
9
C75054 50/F
+ - + - - - - - - - - - + - + - + - - - - -
10
C76543 24/M
+ - + - - - - - - - - - + - + - + - - - - -
11
C74751 33/M
+ - + - - - - - - - - - + - + - + - - - - -
12
C77242 34/M
+ - + - - - - - - - - - + - + - + - - - - -
13
C77701 28/M
+ - + - - - - - + - + - + - + - + - - - - -
14
C78713 53/F
+ - + - - - - - - - - - + - + - + - - - - -
15
C79434 29/F
+ - + - - - - - - - - - + - - - - - - - - -
16
C78007 38/M
+ - + - - - - - - - + - + - + - + - - - - -
17
C80489 40/M
+ - + - - - - - - - - - - - - - + - - - - -
18
C80919 29/F
+ - + - - - - - - - - - + - - - + - - - - -
19
C81353 60/M
+ - + - - - - - - - + - + - + - + - - - - -
20
C81148 36/M
+ - + - - - - - - - - - - - - - + - - - - -
Haematuria
CLINICAL ASSESSMENTS
dysuria oliguria
Burning 
micturition
Painfrom loin 
to groin 
region
Abdominal 
distension
Pain in 
urethra
Agonizing 
pain
Yellow 
coloured 
urination
Sl. No OP/ IP NO Age/Sex
Abdominal 
pain
Nausea/ 
vomiting
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BT AT BT AT BT AT BT AT BT AT BT AT BT AT BT AT BT AT BT AT BT AT
Haematuriadysuria oliguria
Burning 
micturition
Painfrom loin 
to groin 
region
Abdominal 
distension
Pain in 
urethra
Agonizing 
pain
Yellow 
coloured 
urination
Sl. No OP/ IP NO Age/Sex
Abdominal 
pain
Nausea/ 
vomiting
21
C82243 22/M
+ - + - - - - - - - - - - - - - + - - - - -
22
C81712 60/M
+ - + - - - - - - - - - - - - - + - - - - -
23
C82707 42/M
+ - + - - - - - - - - - + - - - - - - - - -
24
C82990 27/M
+ - + - - - - - - - + - - - - - - - - - - -
25
C84030 38/M
+ - + - - - - - - - + - + - + - + - - - - -
26
C80753 48/M
+ - + - - - - - - - - - + - - - - - - - - -
27
C85766 32/M
+ - + - - - - - - - - - + - + - + - - - - -
28
C85523 25/M
+ - + - - - - - - - - - - - + - + - - - - -
29
C87868 42/F
+ - + - - - - - - - - - - - + - - - - - - -
30
C86025 40/M
+ - + - - - - - - - - - - - - - + - - - - -
31
C88682 45/M
+ - + - - - - - - - - - - - - - - - - - - -
32
C89476 33/F
+ - + - - - - - - - - - + - + - + - - - - -
33
C95276 37/F
+ - + - - - - - - - - - - - + - - - - - - -
34 3888
52/F
+ - + - - - - - - - - - + - + - + - - - - -
35
4965 32/M
+ - + - - - - - - - - - - + - + - - - - -
36
5055 48/M
+ - + - - - - - - - + - + - + - + - - - - -
37
4061 32/F
+ - + - - - - - - - - - - - - - + - + - - -
38
4099 35/F
+ - + - - - - - - - - - + - - - - - - - - -
39
4156 55/F
+ - + - - - - - - - - - - - + - - - - - - -
40
5115 27/M
+ - + - - - - - - - - - - - + - + - - - - -
BT - Before Treatment AT – After Treatment
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URINE AND MOTION INVESTIGATIONS 
S. 
NO 
OP/IP 
NO 
 URINE  MOTION 
Before Treatment  After Treatment  Before Treatment After Treatment 
Alb Sug 
Deposits BS BP URO 
Alb Sug 
Deposits BS BP URO 
Ova Cyst 
Occult 
bld 
Ova Cyst 
Occult 
blood Pus 
Cells 
Epi. 
cells 
Pus 
cells 
Epi. 
cells 
1. 
C69642 
NIL NIL 4-5 4-5 NIL 
(-)ve normal NIL NIL 1-2 1-2 NIL 
(-)ve normal 
NIL NIL NIL NIL NIL NIL 
2. C71045 NIL NIL 8-10 5-6 NIL 
(-)ve normal 
NIL NIL 1-2 1-2 NIL 
(-)ve normal 
NIL NIL NIL NIL NIL NIL 
3. C73030 NIL NIL 4-5 4-5 NIL 
(-)ve normal 
NIL NIL 1-2 1-2 NIL 
(-)ve normal 
NIL NIL NIL NIL NIL NIL 
4. C73050 NIL NIL 1-2 2-3 NIL 
(-)ve normal 
NIL NIL 2-3 2-3 NIL 
(-)ve normal 
NIL NIL NIL NIL NIL NIL 
5. C72496 NIL NIL 4-5 4-5 NIL 
(-)ve normal 
NIL NIL 1-2 2-4 NIL 
(-)ve normal 
NIL NIL NIL NIL NIL NIL 
6. C74152 NIL NIL 2-3 1-2 NIL 
(-)ve normal 
NIL NIL 2-3 2-3 NIL 
(-)ve normal 
NIL NIL NIL NIL NIL NIL 
7. C73299 NIL NIL 3-4 3-4 NIL 
(-)ve normal 
NIL NIL 1-2 1-2 NIL 
(-)ve normal 
NIL NIL NIL NIL NIL NIL 
8. C73332 NIL NIL 1-2 2-3 NIL 
(-)ve normal 
NIL NIL 2-4 2-4 NIL 
(-)ve normal 
NIL NIL NIL NIL NIL NIL 
9. C75054 NIL NIL 1-2 1-2 NIL 
(-)ve normal 
NIL NIL 2-4 2-4 NIL 
(-)ve normal 
NIL NIL NIL NIL NIL NIL 
10. C76543 NIL NIL 2-4 2-4 NIL 
(-)ve normal 
NIL NIL 1-2 1-2 NIL 
(-)ve normal 
NIL NIL NIL NIL NIL NIL 
11. C74751 NIL NIL 1-2 1-2 NIL 
(-)ve normal 
NIL NIL 1-2 1-2 NIL 
(-)ve normal 
NIL NIL NIL NIL NIL NIL 
12. C77242 NIL NIL 1-2 1-2 NIL 
(-)ve normal 
NIL NIL 1-2 1-2 NIL 
(-)ve normal 
NIL NIL NIL NIL NIL NIL 
13. C77701 NIL NIL 1-2 1-2 NIL 
(-)ve normal 
NIL NIL 2-4 2-4 NIL 
(-)ve normal 
NIL NIL NIL NIL NIL NIL 
14. C78713 NIL NIL 2-3 2-3 NIL 
(-)ve normal 
NIL NIL 1-2 1-2 NIL 
(-)ve normal 
NIL NIL NIL NIL NIL NIL 
15. C79434 NIL NIL 2-3 2-3 NIL 
(-)ve normal 
NIL NIL 2-4 1-2 NIL 
(-)ve normal 
NIL NIL NIL NIL NIL NIL 
16. C78007 NIL NIL 1-2 1-2 NIL 
(-)ve normal 
NIL NIL 2-3 3-5 NIL 
(-)ve normal 
NIL NIL NIL NIL NIL NIL 
17. C80489 NIL NIL 2-4 2-4 NIL 
(-)ve normal 
NIL NIL 1-2 1-2 NIL 
(-)ve normal 
NIL NIL NIL NIL NIL NIL 
18. C80919 NIL NIL 1-2 2-3 NIL 
(-)ve normal 
NIL NIL 2-4 2-4 NIL 
(-)ve normal 
NIL NIL NIL NIL NIL NIL 
19. C81353 NIL NIL 1-2 1-2 NIL 
(-)ve normal 
NIL NIL 2-3 1-2 NIL 
(-)ve normal 
NIL NIL NIL NIL NIL NIL 
20. 
C81148 
NIL NIL 2-4 2-4 NIL 
(-)ve normal 
NIL NIL 1-2 1-2 NIL 
(-)ve normal 
NIL NIL NIL NIL NIL NIL 
URINE AND MOTION INVESTIGATIONS 
S. 
NO 
OP/IP 
NO 
 URINE  MOTION 
Before Treatment  After Treatment  Before Treatment After Treatment 
Alb Sug 
Deposits BS BP URO 
Album
in 
Sugar 
Deposits BS BP URO 
Ova Cyst 
Occult 
bld 
Ova Cyst 
Occult 
blood 
Pus 
Cell
s 
Epi. 
Cell
s 
Pus 
Cells 
Epi. 
Cells 
21. 
C82243 
NIL NIL 1-2 2-3 NIL 
(-)ve normal 
NIL NIL 2-3 1-2 NIL 
(-)ve normal 
NIL NIL NIL NIL NIL NIL 
22. 
C81712 
NIL NIL 2-4 3-5 NIL 
(-)ve normal 
NIL NIL 3-4 3-4 NIL 
(-)ve normal 
NIL NIL NIL NIL NIL NIL 
23. 
C82707 
NIL NIL 2-4 3-5 NIL 
(-)ve normal 
NIL NIL 2-4 3-5 NIL 
(-)ve normal 
NIL NIL NIL NIL NIL NIL 
24. 
C82990 
NIL NIL 2-4 1-2 NIL 
(-)ve normal 
NIL NIL 2-4 1-2 NIL 
(-)ve normal 
NIL NIL NIL NIL NIL NIL 
25. 
C84030 
NIL NIL 2-3 1-2 NIL 
(-)ve normal 
NIL NIL 1-2 1-2 NIL 
(-)ve normal 
NIL NIL NIL NIL NIL NIL 
26. 
C80753 
NIL NIL 1-2 2-4 NIL 
(-)ve normal 
NIL NIL 1-2 1-2 NIL 
(-)ve normal 
NIL NIL NIL NIL NIL NIL 
27. 
C85766 
NIL NIL 1-2 2-3 NIL 
(-)ve normal 
NIL NIL 2-4 1-2 NIL 
(-)ve normal 
NIL NIL NIL NIL NIL NIL 
28. 
C85523 
NIL NIL 2-4 2-4 NIL 
(-)ve normal 
NIL NIL 2-3 2-3 NIL 
(-)ve normal 
NIL NIL NIL NIL NIL NIL 
29. 
C87868 
NIL NIL 1-3 2-3 NIL 
(-)ve normal 
NIL NIL 3-4 2-3 NIL 
(-)ve normal 
NIL NIL NIL NIL NIL NIL 
30. 
C86025 
NIL NIL 4-5 4-5 NIL 
(-)ve normal 
NIL NIL 2-4 2-4 NIL 
(-)ve normal 
NIL NIL NIL NIL NIL NIL 
31. 
C88682 
NIL NIL 2-4 3-5 NIL 
(-)ve normal 
NIL NIL 2-3 2-3 NIL 
(-)ve normal 
NIL NIL NIL NIL NIL NIL 
32. 
C89476 
NIL NIL 1-2 1-2 NIL 
(-)ve normal 
NIL NIL 1-2 1-2 NIL 
(-)ve normal 
NIL NIL NIL NIL NIL NIL 
33. 
C95276 
NIL NIL 4-5 4-5 NIL 
(-)ve normal 
NIL NIL 2-3 2-3 NIL 
(-)ve normal 
NIL NIL NIL NIL NIL NIL 
34.  
3888 
NIL NIL 1-2 1-2 NIL 
(-)ve normal 
NIL NIL 1-2 1-2 NIL 
(-)ve normal 
NIL NIL NIL NIL NIL NIL 
35. 
4965 
NIL NIL 3-4 1-2 NIL 
(-)ve normal 
NIL NIL 1-2 1-2 NIL 
(-)ve normal 
NIL NIL NIL NIL NIL NIL 
36. 
5055 
NIL NIL 2-4 2-4 NIL 
(-)ve normal 
NIL NIL 1-2 2-4 NIL 
(-)ve normal 
NIL NIL NIL NIL NIL NIL 
37. 
4061 
NIL NIL 1-2 1-2 NIL 
(-)ve normal 
NIL NIL 1-2 1-2 NIL 
(-)ve normal 
NIL NIL NIL NIL NIL NIL 
38. 
4099 
NIL NIL 1-2 2-3 NIL 
(-)ve normal 
NIL NIL 1-2 1-2 NIL 
(-)ve normal 
NIL NIL NIL NIL NIL NIL 
39. 
4156 
NIL NIL 1-2 1-2 NIL 
(-)ve normal 
NIL NIL 2-3 1-2 NIL 
(-)ve normal 
NIL NIL NIL NIL NIL NIL 
40. 
5115 
NIL NIL 1-2 2-3 NIL 
(-)ve normal 
NIL NIL 1-2 1-2 NIL 
(-)ve normal 
NIL NIL NIL NIL NIL NIL 
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Hb and RBC – INVESTIGATIONS BEFORE AND AFTER TREATMENT – IN OP & IP PATIENTS 
 
 
 
 
SL. 
NO 
OP/IP NO NAME 
Age/sex 
Hbgm% 
TRBC 
Million cells /cumm 
Before 
treatment 
After 
treatment 
Before 
treatment 
After 
treatment 
1. C69642 Mrs.P.Sangeetha 24/F 12.9 14.3 4.4 4.9 
2. C71045 Mr.B.Muthusaravanan 31/M 14.2 14.3 5.0 5.0 
3. C73030 Mr.D.Vijayakumar 43/M 17.4 16.4 5.5 5.3 
4. C73050 Mr.E.Esakkimuthu 43/M 15.0 15.4 5.5 5.5 
5. C72496 Mrs.M.Padmavathy 32/F 12.0 11.7 4.4 4.5 
6. C74152 Mr.R.Radhakrishnan 52/M 9.7 10.1 4.0 4.1 
7. C73299 Mr.M.Tamizlselvan 32/M 16.1 15.9 5.2 5.3 
8. C73332 Mr.S.Gothandapani 42/M 15.2 16.1 4.8 5.2 
9. C75054 Mrs.R.Shanthi 50/F 13.0 12.9 4.5 4.3 
10. C76543 Mr.M.Dillibabu 24/M 15.5 15.7 4.9 4.9 
11. C74751 Mr.S.V.anjuman 33/M 16.3 17.3 6.0 6.2 
12. C77242 Mr.N.Vijayakumar 34/M 15.4 15.7 5.0 5.1 
13. C77701 Mr.D.Harish 28/M 12.5 15.5 3.9 4.9 
14. C78713 Mrs.K.Chandra 53/F 13.4 12.9 4.8 4.4 
15. C79434 Msr.V.Logeswari 29/F 12.2 11.8 4.5 4.5 
16. C78007 Mr.B.Raj 38/M 16.0 15.4 5.5 5.2 
17. C80489 Mr.S.Mani 40/M 14.8 15.2 5.5 5.5 
18. C80919 Mrs.S.Amudha 29/F 12.1 12.6 4.1 4.2 
19. C81353 Mr.I.Selvaraj 60/M 14.9 15.0 5.1 5.1 
20. C81148 Mr.R.Baburajan 36/M 15.3 15.8 5.5 5.7 
21. C82243 Mr.J.Chandramohan 22/M 17.2 17.6 5.5 5.6 
22. C81712 Mr.P.Ramadoss 60/M 13.7 14.1 4.5 4.7 
23. C82707 Mr.R.Sachithanantham 42/M 13.9 14.6 4.9 5.2 
24. C82990 Mr.M.Karthick 27/M 16.7 15.8 5.5 5.2 
25. C84030 Mr.D.Karuppasamy 38/M 15.4 15.0 4.9 4.7 
26. C80753 Mr.K.Ravichandiran 48/M 14.6 14.9 4.8 5.0 
27. C85766 Mr.P.Anthonydoss 32/M 16.4 15.4 5.8 5.4 
28. C85523 Mr.S.Raja 25/M 15.8 14.6 5.4 4.9 
29. C87868 Mrs.R.Sumathy 42/F 13.9 13.5 4.7 4.5 
30. C86025 Mr.A.Raman 40/M 15.6 13.8 5.6 5.7 
31. C88682 Mr.C.Kumar 45/M 14.3 14.6 4.8 4.9 
32. C89476 Mr.M.Shankar 33/F 16.5 16.6 5.4 5.6 
33. C95276 Mrs.V.Amudha 37/F 12.6 13.8 4.0 4.0 
34. 3888 Mrs.K.Kanaga 52/F 17.4 16 5.8 5.9 
35. 4965 M.Sathyamoorthy 32/M 15.2 14.8 4.9 4.6 
36. 5055 Mr.M.Gopalsamy 48/M 15.3 15.2 4.3 4.1 
37. 4061 Mrs.R.Devi 32/F 10.7 11.7 4.1 4.0 
38. 4099 Mrs.N.Anjali 35/F 13.8 13.8 4.3 4.4 
39. 4156 Mrs.R.Nalini 55/F 10.3 11.6 3.6 3.9 
40. 5115 Mr.S.Akbarali 27/M 15.1 15.6 4.4 4.9 
LAB INVESTIGATIONS 
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Sno OP/IP   
    No 
Age/Sex   TC  
Cells/ 
cumm 
                   DC%      ESR    
    mm/hr 
Blood 
sugar  
mg/dl 
Blood 
urea 
mg/dl 
S.Creatinine 
    Mg/dl 
S.Uric  
acid 
 mg/dl 
    P     L    E 
1/2 
hr 1 hr F PP 
1 C69642 24/F 10300 62 28 10 4 10 107 129 19 0.6 6.1 
2 C71045 31/M 9800 60 28 2 4 8 95 114 18 0.6 6.4 
3 C73030 43/M 6900 62 35 3 2 6 115 123 28 0.6 7.2 
4 C73050 43/M 6900 63 34 3 2 4 79 101 22 0.7 5.5 
5 C72496 32/F 4900 62 36 2 8 16 86 102 21 0.6 4.9 
6 C74152 52/M 7500 64 32 4 12 18 102 112 37 0.8 6.0 
7 C73299 32/M 4000 56 30 4 2 4 94 92 30 0.7 5.4 
8 C73332 42/M 9500 43 32 5 4 8 104 100 33           0.8 8.2 
9 C75054 50/F 8600 55 34 4 8 22 86 125 15 0.6 4.7 
10 C76543 24/M 6400 64 30 6 2 4 84 99 19 0.6 6.0 
11 C74751 33/M 7200 54 40 6 2 6 81 102 23 0.7 6.5 
12 C77242 34/M 5200 69 25 1 2 6 104 114 18 0.5 5.4 
13 C77701 28/M 4500 50 34 6 4 8 96 86 17 0.5 7.9 
14 C78713 53/F 8600 50 32 6 4 12 68 121 19 0.5 5.2 
15 C79434 29/F 6700 48 34 2 2 6 104 128 16 0.5 4.4 
16 C78007 38/M 9900 59 34 7 4 10 95 107 17 0.5 6.6 
17 C80489 40/M 7600 22 36 3 2 12 104 128 21 0.6 6.8 
18 C80919 29/F 7400 68 30 2 6 16 71 110 20 0.6 3.5 
19 C81353 60/M 7000 64 30 6 4 8 100 108 23 0.8 7.0 
20 C81148 36/M 7400 49 36 5 2 4 93 119 28 0.8 3.7 
21 C82243 22/M 5800 54 20 5 2 4 84 103 23 0.7 5.5 
22 C81712 60/M 5500 65 30 5 2 4 127 138 21 0.7 6.0 
23 C82707 42/M 7800 45 39 6 2 6 85 105 18 0.6 6.7 
24 C82990 27/M 7300 64 30 5 2 4 96 107 20 0.8 7.4 
25 C84030 38/M 7200 47 34 6 2 4 82 123 22 0.6 5.9 
26 C80753 48/M 5900 60 34 6 6 14 101 111 23 0.8 5.3 
27 C85766 32/M 8800 48 37 1 2 4 89 121 16 0.5 6.0 
28 C85523 25/M 10700 66 30 4 10 20 88 112 22 0.7 5.5 
29 C87868 42/F 9800 67 30 3 4 10 107 110 15 0.6 2.7 
30 C86025 40/M 7400 52 30 8 2 6 99 103 19 0.6 4.9 
31 C88682 45/M 5700 54 33 6 2 4 110 125 15 0.5 5.7 
32 C89476 33/F 7800 62 35 3 2 4 86 104 19 0.5 4.5 
33 C95276 37/F 8300 62 34 4 3 8 99 109 18 0.6 4.5 
34 3888 52/F 8600 55 38 5 6 12 70 89 25 0.8 5.8 
35 4965 32/M 5100 53 29 6 2 4 80 100 19 0.5 4.1 
36 5055 48/M 7600 65 30 5 2 4 85 100 14 0.4 5.6 
37 4061 32/F 11000 73 21 6 6 12 93 103 15 0.6 6.9 
38 4099 35/F 10500 56 31 2 6 18 94 118 17 0.5 3.1 
39 4156 55/F 8500 50 40 2 12 24 88 103 23 0.6 3.0 
40 5115 27/M 6500 46 28 5 4 12 83 99 15 0.4 4.6 
LAB INVESTIGATIONS   BEFORE TREATMENT 
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LAB INVESTIGATIONS AFTER TREATMENT 
Sno OP/IP  
    No 
Age/Sex  TC 
Cells/ 
cumm 
               DC% ESR 
 mm/hr 
       Blood    
       sugar   
       mg/dl 
Blood 
urea 
 mg/dl 
S.creatinine 
    Mg/dl 
S.Uric 
 acid 
 mg/dl 
P L E 
1/2 
hr 1 hr 
       
F PP 
1 C69642 24/F 9900 67 30 3 2 6 92 113 30 0.9 6.0 
2 C71045 31/M 9300 66 27 5 2 4 98 109 19 0.6 5.0 
3 C73030 43/M 7700 55 30 5 6 14 103 109 27 0.7 5.9 
4 C73050 43/M 6800 48 22 1 4 8 71 98 12 0.4 4.7 
5 C72496 32/F 5300 65 26 8 6 12 102 108 15 0.5 4.5 
6 C74152 52/M 7400 69 25 6 12 24 104 111 41 1.1 3.0 
7 C73299 32/M 3700 46 27 7 2 6 84 93 22 0.7 4.7 
8 C73332 42/M 9000 55 39 6 2 4 83 103 15 0.5 6.0 
9 C75054 50/F 8900 60 35 5 2 4 115 121 15 0.4 5.3 
10 C76543 24/M 6700 63 35 2 2 4 88 92 15 0.4 5.4 
11 C74751 33/M 8200 66 31 3 2 4 82 104 14 0.4 6.8 
12 C77242 34/M 4800 56 30 4 2 4 104 118 33 0.8 4.0 
13 C77701 28/M 5000 61 34 5 2 4 103 120 14 0.4 7.9 
14 C78713 53/F 8000 50 34 6 2 4 70 88 19 0.5      4.0 
15 C79434 29/F 6600 38 33 4 2 4 99 111 15 0.4 3.7 
16 C78007 38/M 10000 42 28 6 2 4 95 107 17 0.5 6.6 
17 C80489 40/M 7800 41 35 24 4 8 99 106 17 0.5 6.2 
18 C80919 29/F 7000 72 23 05 2 6 83 106 14 0.4 2.9 
19 C81353 60/M 6200 60 34 06 2 8 102 123 18 0.5 6.5 
20 C81148 36/M 7200 50 44 06 2 6 96 109 26 0.6 3.1 
21 C82243 22/M 5000 34 56 03 4 8 76 102 14 0.4 4.3 
22 C81712 60/M 5600 65 30 05 8 18 87 100 14 0.4 4.7 
23 C82707 42/M 8200 54 42 04 2 10 86 98 16 0,5 5.3 
24 C82990 27/M 7300 64 31 5 2 4 98 109 24 0.7 5.5 
25 C84030 38/M 7700 52 26 2 2 4 91 102 22 0.6 5.0 
26 C80753 48/M 7100 56 39 5 2 10 94 106 20 0.6 3.8 
27 C85766 32/M 7800 55 40 5 2 4 94 108 17 0.5 4.8 
28 C85523 25/M 7000 55 40 5 6 12 82 101 15 0.4 5.0 
29 C87868 42/F 7700 60 35 5 8 16 96 103 16 0.5 3.5 
30 C86025 40/M 8600 38 45 7 2 4 99 108 21 0.7 5.0 
31 C88682 45/M 5600 48 32 4 2 4 109 112 15 0.5 5.2 
32 C89476 33/F 7600 58 32 3 2 4 82 103 19 0.5 3.8 
33 C95276 37/F 8600 74 23 3 4 8 87 98      14 0.4 3.8 
34 3888 52/F 8700 53 32 3 5 10 74 90 21 0.8 5.2 
35 4965 32/M 7300 66 30 4 12 24 82 102 15 0.6 3.4 
36 5055 48/M 6800 66 30 4 10 20 116 123 15 0.5 4.5 
37 4061 32/F 10800 76 20 4 8 16 103 124 25 0.5 6.9 
38 4099 35/F 10900 52 28 2 6 12 92 109 15 0.3 3.0 
39 4156 55/F 8800 67 30 3 8 18 96 102 18 0.6 3.0 
40 5115 27/M 6400 44 23 4 4 12 80 93 16 0.4 4.0 
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CHOLESTEROL PROFILE OF THE OPD AND IPD PATIENTS (BEFORE AND AFTER TREATMENT) 
 
 
S.NO 
OP/IP 
NO 
Age/sex T.CHOLESTEROL 
mg/dl 
HDL 
mg/dl 
LDL 
mg/dl 
VLDL 
mg/dl 
TGL 
mg/dl 
BT AT BT AT BT AT BT AT BT AT 
1. C69642 24/F 151 151 37 30 93 89 21 20 103 106 
2. C71045 31/M 168 112 38 29 109 102 21 21 104 96 
3. C73030 43/M 216 207 59 38 121 108 41 39 129 120 
4. C73050 43/M 232 202 60 35 116 106 36 23 78 75 
5. C72496 32/F 178 111 35 22 105 62 38 30 159 151 
6. C74152 52/M 169 117 36 26 93 44 40 25 120 114 
7. C73299 32/M 180 132 35 29 120 50 25 21 124 106 
8. C73332 42/M 182 156 37 32 118 90 27 19 136 98 
9. C75054 50/F 168 140 43 29 79 62 42 40 134 120 
10. C76543 24/M 191 135 35 30 124 90 12 11 62 57 
11. C74751 33/M 210 186 38 35 115 110 27 23 139 125 
12. C77242 34/M 185 169 32 32 124 106 19 24 98 72 
13. C77701 28/M 186 137 38 30 101 92 42 25 139 127 
14. C78713 53/F 223 219 42 40 122 115 29 23 149 136 
15. C79434 29/F 160 106 35 30 113 63 12 11 61 57 
16. C78007 38/M 180 178 30 36 120 112 30 28 154 143 
17. C80489 40/M 213 198 47 42 112 102 44 28 150 142 
18. C80919 29/F 190 147 36 30 117 108 41 27 106 98 
19. C81353 60/M 209 192 40 42 125 120 39 34 118 112 
20. C81148 36/M 195 190 38 35 109 102 42 40 123 119 
21. C82243 22/M 186 149 36 34 130 119 28 25 129 127 
22. C81712 60/M 150 138 30 30 102 99 34 29 123 107 
23. C82707 42/M 143 136 26 35 94 86 26 25 132 227 
24. C82990 27/M 195 178 38 38 116 108 34 29 134 125 
25. C84030 38/M 95 92 19 30 126 40 16 20 83 81 
26. C80753 48/M 176 168 30 40 100 79 41 32 106 93 
27. C85766 32/M 225 192 45 45 121 119 37 22 158 112 
28. C85523 25/M 176 143 29 31 100 86 42 35 112 108 
29. C87868 42/F 180 154 54 35 110 80 30 28 122 110 
30. C86025 40/M 194 189 29 36 104 86 39 25 149 79 
31. C88682 45/M 144 140 30 28 101 98 34 31 150 115 
32. C89476 33/F 150 148 32 28 90 87 24 23 122 120 
33. C95276 37/F 176 158 35 36 116 96 36 31 164 156 
34. 3888 52/F 145 140 36 32 77 75 32 30 161 158 
35. 4965 32/M 134 128 21 30 115 90 27 26 137 122 
36. 5055 48/M 160 157 24 34 60 61 13 12 67 61 
37. 4061 32/F 159 154 32 39 117 98 12 15 62 59 
38. 4099 35/F 211 200 40 38 106 104 21 20 107 102 
39. 4156 55/F 153 152 32 35 100 96 13 18 66 64 
40. 5115 27/M 131 128 30 25 70 64 27 24 139 130 
 
BT – BEFORE TREATMENT AT – AFTER TREATMENT 
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URINE CULTURE AND SENSITIVITY 
 
S.NO OP/IP 
NO 
Age/sex      BEFORE TREATMENT         AFTER TREATMENT 
1. C69642      24/F No growth in culture No growth in culture 
2. C71045 31/M No grown in culture No grown in culture 
3. C73030 43/M No grown in culture No grown in culture 
4. C73050 43/M E-coli Grown in culture E-coli Grown in culture 
5. C72496 32/F No growth in culture No growth in culture 
6. C74152 52/M E-coli Grown in culture Proteus species grown in culture 
7. C73299 32/M No growth in culture No growth in culture 
8. C73332 42/M E-coli Grown in culture No grown in culture 
9. C75054 50/F E-coli Grown in culture No grown in culture 
10. C76543 24/M No growth in culture No growth in culture 
11. C74751 33/M No growth in culture No growth in culture 
12. C77242 34/M No growth in culture No growth in culture 
13. C77701 28/M Pseudomonas isolated in culture Pseudomonas isolated in culture 
14. C78713 53/F Bacterial aerobic culture No growth in culture 
15. C79434 29/F No growth in culture No growth in culture 
16. C78007 38/M No growth in culture No growth in culture 
17. C80489 40/M No growth in culture No growth in culture 
18. C80919 29/F No growth in culture No growth in culture 
19. C81353 60/M No growth in culture No growth in culture 
20. C81148 36/M No growth in culture No growth in culture 
21. C82243 22/M No growth in culture No growth in culture 
22. C81712 60/M No growth in culture No growth in culture 
23. C82707 42/M No growth in culture No growth in culture 
24. C82990 27/M No growth in culture No growth in culture 
25. C84030 38/M No growth in culture No growth in culture 
26. C80753 48/M No growth in culture No growth in culture 
27. C85766 32/M No growth in culture No growth in culture 
28. C85523 25/M No growth in culture No growth in culture 
29. C87868 42/F No growth in culture No growth in culture 
30. C86025 40/M No growth in culture No growth in culture 
31. C88682 45/M Enterococcus faecalis isolated in culture Enterococcus faecalis isolated in culture 
32. C89476 33/F E-coli Grown in culture                                                                                                                                                                                                                                                                                                                                                                                            No growth in culture
33. C95276 37/F E-coli Grown in culture No Growth in culture 
34. 3888 52/F E-coli Grown in culture E-coli Grown in culture 
35. 4965 32/M E-coli Grown in culture E-coli Grown in culture 
36. 5055 48/M No growth in culture No growth in culture 
37. 4061 32/F No organism grown No organism grown 
38. 4099 35/F No growth in culture No growth in culture 
39. 4156 55/F E-coli Grown in culture Klebsiella  grown in culture 
40. 5115 27/M No growth in culture No growth in culture 
T.Billirubin D.Billirubin ID.billirubin SGOT SGPT SAP T.Protein Albumin Globulin Calcium Phosphorous
mg/dl mg/dl mg/dl U/l U/l U/l Gm/dl gm/dl gm/dl mg/dl mg/dl
1
C69642 24/F 0.5 0.3 0.2 20 22 131 6.8 5.4 1.4 11.8 3.3
2
C71045 31/M 0.9 0.5 0.4 24 25 115 7.2 5.3 1.9 13.3 2.9
3
C73030 43/M 0.5 0.3 0.2 18 26 127 7.9 5.8 2.1 12.4 5.1
4
C73050 43/M 0.5 0.3 0.2 22 21 230 7.4 5.4 2 10.6 5.9
5
C72496 32/F 0.4 0.2 0.2 19 21 121 7.6 5.5 2.1 11.6 4.2
6
C74152 52/M 0.7 0.4 0.3 17 16 185 6.9 5.4 1.5 11.5 3.6
7
C73299 32/M 0.5 0.3 0.2 25 27 170 6.9 5.4 1.5 11.9 2.6
8
C73332 42/M 0.5 0.3 0.2 21 28 200 6.7 4.8 1.9 11.7 2.8
9
C75054 50/F 0.7 0.4 0.3 20 22 240 7.7 5.1 2.6 12 3
10
C76543 24/M 0.6 0.2 0.4 17 19 202 7.5 4.4 3.1 13.4 3
11
C74751 33/M 0.6 0.3 0.3 22 25 146 7.9 5 2.9 11 3.9
12
C77242 34/M 0.6 0.3 0.3 20 22 128 7 5.1 1.9 12.1 2.3
13
C77701 28/M 0.7 0.3 0.4 23 25 218 7 4.9 2.1 9.6 2.5
14
C78713 53/F 0.6 0.2 0.4 20 21 129 7.6 4.1 3.5 9.1 3.2
15
C79434 29/F 0.6 0.4 0.2 13 15 138 6.5 4.3 2.2 10 2.3
16
C78007 38/M 0.6 0.2 0.4 18 20 269 6.9 4.3 2.6 11 3.7
17
C80489 40/M 0.6 0.2 0.4 20 24 221 7.5 5.1 2.4 11.2 3.3
18
C80919 29/F 0.6 0.2 0.4 24 26 185 6.2 4 2.2 10.2 3.9
19
C81353 60/M 0.8 0.3 0.5 23 28 166 7.1 4.5 2.6 11.2 4.4
20
C81148 36/M 1.2 0.6 0.6 22 21 129 6.8 4.5 2.3 10.8 4
LAB INVESTIGATIONS BEFORE  TREATMENT
S.no Age/ SexOP/IP   
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T.Billirubin D.Billirubin ID.billirubin SGOT SGPT SAP T.Protein Albumin Globulin Calcium Phosphorous
mg/dl mg/dl mg/dl U/l U/l U/l Gm/dl gm/dl gm/dl mg/dl mg/dl
S.no Age/ SexOP/IP   
21
C82243 22/M 0.6 0.2 0.4 27 23 157 6.9 4.6 2.2 10.9 3.1
22
C81712 60/M 0.5 0.2 0.3 16 18 184 7.1 5 2.1 10.3 2.8
23
C82707 42/M 0.5 0.2 0.3 24 22 260 7 4 3 9.8 3.1
24
C82990 27/M 0.9 0.4 0.5 15 16 186 7.1 4.5 2.6 10.1 3
25
C84030 38/M 0.6 0.2 0.4 21 22 238 7.7 4.8 2.9 10.6 3.1
26
C80753 48/M 0.5 0.2 0.3 16 18 170 7.6 5.6 2 9 3.8
27
C85766 32/M 1 0.6 0.4 25 24 165 7.9 4.7 3.2 11.3 3.6
28
C85523 25/M 0.4 0.2 0.2 24 25 200 7 5 2 10.4 3.6
29
C87868 42/F 0.4 0.2 0.2 24 26 180 7 4 3 10 2.9
30
C86025 40/M 0.5 0.2 0.3 25 23 220 7.1 3 4.1 10.7 2.8
31
C88682 45/M 0.6 0.2 0.4 17 19 149 6.2 4 2.2 10.4 3
32
C89476 33/F 0.5 0.2 0.3 14 15 187 6.9 3.4 3.5 11.4 2.8
33
C95276 37/F 0.6 0.2 0.4 15 17 220 5 3 2 10.8 3
34 3888 52/F 0.4 0.2 0.2 24 21 256 7 4.3 2.7 12.8 2.8
35
4965 32/M 0.8 0.3 0.5 18 20 145 7.8 4.6 3.2 10.4 3
36
5055 48/M 0.4 0.2 0.2 21 22 170 6.6 4.5 2.1 10.6 3.1
37
4061 32/F 1 0.6 0.4 12 10 136 6.6 4.5 2.1 10 3
38
4099 35/F 0.5 0.2 0.3 20 22 159 6.4 4.2 2.2 10.5 3
39
4156 55/F 0.6 0.2 0.4 21 23 168 6.8 4.8 2 12.4 2.8
40
5115 27/M 1 0.5 0.5 20 21 166 6.5 4 2.5 10.9 2.9
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T.Billirubin D.Billirubin ID.billirubin SGOT SGPT SAP T.Protein Albumin Globulin Calcium Phosphorous
mg/dl mg/dl mg/dl U/l U/l U/l gm/dl gm/dl gm/dl mg/dl mg/dl
1 C69642 24/F 0.6 0.2 0.4 18 19 190 7 5.2 1.8 11 3
2 C71045 31/M 0.7 0.2 0.5 21 26 216 6 4 2 11.3 2.7
3 C73030 43/M 1.1 0.5 0.6 19 28 119 6.1 3.2 2.9 11 3
4 C73050 43/M 0.4 0.2 0.2 24 24 262 6.8 4 2.8 10.1 4.6
5 C72496 32/F 0.5 0.2 0.3 15 16 121 7 5 2 11 3
6 C74152 52/M 0.4 0.2 0.2 21 28 190 6.9 3.9 3 10 3
7 C73299 32/M 0.3 0.2 0.1 16 17 195 7.4 4.4 3 10.6 2.8
8 C73332 42/M 0.6 0.2 0.4 21 24 211 6.5 4.5 2 11 3.6
9 C75054 50/F 0.5 0.2 0.3 19 20 152 7.7 5.7 2 12.2 3.6
10 C76543 24/M 0.5 0.2 0.3 23 26 236 6.4 3.4 3 12.2 2.8
11 C74751 33/M 0.7 0.3 0.4 16 20 186 7.5 5.5 2 10.5 3
12 C77242 34/M 0.5 0.2 0.3 22 27 196 7.5 5.5 2 9.3 2
13 C77701 28/M 0.6 0.2 0.4 24 23 213 6.7 4.2 2.5 11 3.2
14 C78713 53/F 0.5 0.2 0.3 12 14 147 6.6 4.1 2.5 10.1 3
15 C79434 29/F 0.4 0.2 0.2 11 12 145 6 3.6 2.4 9.8 2
16 C78007 38/M 1.1 0.5 0.6 19 25 176 6.6 3.7 2.9 10.8 3.1
17 C80489 40/M 0.4 0.2 0.2 11 23 177 6 3.6 2.4 9.9 2.7
18 C80919 29/F 0.5 0.2 0.3 16 26 186 6.6 4.1 2.4 10.1 3.5
19 C81353 60/M 0.5 0.2 0.3 16 17 183 5.6 3.1 2.5 10.8 3.5
20 C81148 36/M 1 0.5 0.5 18 22 220 6.2 4.2 2 9.2 3.8
S.no Age/Sex
LAB INVESTIGATIONS AFTER TREATMENT
OP/IP
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T.Billirubin D.Billirubin ID.billirubin SGOT SGPT SAP T.Protein Albumin Globulin Calcium Phosphorous
mg/dl mg/dl mg/dl U/l U/l U/l gm/dl gm/dl gm/dl mg/dl mg/dl
S.no Age/SexOP/IP
21 C82243 22/M 0.7 0.3 0.4 23 26 176 6 4 2 9.8 2.8
22 C81712 60/M 0.7 0.3 0.4 19 20 156 6.4 4.4 2 9.6 2.6
23 C82707 42/M 0.6 0.2 0.4 23 25 170 6.9 4.3 2.6 10.1 3
24 C82990 27/M 1 0.7 0.3 22 27 166 6.5 4.4 2.1 10.8 3
25 C84030 38/M 0.5 0.2 0.3 22 24 198 6.2 4 2.2 10.8 2.9
26 C80753 48/M 0.5 0.2 0.3 24 26 179 6.5 4.5 2 11 3.2
27 C85766 32/M 1 0.5 0.5 23 26 168 5.9 2.6 3.3 10.2 2.9
28 C85523 25/M 0.9 0.3 0.6 16 18 144 5 3 2 10 2.9
29 C87868 42/F 0.5 0.2 0.3 19 21 149 6.6 3.6 3 10.4 2.9
30 C86025 40/M 0.8 0.3 0.5 24 26 242 6.6 4.4 2.2 11.1 3.3
31 C88682 45/M 0.6 0.2 0.4 16 14 135 6 4 2 9.6 2.3
32 C89476 33/F 0.4 0.2 0.2 13 15 164 6.2 4.2 2 10.2 2.5
33 C95276 37/F 0.6 0.2 0.4 13 14 135 5.9 4.5 1.4 9.7 2.9
34 3888 52/F 0.4 0.2 0.2 23 21 220 6.4 4.4 4 10.2 2.4
35 4965 32/M 0.8 0.3 0.5 18 20 145 7.8 4.6 3.2 10 3
36 5055 48/M 1.2 0.6 0.6 16 17 161 7 5 2 10.4 2.9
37 4061 32/F 3.6 1.2 2.4 12 14 150 6.5 4.1 2.4 10.2 2.9
38 4099 35/F 0.5 0.2 0.3 18 16 154 6.2 4.2 2 9.6 2.8
39 4156 55/F 0.5 0.2 0.3 11 12 140 6 3 2 10.8 3.3
40 5115 27/M 0.8 0.4 0.4 18 17 160 6.4 4 2.4 9.8 2.5
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